| (+)-alpha-tocopherol | multiple interactions | ISO | RGD:2199 | 6480464 | alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of BCL2 protein] | CTD | PMID:16135673 |
| (+)-alpha-tocopherol | multiple interactions | EXP | | 6480464 | DDIT3 mRNA affects the reaction [alpha-Tocopherol analog results in decreased expression of BCL2 protein]; more ... | CTD | PMID:20686688 |
| (+)-alpha-tocopherol | decreases expression | EXP | | 6480464 | alpha-Tocopherol analog results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:20686688 |
| (+)-alpha-tocopherol | multiple interactions | EXP | | 6480464 | alpha-Tocopherol affects the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] | CTD | PMID:11805214 |
| (+)-alpha-tocopherol | multiple interactions | ISO | RGD:2199 | 6480464 | alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of BCL2 protein] | CTD | PMID:16005924 |
| (+)-catechin | multiple interactions | EXP | | 6480464 | Catechin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] | CTD | PMID:19557821 |
| (+)-catechin | multiple interactions | ISO | RGD:2199 | 6480464 | Catechin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:18611398 |
| (+)-pilocarpine | decreases expression | ISO | RGD:2199 | 6480464 | Pilocarpine results in decreased expression of BCL2 protein | CTD | PMID:19429016 |
| (-)-citrinin | decreases expression | ISO | RGD:10230 | 6480464 | Citrinin results in decreased expression of BCL2 protein | CTD | PMID:21622943 |
| (-)-citrinin | affects expression | ISO | RGD:10230 | 6480464 | Citrinin affects the expression of BCL2 protein | CTD | PMID:22771370 |
| (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [decitabine co-treated with epigallocatechin gallate] affects the expression of BCL2 mRNA | CTD | PMID:18250043 |
| (-)-epigallocatechin 3-gallate | decreases expression | EXP | | 6480464 | epigallocatechin gallate analog results in decreased expression of BCL2 protein | CTD | PMID:16115949 |
| (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | CAT protein inhibits the reaction [epigallocatechin gallate analog results in decreased expression of BCL2 protein] | CTD | PMID:16115949 |
| (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2 protein | CTD | PMID:20950636 |
| (-)-epigallocatechin 3-gallate | affects expression | ISO | RGD:2199 | 6480464 | epigallocatechin gallate affects the expression of BCL2 protein | CTD | PMID:22000973 |
| (-)-epigallocatechin 3-gallate | decreases expression | EXP | | 6480464 | epigallocatechin gallate results in decreased expression of BCL2 protein | CTD | PMID:20149610 PMID:15657356 |
| (-)-epigallocatechin 3-gallate | multiple interactions | ISO | RGD:10230 | 6480464 | epigallocatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of BCL2 mRNA] | CTD | PMID:18656336 |
| (-)-epigallocatechin 3-gallate | decreases expression | EXP | | 6480464 | epigallocatechin gallate results in decreased expression of BCL2 protein | CTD | PMID:15657356 PMID:20149610 |
| (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] | CTD | PMID:12672908 |
| (-)-epigallocatechin 3-gallate | affects expression | EXP | | 6480464 | epigallocatechin gallate affects the expression of BCL2 protein | CTD | PMID:15975156 |
| (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | epigallocatechin gallate inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] | CTD | PMID:19557821 |
| (-)-perillyl alcohol | multiple interactions | ISO | RGD:10230 | 6480464 | perilla alcohol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein] | CTD | PMID:19161993 |
| (-)-selegiline | multiple interactions | ISO | RGD:10230 | 6480464 | Selegiline inhibits the reaction [3-morpholino-sydnonimine results in decreased expression of BCL2 protein]; more ... | CTD | PMID:12880480 |
| (E)-roxithromycin | decreases expression | EXP | | 6480464 | Roxithromycin results in decreased expression of BCL2 protein | CTD | PMID:12921874 |
| (R)-lipoic acid | multiple interactions | EXP | | 6480464 | Thioctic Acid results in increased degradation of and results in decreased expression of BCL2 protein | CTD | PMID:16990509 |
| (R)-lipoic acid | multiple interactions | EXP | | 6480464 | Thioctic Acid inhibits the reaction [Zinc deficiency results in decreased expression of BCL2 protein] | CTD | PMID:21600978 |
| (R)-lipoic acid | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Thioctic Acid | CTD | PMID:16990509 |
| (R)-mevalonic acid | multiple interactions | ISO | RGD:2199 | 6480464 | Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] | CTD | PMID:11178870 |
| (R)-mevalonic acid | multiple interactions | EXP | | 6480464 | Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] | CTD | PMID:12094262 |
| (R)-noradrenaline | multiple interactions | ISO | RGD:2199 | 6480464 | Acetylcysteine inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein] | CTD | PMID:17041759 |
| (R)-noradrenaline | decreases expression | ISO | RGD:2199 | 6480464 | Norepinephrine results in decreased expression of BCL2 protein | CTD | PMID:14732211 more ... |
| (R)-noradrenaline | decreases expression | ISO | RGD:2199 | 6480464 | Norepinephrine results in decreased expression of BCL2 protein | CTD | PMID:20374255 more ... |
| (R)-noradrenaline | decreases expression | ISO | RGD:2199 | 6480464 | Norepinephrine results in decreased expression of BCL2 protein | CTD | PMID:17041759 more ... |
| (R)-noradrenaline | decreases expression | ISO | RGD:2199 | 6480464 | Norepinephrine results in decreased expression of BCL2 protein | CTD | PMID:17041759 more ... |
| (R)-noradrenaline | multiple interactions | ISO | RGD:2199 | 6480464 | N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein] | CTD | PMID:20374255 |
| (S)-colchicine | multiple interactions | ISO | RGD:2199 | 6480464 | Colchicine inhibits the reaction [Ethanol results in increased expression of BCL2 mRNA] | CTD | PMID:22446813 |
| (S)-colchicine | decreases expression | EXP | | 6480464 | Colchicine results in decreased expression of BCL2 protein | CTD | PMID:22342440 |
| (S)-naringenin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to naringenin | CTD | PMID:19124070 |
| (S)-naringenin | multiple interactions | EXP | | 6480464 | ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate inhibits the reaction [BCL2 protein results in decreased susceptibility to naringenin] | CTD | PMID:19124070 |
| (S)-nicotine | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [Nicotine results in increased expression of BCL2 protein] | CTD | PMID:20727180 |
| (S)-nicotine | multiple interactions | EXP | | 6480464 | Nicotine inhibits the reaction [Aflatoxin B1 results in decreased expression of BCL2 protein] | CTD | PMID:22743290 |
| (S)-nicotine | increases expression | EXP | | 6480464 | Nicotine results in increased expression of BCL2 protein | CTD | PMID:18448488 more ... |
| (S)-nicotine | increases expression | EXP | | 6480464 | Nicotine results in increased expression of BCL2 protein | CTD | PMID:18448488 more ... |
| (S)-nicotine | increases expression | EXP | | 6480464 | Nicotine results in increased expression of BCL2 protein | CTD | PMID:20727180 more ... |
| (S)-nicotine | decreases expression | ISO | RGD:2199 | 6480464 | Nicotine results in decreased expression of BCL2 mRNA | CTD | PMID:20339300 |
| (S)-nicotine | decreases expression | ISO | RGD:10230 | 6480464 | Nicotine results in decreased expression of BCL2 mRNA | CTD | PMID:15831280 |
| (S)-nicotine | increases expression | EXP | | 6480464 | Nicotine results in increased expression of BCL2 protein modified form | CTD | PMID:18676776 |
| (S)-nicotine | increases phosphorylation | EXP | | 6480464 | Nicotine results in increased phosphorylation of BCL2 protein | CTD | PMID:12421819 |
| (S)-nicotine | increases expression | EXP | | 6480464 | Nicotine results in increased expression of BCL2 protein | CTD | PMID:20727180 more ... |
| (S)-nicotine | multiple interactions | EXP | | 6480464 | L 663536 inhibits the reaction [Nicotine results in increased expression of BCL2 protein] | CTD | PMID:20061081 |
| (S)-nicotine | multiple interactions | EXP | | 6480464 | edelfosine inhibits the reaction [Nicotine results in increased phosphorylation of BCL2 protein] | CTD | PMID:12421819 |
| (S)-ropivacaine | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [ropivacaine results in increased cleavage of CASP3 protein]; more ... | CTD | PMID:15538973 |
| (S)-ropivacaine | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to ropivacaine | CTD | PMID:15538973 |
| 1'-acetoxychavicol acetate | multiple interactions | EXP | | 6480464 | 1'-acetoxychavicol acetate inhibits the reaction [TNF protein results in increased expression of BCL2 protein] | CTD | PMID:15905586 |
| 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane | increases expression | ISO | RGD:10230 | 6480464 | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in increased expression of BCL2 protein | CTD | PMID:15525693 |
| 1,3-dinitrobenzene | increases expression | ISO | RGD:2199 | 6480464 | 3-dinitrobenzene results in increased expression of BCL2 mRNA | CTD | PMID:16025311 |
| 1,3-dinitrobenzene | decreases expression | ISO | RGD:10230 | 6480464 | 3-dinitrobenzene results in decreased expression of BCL2 protein; more ... | CTD | PMID:19477251 |
| 1,3-thiazolidine-2,4-dione | decreases expression | EXP | | 6480464 | 2,4-thiazolidinedione results in decreased expression of BCL2 protein | CTD | PMID:15916743 |
| 1,4-benzoquinone | decreases expression | EXP | | 6480464 | benzoquinone results in decreased expression of BCL2 protein | CTD | PMID:20499891 |
| 1-naphthyl isothiocyanate | increases expression | ISO | RGD:2199 | 6480464 | 1-Naphthylisothiocyanate results in increased expression of BCL2 mRNA | CTD | PMID:12883083 |
| 11-deoxycorticosterone | multiple interactions | ISO | RGD:2199 | 6480464 | acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of BCL2 protein]; more ... | CTD | PMID:22431579 |
| 17alpha-ethynylestradiol | increases expression | ISO | RGD:2199 | 6480464 | Ethinyl Estradiol results in increased expression of BCL2 protein | CTD | PMID:12857939 |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | ARTN protein inhibits the reaction [Tamoxifen inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]; more ... | CTD | PMID:20305694 |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | MIR21 mRNA mutant form promotes the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:23052036 |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:11356682 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:10455518 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:11356682 more ... |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | Benzo(a)pyrene inhibits the reaction [Estradiol results in increased expression of BCL2 protein]; more ... | CTD | PMID:18174961 |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | [Estradiol results in increased activity of ESR1 protein] which results in increased expression of BCL2 mRNA | CTD | PMID:22403704 |
| 17beta-estradiol | increases expression | ISO | RGD:10230 | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:17578864 |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:19796866 |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:10455518 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:11356682 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:10455518 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:11356682 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:15870704 more ... |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:10545406 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:11356682 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:10545406 more ... |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:10545406 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:19698761 more ... |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:15870704 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:19264808 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:10545406 more ... |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:20305694 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:15870704 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:16051634 more ... |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:20305694 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:10455518 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:19698761 more ... |
| 17beta-estradiol | multiple interactions | ISO | RGD:2199 | 6480464 | Estradiol inhibits the reaction [Dimethylnitrosamine results in decreased expression of BCL2 protein] | CTD | PMID:14659978 |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:15870704 more ... |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | Ethidium inhibits the reaction [Estradiol results in increased expression of BCL2 mRNA] | CTD | PMID:15897899 |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 protein | CTD | PMID:20305694 more ... |
| 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of BCL2 mRNA | CTD | PMID:19264808 more ... |
| 17beta-estradiol | affects expression | EXP | | 6480464 | Estradiol affects the expression of BCL2 mRNA | CTD | PMID:11896290 |
| 17beta-estradiol | decreases expression | EXP | | 6480464 | Estradiol results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:20945400 |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | ESR1 protein affects the reaction [Estradiol results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:19264808 |
| 17beta-estradiol | multiple interactions | EXP | | 6480464 | dibenzoylmethane inhibits the reaction [Estradiol results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:16051634 |
| 17beta-hydroxy-5alpha-androstan-3-one | multiple interactions | ISO | RGD:2199 | 6480464 | Dihydrotestosterone inhibits the reaction [Dehydroepiandrosterone results in increased expression of BCL2 protein] | CTD | PMID:16407456 |
| 2,2',4,4',5,5'-hexachlorobiphenyl | decreases expression | ISO | RGD:10230 | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of BCL2 protein | CTD | PMID:21291966 |
| 2,2',4,4',5,5'-hexachlorobiphenyl | decreases expression | EXP | | 6480464 | 2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of BCL2 protein | CTD | PMID:20638727 |
| 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | RGD:10230 | 6480464 | [2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of BCL2 protein | CTD | PMID:21291966 |
| 2,2,2-tetramine | decreases expression | EXP | | 6480464 | Trientine results in decreased expression of BCL2 protein | CTD | PMID:11369509 |
| 2,2,2-tetramine | increases expression | EXP | | 6480464 | Trientine results in increased expression of BCL2 protein | CTD | PMID:14513838 |
| 2,2,2-tetramine | multiple interactions | EXP | | 6480464 | Copper Sulfate inhibits the reaction [Trientine results in increased expression of BCL2 protein] | CTD | PMID:14513838 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 protein | CTD | PMID:9677421 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:10230 | 6480464 | Tetrachlorodibenzodioxin affects the expression of BCL2 mRNA | CTD | PMID:21570461 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:10230 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 mRNA | CTD | PMID:19770486 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:10230 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 mRNA | CTD | PMID:19933214 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:2199 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 mRNA | CTD | PMID:15965093 PMID:19520675 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:10230 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 mRNA | CTD | PMID:20044593 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:10230 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 mRNA | CTD | PMID:19933214 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:2199 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 protein | CTD | PMID:15965093 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:2199 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of BCL2 mRNA; more ... | CTD | PMID:15965093 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of BCL2 mRNA | CTD | PMID:20044593 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:2199 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 mRNA | CTD | PMID:19520675 PMID:15965093 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:10230 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BCL2 mRNA | CTD | PMID:19933214 PMID:20044593 |
| 2,4,6-trinitrobenzenesulfonic acid | decreases expression | ISO | RGD:2199 | 6480464 | Trinitrobenzenesulfonic Acid results in decreased expression of BCL2 mRNA | CTD | PMID:15502641 |
| 2,4,6-trinitrobenzenesulfonic acid | multiple interactions | ISO | RGD:2199 | 6480464 | Losartan promotes the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of BCL2 mRNA] | CTD | PMID:15502641 |
| 2-acetamidofluorene | increases expression | ISO | RGD:2199 | 6480464 | 2-Acetylaminofluorene results in increased expression of BCL2 mRNA | CTD | PMID:19167416 |
| 2-acetamidofluorene | multiple interactions | ISO | RGD:2199 | 6480464 | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of BCL2 protein; more ... | CTD | PMID:11915028 |
| 2-amino-2-deoxy-D-galactopyranose | multiple interactions | ISO | RGD:10230 | 6480464 | baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; more ... | CTD | PMID:20850421 |
| 2-amino-2-deoxy-D-galactopyranose | multiple interactions | ISO | RGD:10230 | 6480464 | [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; more ... | CTD | PMID:20558151 |
| 2-trans,6-trans,10-trans-geranylgeranyl diphosphate | multiple interactions | EXP | | 6480464 | geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA] | CTD | PMID:18031796 |
| 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine | multiple interactions | ISO | RGD:2199 | 6480464 | [Puromycin Aminonucleoside co-treated with Melatonin] results in increased expression of BCL2 protein | CTD | PMID:14993511 |
| 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine | increases expression | ISO | RGD:2199 | 6480464 | Puromycin Aminonucleoside results in increased expression of BCL2 protein | CTD | PMID:15113391 PMID:16152783 |
| 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine | increases expression | ISO | RGD:2199 | 6480464 | Puromycin Aminonucleoside results in increased expression of BCL2 protein | CTD | PMID:16152783 PMID:15113391 |
| 3,3',4,4',5-pentachlorobiphenyl | multiple interactions | EXP | | 6480464 | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein] | CTD | PMID:20840854 |
| 3,3',5'-triiodothyronine | multiple interactions | ISO | RGD:2199 | 6480464 | alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of BCL2 protein] | CTD | PMID:16135673 |
| 3,3',5'-triiodothyronine | increases activity | ISO | RGD:2199 | 6480464 | Triiodothyronine, Reverse results in increased activity of BCL2 protein | CTD | PMID:16135673 |
| 3,3',5,5'-tetrabromobisphenol A | decreases expression | ISO | RGD:10230 | 6480464 | tetrabromobisphenol A results in decreased expression of BCL2 mRNA | CTD | PMID:22677475 |
| 3,3',5-triiodo-L-thyronine | multiple interactions | EXP | | 6480464 | Triiodothyronine promotes the reaction [Am 80 results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:11201846 |
| 3,3',5-triiodo-L-thyronine | increases expression | ISO | RGD:2199 | 6480464 | Triiodothyronine results in increased expression of BCL2 protein | CTD | PMID:16021636 |
| 3,3',5-triiodo-L-thyronine | increases expression | EXP | | 6480464 | Triiodothyronine results in increased expression of BCL2 protein | CTD | PMID:16021636 |
| 3,3'-diindolylmethane | decreases expression | EXP | | 6480464 | 3,3'-diindolylmethane results in decreased expression of BCL2 protein | CTD | PMID:16580691 |
| 3,3'-diindolylmethane | decreases expression | EXP | | 6480464 | 3,3'-diindolylmethane results in decreased expression of BCL2 protein | CTD | PMID:16580691 PMID:22290291 |
| 3,3'-diindolylmethane | multiple interactions | EXP | | 6480464 | 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein] | CTD | PMID:16580691 |
| 3,4-dihydroxybenzoic acid | multiple interactions | ISO | RGD:2199 | 6480464 | protocatechuic acid inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] | CTD | PMID:18082360 |
| 3,4-methylenedioxymethamphetamine | increases expression | ISO | RGD:10230 | 6480464 | N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of BCL2 mRNA | CTD | PMID:20188158 |
| 3-methylthiopropanal | affects response to substance | ISO | RGD:10230 | 6480464 | BCL2 protein affects the susceptibility to methional | CTD | PMID:8611183 |
| 3-nitropropanoic acid | multiple interactions | ISO | RGD:2199 | 6480464 | [Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BCL2 protein | CTD | PMID:15571979 |
| 3-nitropropanoic acid | multiple interactions | ISO | RGD:2199 | 6480464 | BCL2 protein promotes the reaction [BDNF protein results in decreased susceptibility to 3-nitropropionic acid] | CTD | PMID:19428112 |
| 4'-epidoxorubicin | increases expression | EXP | | 6480464 | Epirubicin results in increased expression of BCL2 mRNA | CTD | PMID:14503796 |
| 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one | increases expression | EXP | | 6480464 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BCL2 mRNA | CTD | PMID:16582591 PMID:16835749 |
| 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one | increases expression | EXP | | 6480464 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BCL2 protein | CTD | PMID:18508827 PMID:21776270 |
| 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one | multiple interactions | EXP | | 6480464 | U 0126 inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BCL2 protein]; more ... | CTD | PMID:18508827 |
| 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one | multiple interactions | EXP | | 6480464 | Bungarotoxins inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BCL2 mRNA] | CTD | PMID:16835749 |
| 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one | increases expression | EXP | | 6480464 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BCL2 mRNA | CTD | PMID:16835749 PMID:16582591 |
| 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one | increases expression | EXP | | 6480464 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BCL2 protein | CTD | PMID:18508827 |
| 4-hydroxyphenyl retinamide | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Fenretinide | CTD | PMID:7811993 |
| 4-hydroxyphenyl retinamide | decreases expression | EXP | | 6480464 | Fenretinide results in decreased expression of BCL2 protein | CTD | PMID:16187019 PMID:17159502 |
| 4-hydroxyphenyl retinamide | decreases expression | EXP | | 6480464 | Fenretinide results in decreased expression of BCL2 protein | CTD | PMID:17159502 PMID:16187019 |
| 4-hydroxyphenyl retinamide | multiple interactions | EXP | | 6480464 | Fenretinide inhibits the reaction [TNF protein results in increased expression of BCL2 protein] | CTD | PMID:16230421 |
| 4-hydroxyphenyl retinamide | decreases expression | EXP | | 6480464 | Fenretinide results in decreased expression of BCL2 mRNA | CTD | PMID:7811993 |
| 4-hydroxyphenyl retinamide | decreases reaction | EXP | | 6480464 | Fenretinide inhibits the reaction BCL2 protein | CTD | PMID:16230421 |
| 4-hydroxyphenyl retinamide | multiple interactions | EXP | | 6480464 | [Fenretinide co-treated with Carmustine] results in decreased expression of BCL2 protein | CTD | PMID:16187019 |
| 4-nitroaniline | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [resveratrol promotes the reaction [[CASP3 protein results in increased cleavage of aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide] which results in increased chemical synthesis of 4-nitroaniline]] | CTD | PMID:11577002 |
| 4-nonylphenol | increases expression | EXP | | 6480464 | 4-nonylphenol results in increased expression of BCL2 mRNA | CTD | PMID:15461258 |
| 5-aminolevulinic acid | decreases expression | EXP | | 6480464 | Aminolevulinic Acid analog results in decreased expression of BCL2 mRNA | CTD | PMID:20676910 |
| 5-aza-2'-deoxycytidine | multiple interactions | EXP | | 6480464 | [decitabine co-treated with epigallocatechin gallate] affects the expression of BCL2 mRNA | CTD | PMID:18250043 |
| 5-aza-2'-deoxycytidine | multiple interactions | ISO | RGD:2199 | 6480464 | [Paraquat co-treated with decitabine] results in decreased expression of BCL2 protein | CTD | PMID:22796470 |
| 5-aza-2'-deoxycytidine | increases expression | EXP | | 6480464 | decitabine results in increased expression of BCL2 mRNA | CTD | PMID:21515334 |
| 5-aza-2'-deoxycytidine | decreases expression | EXP | | 6480464 | decitabine results in decreased expression of BCL2 protein | CTD | PMID:18636160 |
| 5-azacytidine | decreases expression | EXP | | 6480464 | Azacitidine results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:15547111 |
| 5-azacytidine | multiple interactions | EXP | | 6480464 | pifithrin inhibits the reaction [Azacitidine results in decreased expression of BCL2 protein]; more ... | CTD | PMID:15547111 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | BAY 11-7085 inhibits the reaction [[Fluorouracil co-treated with RNF34 protein] results in increased expression of BCL2 mRNA] | CTD | PMID:16407826 |
| 5-fluorouracil | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:15177426 more ... |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | [wogonin co-treated with Fluorouracil] results in decreased expression of BCL2 protein | CTD | PMID:20570612 |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:15754201 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 mRNA | CTD | PMID:15996812 more ... |
| 5-fluorouracil | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:15177426 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:15996812 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 mRNA | CTD | PMID:17589894 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:18205257 more ... |
| 5-fluorouracil | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:15177426 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 mRNA | CTD | PMID:17287894 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:15754201 more ... |
| 5-fluorouracil | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:16412276 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:15754201 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 mRNA | CTD | PMID:15996812 more ... |
| 5-fluorouracil | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:16332177 more ... |
| 5-fluorouracil | decreases expression | ISO | RGD:10230 | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:18567086 PMID:20844880 |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:16557594 more ... |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 mRNA | CTD | PMID:15996812 more ... |
| 5-fluorouracil | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:15177426 more ... |
| 5-fluorouracil | increases expression | ISO | RGD:2199 | 6480464 | Fluorouracil results in increased expression of BCL2 mRNA | CTD | PMID:16888818 |
| 5-fluorouracil | multiple interactions | ISO | RGD:10230 | 6480464 | IL1RN protein inhibits the reaction [Fluorouracil results in decreased expression of BCL2 protein] | CTD | PMID:20844880 |
| 5-fluorouracil | decreases expression | ISO | RGD:10230 | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:20844880 PMID:18567086 |
| 5-fluorouracil | multiple interactions | ISO | RGD:10230 | 6480464 | [Fluorouracil co-treated with Chitosan co-treated with polyaspartate] results in decreased expression of BCL2 protein | CTD | PMID:18567086 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:16929163 |
| 5-fluorouracil | increases phosphorylation | EXP | | 6480464 | Fluorouracil results in increased phosphorylation of BCL2 protein | CTD | PMID:7654318 |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 protein | CTD | PMID:16557594 more ... |
| 5-fluorouracil | increases expression | EXP | | 6480464 | Fluorouracil results in increased expression of BCL2 mRNA | CTD | PMID:14503796 |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 | CTD | PMID:9388485 |
| 5-fluorouracil | decreases expression | EXP | | 6480464 | Fluorouracil results in decreased expression of BCL2 mRNA | CTD | PMID:17589894 more ... |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | Fluorouracil promotes the reaction [gambogic acid results in decreased expression of BCL2 mRNA] | CTD | PMID:19084572 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | [Fluorouracil co-treated with RNF34 protein] results in increased expression of BCL2 protein | CTD | PMID:16596200 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | [Fluorouracil co-treated with irinotecan] results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:16391804 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | [Fluorouracil co-treated with irinotecan co-treated with vorinostat] results in decreased expression of BCL2 protein | CTD | PMID:15754201 |
| 5-fluorouracil | multiple interactions | EXP | | 6480464 | [Docosahexaenoic Acids co-treated with Fluorouracil] results in decreased expression of BCL2 mRNA | CTD | PMID:19015929 |
| 5-fluorouracil | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Fluorouracil | CTD | PMID:17439414 |
| 5-fluorouracil | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Fluorouracil | CTD | PMID:15177426 more ... |
| 6alpha-methylprednisolone | multiple interactions | ISO | RGD:2199 | 6480464 | Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2 mRNA]; more ... | CTD | PMID:17570061 |
| 7,12-dimethyltetraphene | increases expression | ISO | RGD:10230 | 6480464 | 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA | CTD | PMID:20103723 |
| 7,12-dimethyltetraphene | increases expression | ISO | RGD:10230 | 6480464 | 9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein | CTD | PMID:18791811 |
| 7,12-dimethyltetraphene | multiple interactions | ISO | RGD:10230 | 6480464 | resveratrol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein] | CTD | PMID:18791811 |
| 7,12-dimethyltetraphene | multiple interactions | ISO | RGD:10230 | 6480464 | [9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of BCL2 mRNA; more ... | CTD | PMID:20537511 |
| 7,12-dimethyltetraphene | multiple interactions | ISO | RGD:10230 | 6480464 | [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:20103723 |
| 8-bromo-3',5'-cyclic AMP | decreases expression | EXP | | 6480464 | 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BCL2 | CTD | PMID:11802967 |
| 9,11,13-octadecatrienoic acid | decreases expression | EXP | | 6480464 | eleostearic acid results in decreased expression of BCL2 protein | CTD | PMID:15961301 |
| 9-cis-retinoic acid | decreases expression | EXP | | 6480464 | alitretinoin results in decreased expression of BCL2 protein | CTD | PMID:16109544 more ... |
| 9-cis-retinoic acid | decreases expression | EXP | | 6480464 | alitretinoin results in decreased expression of BCL2 protein | CTD | PMID:12189556 more ... |
| 9-cis-retinoic acid | decreases expression | EXP | | 6480464 | alitretinoin results in decreased expression of BCL2 protein | CTD | PMID:12189556 more ... |
| 9-cis-retinoic acid | decreases expression | EXP | | 6480464 | alitretinoin results in decreased expression of BCL2 protein | CTD | PMID:17077328 more ... |
| 9-cis-retinoic acid | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to alitretinoin | CTD | PMID:12189556 |
| 9-cis-retinoic acid | decreases expression | EXP | | 6480464 | alitretinoin results in decreased expression of BCL2 protein | CTD | PMID:16109544 more ... |
| 9-cis-retinoic acid | decreases expression | EXP | | 6480464 | alitretinoin results in decreased expression of BCL2 | CTD | PMID:16909596 |
| acetaldehyde | decreases expression | EXP | | 6480464 | Acetaldehyde results in decreased expression of BCL2 mRNA | CTD | PMID:16814256 |
| acetaldehyde | multiple interactions | EXP | | 6480464 | ADIPOQ protein inhibits the reaction [Acetaldehyde results in decreased expression of BCL2 mRNA] | CTD | PMID:16814256 |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 protein | CTD | PMID:16199534 more ... |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 protein | CTD | PMID:12490308 more ... |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 mRNA | CTD | PMID:16199534 more ... |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 protein | CTD | PMID:12490308 more ... |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 mRNA | CTD | PMID:18564172 more ... |
| acetylsalicylic acid | multiple interactions | ISO | RGD:2199 | 6480464 | Aspirin inhibits the reaction [Azoxymethane results in increased expression of BCL2 mRNA] | CTD | PMID:20043115 |
| acetylsalicylic acid | increases expression | EXP | | 6480464 | Aspirin results in increased expression of BCL2 mRNA | CTD | PMID:17342322 |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 protein | CTD | PMID:19424877 more ... |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 mRNA | CTD | PMID:20457246 more ... |
| acetylsalicylic acid | decreases expression | ISO | RGD:10230 | 6480464 | Aspirin results in decreased expression of BCL2 protein | CTD | PMID:20886344 |
| acetylsalicylic acid | increases expression | EXP | | 6480464 | Aspirin results in increased expression of BCL2 protein | CTD | PMID:18636671 |
| acetylsalicylic acid | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Aspirin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; more ... | CTD | PMID:16199534 |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 protein | CTD | PMID:19424877 more ... |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 mRNA | CTD | PMID:18564172 PMID:16199534 |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 protein | CTD | PMID:19966835 more ... |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 mRNA | CTD | PMID:20457246 more ... |
| acetylsalicylic acid | decreases expression | EXP | | 6480464 | Aspirin results in decreased expression of BCL2 protein | CTD | PMID:18564172 more ... |
| acrylonitrile | decreases expression | EXP | | 6480464 | Acrylonitrile results in decreased expression of BCL2 protein | CTD | PMID:16173056 |
| actinomycin D | multiple interactions | EXP | | 6480464 | Dactinomycin inhibits the reaction [IL1B results in increased expression of BCL2 protein]; more ... | CTD | PMID:16492401 |
| actinomycin D | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Dactinomycin results in increased susceptibility to TNF protein] | CTD | PMID:11880364 |
| actinomycin D | multiple interactions | EXP | | 6480464 | Morphine inhibits the reaction [Dactinomycin results in decreased expression of BCL2 protein]; more ... | CTD | PMID:12927789 |
| actinomycin D | decreases expression | EXP | | 6480464 | Dactinomycin results in decreased expression of BCL2 protein | CTD | PMID:12927789 |
| actinomycin D | decreases expression | EXP | | 6480464 | Dactinomycin results in decreased expression of BCL2 mRNA | CTD | PMID:17581298 |
| actinomycin D | multiple interactions | EXP | | 6480464 | Dactinomycin inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:11726273 |
| afimoxifene | decreases expression | EXP | | 6480464 | 4-hydroxytamoxifen results in decreased expression of BCL2 mRNA | CTD | PMID:19698761 |
| aflatoxin B1 | decreases expression | ISO | RGD:10230 | 6480464 | Aflatoxin B1 results in decreased expression of BCL2 mRNA | CTD | PMID:19770486 |
| aflatoxin B1 | multiple interactions | EXP | | 6480464 | Nicotine inhibits the reaction [Aflatoxin B1 results in decreased expression of BCL2 protein]; more ... | CTD | PMID:22743290 |
| aflatoxin B1 | decreases expression | EXP | | 6480464 | Aflatoxin B1 results in decreased expression of BCL2 protein | CTD | PMID:22743290 |
| alachlor | increases expression | EXP | | 6480464 | alachlor results in increased expression of BCL2 protein | CTD | PMID:10545406 |
| alachlor | multiple interactions | EXP | | 6480464 | PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to alachlor] | CTD | PMID:12730627 |
| alachlor | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [alachlor results in increased expression of BCL2 protein] | CTD | PMID:10545406 |
| alachlor | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to alachlor | CTD | PMID:12730627 |
| alantolactone | increases expression | EXP | | 6480464 | alantolactone results in increased expression of BCL2 protein | CTD | PMID:22721982 |
| albuterol | decreases expression | EXP | | 6480464 | Albuterol results in decreased expression of BCL2 | CTD | PMID:11802967 |
| all-trans-acitretin | decreases expression | EXP | | 6480464 | Acitretin results in decreased expression of BCL2 protein | CTD | PMID:16196285 PMID:16109552 |
| all-trans-acitretin | decreases expression | EXP | | 6480464 | Acitretin results in decreased expression of BCL2 protein | CTD | PMID:16109552 PMID:16196285 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [1,5-isoquinolinediol co-treated with Tretinoin] results in decreased expression of BCL2 protein; more ... | CTD | PMID:10713328 |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:10713328 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 mRNA | CTD | PMID:12644474 more ... |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with arsenic trioxide] results in decreased expression of BCL2 mRNA | CTD | PMID:15894607 |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:10713328 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 mRNA | CTD | PMID:12644474 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 mRNA | CTD | PMID:15498508 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:16572199 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 mRNA | CTD | PMID:15770638 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:17701358 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:14592536 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 mRNA | CTD | PMID:15770638 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:16242776 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 mRNA | CTD | PMID:9342185 more ... |
| all-trans-retinoic acid | decreases expression | ISO | RGD:10230 | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:16712891 PMID:11851873 |
| all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of BCL2 mRNA | CTD | PMID:21934132 |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:16242776 more ... |
| all-trans-retinoic acid | decreases expression | ISO | RGD:2199 | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:17962954 |
| all-trans-retinoic acid | decreases expression | ISO | RGD:10230 | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:11851873 PMID:16712891 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [troglitazone co-treated with Tretinoin] results in decreased expression of BCL2 protein | CTD | PMID:9671760 |
| all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of BCL2 protein | CTD | PMID:10750663 |
| all-trans-retinoic acid | increases phosphorylation | EXP | | 6480464 | Tretinoin results in increased phosphorylation of BCL2 protein | CTD | PMID:18098270 |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 protein | CTD | PMID:16109552 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 mRNA | CTD | PMID:15770638 more ... |
| all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of BCL2 | CTD | PMID:16909596 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein | CTD | PMID:18098270 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with zoledronic acid] results in decreased expression of BCL2 protein | CTD | PMID:20349282 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with IFNG protein] results in decreased expression of BCL2 protein | CTD | PMID:17960384 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with Melatonin] results in decreased expression of BCL2 protein | CTD | PMID:9649124 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with Paclitaxel] results in decreased expression of BCL2 protein | CTD | PMID:17701358 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | [Melatonin co-treated with Tretinoin] results in decreased expression of BCL2 protein | CTD | PMID:10965999 |
| all-trans-retinoic acid | multiple interactions | EXP | | 6480464 | leptomycin B inhibits the reaction [Tretinoin results in decreased expression of BCL2 protein] | CTD | PMID:14592536 |
| all-trans-retinol | decreases expression | ISO | RGD:2199 | 6480464 | Vitamin A results in decreased expression of BCL2 protein | CTD | PMID:16216918 |
| aluminium trichloride | decreases expression | ISO | RGD:2199 | 6480464 | aluminum chloride results in decreased expression of BCL2 mRNA | CTD | PMID:17096939 PMID:23065425 |
| aluminium trichloride | increases expression | ISO | RGD:2199 | 6480464 | aluminum chloride results in increased expression of BCL2 protein | CTD | PMID:17967740 |
| aluminium trichloride | decreases expression | ISO | RGD:2199 | 6480464 | aluminum chloride results in decreased expression of BCL2 mRNA | CTD | PMID:16535832 more ... |
| aluminium trichloride | decreases expression | ISO | RGD:2199 | 6480464 | aluminum chloride results in decreased expression of BCL2 protein; more ... | CTD | PMID:17096939 |
| amidotrizoic acid | multiple interactions | EXP | | 6480464 | [Diatrizoate co-treated with Iodine] results in increased expression of BCL2 protein | CTD | PMID:17173243 |
| amifostine | multiple interactions | EXP | | 6480464 | [Amifostine co-treated with Doxorubicin] results in decreased expression of BCL2 mRNA | CTD | PMID:15985719 |
| aminoguanidine | multiple interactions | ISO | RGD:10230 | 6480464 | pimagedine inhibits the reaction [Cardiotoxins results in increased phosphorylation of BCL2 protein] | CTD | PMID:17786558 |
| aminoguanidine | multiple interactions | ISO | RGD:10230 | 6480464 | [pimagedine results in decreased activity of NOS2 protein] which results in decreased expression of BCL2 mRNA | CTD | PMID:17135264 |
| amiodarone | decreases expression | ISO | RGD:2199 | 6480464 | Amiodarone results in decreased expression of BCL2 protein | CTD | PMID:21224497 |
| amitriptyline | multiple interactions | ISO | RGD:2199 | 6480464 | Amitriptyline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] | CTD | PMID:19135049 |
| amlodipine | multiple interactions | EXP | | 6480464 | Amlodipine inhibits the reaction [AGT results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:21376258 |
| amlodipine | multiple interactions | ISO | RGD:2199 | 6480464 | Amlodipine inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein] | CTD | PMID:19698708 |
| amlodipine | multiple interactions | ISO | RGD:2199 | 6480464 | Amlodipine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:17234320 |
| ammonium chloride | affects expression | ISO | RGD:2199 | 6480464 | Ammonium Chloride affects the expression of BCL2 mRNA | CTD | PMID:16483693 |
| amphetamine | decreases expression | ISO | RGD:10230 | 6480464 | Amphetamine results in decreased expression of BCL2 protein | CTD | PMID:15731293 |
| amsacrine | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Amsacrine | CTD | PMID:10920913 |
| antimycin A | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Antimycin A | CTD | PMID:12730627 |
| antimycin A | multiple interactions | EXP | | 6480464 | PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to Antimycin A] | CTD | PMID:12730627 |
| apigenin | decreases expression | EXP | | 6480464 | Apigenin results in decreased expression of BCL2 protein | CTD | PMID:15486995 |
| apigenin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Apigenin | CTD | PMID:15486995 |
| apocynin | multiple interactions | ISO | RGD:2199 | 6480464 | acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of BCL2 protein] | CTD | PMID:22431579 |
| arachidonic acid | decreases expression | EXP | | 6480464 | Arachidonic Acid results in decreased expression of BCL2 protein | CTD | PMID:19540902 |
| arachidonic acid | decreases expression | EXP | | 6480464 | Arachidonic Acid results in decreased expression of BCL2 protein | CTD | PMID:19540902 PMID:19720122 |
| arachidonic acid | multiple interactions | EXP | | 6480464 | [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; more ... | CTD | PMID:19620254 |
| arachidonic acid | multiple interactions | EXP | | 6480464 | 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; more ... | CTD | PMID:19540902 |
| Aroclor 1254 | increases expression | ISO | RGD:2199 | 6480464 | Chlorodiphenyl (54% Chlorine) results in increased expression of BCL2 mRNA; more ... | CTD | PMID:23281070 |
| Aroclor 1254 | multiple interactions | ISO | RGD:2199 | 6480464 | Quercetin inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in increased expression of BCL2 protein]; more ... | CTD | PMID:23281070 |
| arsenic acid | increases expression | ISO | RGD:10230 | 6480464 | arsenic acid results in increased expression of BCL2 mRNA | CTD | PMID:8946558 |
| arsenic atom | increases expression | EXP | | 6480464 | Arsenic results in increased expression of BCL2 protein | CTD | PMID:12899209 |
| arsenic atom | increases expression | ISO | RGD:2199 | 6480464 | Arsenic results in increased expression of BCL2 protein | CTD | PMID:11756236 |
| arsenite(3-) | decreases expression | EXP | | 6480464 | arsenite results in decreased expression of BCL2 mRNA alternative form; more ... | CTD | PMID:20083129 |
| arsenite(3-) | increases expression | ISO | RGD:2199 | 6480464 | arsenite results in increased expression of BCL2 protein | CTD | PMID:18077580 |
| arsenite(3-) | multiple interactions | ISO | RGD:2199 | 6480464 | Acetylcysteine inhibits the reaction [arsenite results in increased expression of BCL2 protein] | CTD | PMID:18077580 |
| asbestos | increases expression | EXP | | 6480464 | Asbestos results in increased expression of BCL2 mRNA | CTD | PMID:22398240 |
| asbestos | increases expression | EXP | | 6480464 | Asbestos results in increased expression of BCL2 mRNA | CTD | PMID:22076105 PMID:22398240 |
| astemizole | decreases expression | ISO | RGD:2199 | 6480464 | Astemizole results in decreased expression of BCL2 mRNA | CTD | PMID:20221588 |
| ATP | multiple interactions | EXP | | 6480464 | [Adenosine Triphosphate binds to P2RY11 protein] which results in decreased expression of BCL2 protein | CTD | PMID:21503959 |
| atrazine | decreases expression | EXP | | 6480464 | Atrazine results in decreased expression of BCL2 protein; more ... | CTD | PMID:21333729 |
| atrazine | multiple interactions | ISO | RGD:2199 | 6480464 | kolaviron inhibits the reaction [Atrazine affects the expression of BCL2] | CTD | PMID:21726175 |
| atrazine | affects expression | ISO | RGD:2199 | 6480464 | Atrazine affects the expression of BCL2 | CTD | PMID:21726175 |
| atrazine | multiple interactions | EXP | | 6480464 | kolaviron inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:21333729 |
| auranofin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Auranofin results in increased activity of CASP3 protein] | CTD | PMID:18789312 |
| azadirachtin A | decreases expression | EXP | | 6480464 | azadirachtin results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:20429769 |
| baicalein | multiple interactions | ISO | RGD:10230 | 6480464 | baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form] | CTD | PMID:20850421 |
| benazepril | increases expression | ISO | RGD:2199 | 6480464 | benazepril results in increased expression of BCL2 protein | CTD | PMID:20026869 |
| benomyl | multiple interactions | EXP | | 6480464 | Benomyl inhibits the reaction [BCL2 protein binds to BAX protein] | CTD | PMID:16903866 |
| benomyl | increases phosphorylation | EXP | | 6480464 | Benomyl results in increased phosphorylation of BCL2 protein | CTD | PMID:16903866 |
| benzene | decreases expression | EXP | | 6480464 | Benzene results in decreased expression of BCL2 mRNA | CTD | PMID:18724895 |
| benzene | multiple interactions | ISO | RGD:10230 | 6480464 | TRP53 protein affects the reaction [Benzene results in increased expression of BCL2 mRNA] | CTD | PMID:11896287 |
| benzene | affects expression | ISO | RGD:10230 | 6480464 | Benzene affects the expression of BCL2 mRNA | CTD | PMID:11896287 |
| benzene | increases expression | EXP | | 6480464 | Benzene results in increased expression of BCL2 protein | CTD | PMID:20850422 |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:20064835 more ... |
| benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of BCL2 protein | CTD | PMID:18174961 PMID:20850422 |
| benzo[a]pyrene | multiple interactions | EXP | | 6480464 | Benzo(a)pyrene inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:18174961 |
| benzo[a]pyrene | increases expression | ISO | RGD:10230 | 6480464 | Benzo(a)pyrene results in increased expression of BCL2 mRNA | CTD | PMID:18656336 more ... |
| benzo[a]pyrene | increases expression | ISO | RGD:10230 | 6480464 | Benzo(a)pyrene results in increased expression of BCL2 protein | CTD | PMID:21964900 |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:11782367 more ... |
| benzo[a]pyrene | increases expression | ISO | RGD:10230 | 6480464 | Benzo(a)pyrene results in increased expression of BCL2 mRNA | CTD | PMID:18656336 PMID:22228805 |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 protein | CTD | PMID:20840854 |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:11782367 more ... |
| benzo[a]pyrene | multiple interactions | EXP | | 6480464 | 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein]; more ... | CTD | PMID:20840854 |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:11782367 more ... |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:11782367 more ... |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:21871943 more ... |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:20064835 more ... |
| benzo[a]pyrene | decreases expression | ISO | RGD:10230 | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:19770486 |
| benzo[a]pyrene | multiple interactions | ISO | RGD:10230 | 6480464 | epicatechin gallate inhibits the reaction [Benzo(a)pyrene results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:18656336 |
| benzo[a]pyrene | increases expression | ISO | RGD:10230 | 6480464 | Benzo(a)pyrene results in increased expression of BCL2 mRNA | CTD | PMID:18656336 |
| benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of BCL2 mRNA | CTD | PMID:20064835 more ... |
| benzo[a]pyrene | multiple interactions | EXP | | 6480464 | [Benzo(a)pyrene co-treated with Nitrogen Oxides] results in increased expression of BCL2 protein | CTD | PMID:16041517 |
| benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of BCL2 protein | CTD | PMID:20850422 |
| benzo[b]fluoranthene | increases expression | EXP | | 6480464 | benzo(b)fluoranthene results in increased expression of BCL2 protein | CTD | PMID:21776270 |
| berberine | decreases expression | EXP | | 6480464 | Berberine results in decreased expression of BCL2 protein | CTD | PMID:16505103 |
| berberine | decreases expression | EXP | | 6480464 | Berberine results in decreased expression of BCL2 protein | CTD | PMID:16505103 PMID:20656010 |
| berberine | decreases expression | EXP | | 6480464 | Berberine results in decreased expression of BCL2 mRNA | CTD | PMID:20656010 |
| bezafibrate | decreases expression | ISO | RGD:2199 | 6480464 | Bezafibrate results in decreased expression of BCL2 mRNA | CTD | PMID:12704018 |
| bezafibrate | multiple interactions | ISO | RGD:2199 | 6480464 | Bezafibrate inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2 protein] | CTD | PMID:12704018 |
| bicalutamide | increases expression | EXP | | 6480464 | bicalutamide results in increased expression of BCL2 | CTD | PMID:11845989 |
| biochanin A | decreases expression | EXP | | 6480464 | biochanin A results in decreased expression of BCL2 protein | CTD | PMID:12791511 |
| bis(2-chloroethyl) sulfide | decreases expression | EXP | | 6480464 | Mustard Gas results in decreased expression of BCL2 protein | CTD | PMID:9665388 PMID:11428642 |
| bis(2-chloroethyl) sulfide | affects localization | ISO | RGD:10230 | 6480464 | Mustard Gas affects the localization of BCL2 protein | CTD | PMID:19560481 |
| bis(2-chloroethyl) sulfide | decreases expression | EXP | | 6480464 | Mustard Gas results in decreased expression of BCL2 protein | CTD | PMID:11428642 PMID:9665388 |
| bis(2-ethylhexyl) phthalate | decreases expression | EXP | | 6480464 | Diethylhexyl Phthalate results in decreased expression of BCL2 mRNA | CTD | PMID:22155658 |
| bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of BCL2 protein | CTD | PMID:21277958 |
| bisphenol A | decreases expression | ISO | RGD:2199 | 6480464 | bisphenol A results in decreased expression of BCL2 protein | CTD | PMID:16909604 PMID:23328667 |
| bisphenol A | multiple interactions | EXP | | 6480464 | ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate inhibits the reaction [bisphenol A results in increased expression of BCL2 protein] | CTD | PMID:19796866 |
| bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of BCL2 protein | CTD | PMID:19270784 PMID:19796866 |
| bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A results in increased activity of ESR1 protein] which results in increased expression of BCL2 mRNA | CTD | PMID:22403704 |
| bisphenol A | decreases expression | ISO | RGD:2199 | 6480464 | bisphenol A results in decreased expression of BCL2 protein | CTD | PMID:16909604 |
| bisphenol A | decreases expression | ISO | RGD:10230 | 6480464 | bisphenol A results in decreased expression of BCL2 protein; more ... | CTD | PMID:11906184 |
| bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of BCL2 mRNA | CTD | PMID:15461258 |
| bisphenol A | multiple interactions | EXP | | 6480464 | [Doxorubicin co-treated with bisphenol A] results in increased expression of BCL2 protein | CTD | PMID:19270784 |
| bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of BCL2 protein | CTD | PMID:19270784 |
| brassinolide | decreases expression | EXP | | 6480464 | brassinolide results in decreased expression of BCL2 protein | CTD | PMID:17557751 PMID:20833159 |
| brassinolide | decreases expression | EXP | | 6480464 | brassinolide results in decreased expression of BCL2 protein | CTD | PMID:20833159 PMID:17557751 |
| brassinolide | decreases expression | EXP | | 6480464 | brassinolide results in decreased expression of BCL2 protein | CTD | PMID:17557751 |
| bucladesine | multiple interactions | EXP | | 6480464 | adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]] | CTD | PMID:16822680 |
| bucladesine | decreases expression | EXP | | 6480464 | Bucladesine results in decreased expression of BCL2 protein | CTD | PMID:10697531 |
| budesonide | decreases expression | EXP | | 6480464 | Budesonide results in decreased expression of BCL2 protein | CTD | PMID:15475437 |
| bufalin | decreases expression | EXP | | 6480464 | bufalin results in decreased expression of BCL2 mRNA | CTD | PMID:7658701 |
| cadmium atom | multiple interactions | ISO | RGD:2199 | 6480464 | Lithium inhibits the reaction [Cadmium results in decreased expression of BCL2 protein] | CTD | PMID:20455018 |
| cadmium atom | increases expression | EXP | | 6480464 | Cadmium results in increased expression of BCL2 mRNA | CTD | PMID:21694771 |
| cadmium atom | increases expression | ISO | RGD:2199 | 6480464 | Cadmium results in increased expression of BCL2 protein | CTD | PMID:11781163 |
| cadmium atom | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Cadmium | CTD | PMID:11781163 |
| cadmium atom | decreases response to substance | ISO | RGD:2199 | 6480464 | BCL2 results in decreased susceptibility to Cadmium | CTD | PMID:12189181 |
| cadmium atom | decreases expression | ISO | RGD:2199 | 6480464 | Cadmium results in decreased expression of BCL2 protein | CTD | PMID:20455018 |
| cadmium dichloride | decreases expression | ISO | RGD:10230 | 6480464 | Cadmium Chloride results in decreased expression of BCL2 protein | CTD | PMID:19887573 PMID:21420465 |
| cadmium dichloride | decreases expression | ISO | RGD:10230 | 6480464 | Cadmium Chloride results in decreased expression of BCL2 protein | CTD | PMID:17706638 more ... |
| cadmium dichloride | decreases expression | ISO | RGD:10230 | 6480464 | Cadmium Chloride results in decreased expression of BCL2 protein | CTD | PMID:19887573 more ... |
| cadmium dichloride | decreases expression | ISO | RGD:10230 | 6480464 | Cadmium Chloride results in decreased expression of BCL2 mRNA | CTD | PMID:15501611 PMID:17499415 |
| cadmium dichloride | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein] | CTD | PMID:11341981 |
| cadmium dichloride | multiple interactions | ISO | RGD:10230 | 6480464 | piperidine inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] | CTD | PMID:17706638 |
| cadmium dichloride | decreases expression | ISO | RGD:10230 | 6480464 | Cadmium Chloride results in decreased expression of BCL2 protein | CTD | PMID:21420465 more ... |
| cadmium dichloride | decreases expression | ISO | RGD:10230 | 6480464 | Cadmium Chloride results in decreased expression of BCL2 mRNA | CTD | PMID:17499415 |
| cadmium dichloride | multiple interactions | ISO | RGD:10230 | 6480464 | pifithrin inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein]; more ... | CTD | PMID:19887573 |
| cadmium dichloride | decreases expression | ISO | RGD:10230 | 6480464 | Cadmium Chloride results in decreased expression of BCL2 protein | CTD | PMID:19887573 |
| cadmium dichloride | increases expression | ISO | RGD:2199 | 6480464 | Cadmium Chloride results in increased expression of BCL2 | CTD | PMID:11170127 |
| cadmium dichloride | multiple interactions | ISO | RGD:10230 | 6480464 | arjunolic acid inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] | CTD | PMID:21420465 |
| calciol | increases expression | EXP | | 6480464 | Cholecalciferol results in increased expression of BCL2 protein | CTD | PMID:18628207 |
| calcitriol | multiple interactions | EXP | | 6480464 | [Calcitriol co-treated with Genistein] results in decreased expression of BCL2 mRNA | CTD | PMID:15955619 |
| calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of BCL2 protein | CTD | PMID:12479363 more ... |
| calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of BCL2 protein | CTD | PMID:9528999 more ... |
| calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of BCL2 protein | CTD | PMID:12479363 more ... |
| calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of BCL2 mRNA | CTD | PMID:21592394 PMID:15955619 |
| calcitriol | increases expression | ISO | RGD:2199 | 6480464 | Calcitriol results in increased expression of BCL2 protein | CTD | PMID:17570329 |
| calcitriol | increases expression | ISO | RGD:10230 | 6480464 | Calcitriol results in increased expression of BCL2 | CTD | PMID:19603526 |
| calcitriol | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of BCL2 mRNA | CTD | PMID:21592394 |
| calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of BCL2 mRNA | CTD | PMID:15955619 PMID:21592394 |
| calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of BCL2 | CTD | PMID:8593782 |
| calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of BCL2 protein | CTD | PMID:10614618 more ... |
| calcitriol | multiple interactions | EXP | | 6480464 | [Calcitriol co-treated with Tretinoin] results in decreased expression of BCL2 protein | CTD | PMID:10713328 |
| camptothecin | decreases expression | EXP | | 6480464 | Camptothecin results in decreased expression of BCL2 protein | CTD | PMID:19481069 more ... |
| camptothecin | decreases expression | EXP | | 6480464 | Camptothecin results in decreased expression of BCL2 protein | CTD | PMID:10692111 more ... |
| camptothecin | decreases expression | EXP | | 6480464 | Camptothecin results in decreased expression of BCL2 protein | CTD | PMID:19481069 more ... |
| camptothecin | decreases response to substance | EXP | | 6480464 | BCL2 results in decreased susceptibility to Camptothecin | CTD | PMID:10896673 |
| camptothecin | multiple interactions | EXP | | 6480464 | 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in decreased expression of BCL2 protein] | CTD | PMID:19481069 |
| cantharidin | decreases expression | EXP | | 6480464 | Cantharidin results in decreased expression of BCL2 protein | CTD | PMID:16117893 |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:11275362 more ... |
| capsaicin | increases expression | EXP | | 6480464 | Capsaicin results in increased expression of BCL2 mRNA | CTD | PMID:19502594 more ... |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:11275362 more ... |
| capsaicin | decreases expression | ISO | RGD:10230 | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:17306913 more ... |
| capsaicin | decreases expression | ISO | RGD:10230 | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:15595419 more ... |
| capsaicin | increases expression | EXP | | 6480464 | Capsaicin results in increased expression of BCL2 mRNA | CTD | PMID:21310942 more ... |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:18405923 more ... |
| capsaicin | decreases expression | ISO | RGD:10230 | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:17306913 PMID:17295509 |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:18405923 more ... |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:11275362 more ... |
| capsaicin | increases expression | EXP | | 6480464 | Capsaicin results in increased expression of BCL2 mRNA | CTD | PMID:19502594 |
| capsaicin | decreases expression | ISO | RGD:10230 | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:17295509 PMID:17306913 |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:18991268 more ... |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of BCL2 | CTD | PMID:19002586 |
| capsaicin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Capsaicin | CTD | PMID:9580328 |
| capsaicin | decreases expression | ISO | RGD:10230 | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:17306913 more ... |
| capsaicin | increases expression | EXP | | 6480464 | Capsaicin results in increased expression of BCL2 mRNA | CTD | PMID:19502594 more ... |
| capsaicin | decreases expression | EXP | | 6480464 | Capsaicin results in decreased expression of BCL2 protein | CTD | PMID:11275362 more ... |
| carbachol | multiple interactions | ISO | RGD:10230 | 6480464 | Carbachol inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein] | CTD | PMID:10758335 |
| carbachol | increases expression | ISO | RGD:2199 | 6480464 | Carbachol results in increased expression of BCL2 protein | CTD | PMID:17708838 |
| carbachol | increases expression | ISO | RGD:10230 | 6480464 | Carbachol results in increased expression of BCL2 protein | CTD | PMID:19200344 |
| carbamazepine | increases expression | ISO | RGD:2199 | 6480464 | Carbamazepine results in increased expression of BCL2 mRNA; more ... | CTD | PMID:18719996 |
| carboplatin | decreases expression | EXP | | 6480464 | Carboplatin results in decreased expression of BCL2 mRNA | CTD | PMID:15996812 more ... |
| carboplatin | decreases expression | EXP | | 6480464 | Carboplatin results in decreased expression of BCL2 mRNA | CTD | PMID:17404015 more ... |
| carboplatin | decreases expression | EXP | | 6480464 | Carboplatin results in decreased expression of BCL2 mRNA | CTD | PMID:15996812 more ... |
| carboplatin | decreases expression | EXP | | 6480464 | Carboplatin results in decreased expression of BCL2 mRNA | CTD | PMID:15576332 more ... |
| carboplatin | decreases expression | EXP | | 6480464 | Carboplatin results in decreased expression of BCL2 protein | CTD | PMID:15996812 PMID:9664115 |
| carboplatin | decreases expression | EXP | | 6480464 | Carboplatin results in decreased expression of BCL2 mRNA | CTD | PMID:15576332 more ... |
| carboplatin | decreases expression | EXP | | 6480464 | Carboplatin results in decreased expression of BCL2 protein | CTD | PMID:9664115 PMID:15996812 |
| carmustine | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Carmustine | CTD | PMID:18430789 PMID:15332326 |
| carmustine | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Carmustine | CTD | PMID:15332326 PMID:18430789 |
| carmustine | decreases expression | EXP | | 6480464 | Carmustine results in decreased expression of BCL2 protein | CTD | PMID:15332326 PMID:20920327 |
| carmustine | multiple interactions | EXP | | 6480464 | [Fenretinide co-treated with Carmustine] results in decreased expression of BCL2 protein | CTD | PMID:16187019 |
| carmustine | decreases expression | EXP | | 6480464 | Carmustine results in decreased expression of BCL2 protein | CTD | PMID:20920327 PMID:15332326 |
| carvedilol | multiple interactions | ISO | RGD:2199 | 6480464 | carvedilol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA] | CTD | PMID:15380674 |
| carvedilol | increases expression | ISO | RGD:2199 | 6480464 | carvedilol results in increased expression of BCL2 mRNA | CTD | PMID:16909474 PMID:16780994 |
| carvedilol | affects expression | ISO | RGD:2199 | 6480464 | carvedilol affects the expression of BCL2 protein | CTD | PMID:22000973 |
| carvedilol | increases expression | ISO | RGD:2199 | 6480464 | carvedilol results in increased expression of BCL2 mRNA | CTD | PMID:16780994 PMID:16909474 |
| celastrol | decreases expression | EXP | | 6480464 | tripterine results in decreased expression of BCL2 protein | CTD | PMID:21466843 |
| celecoxib | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; more ... | CTD | PMID:20104024 |
| celecoxib | decreases expression | EXP | | 6480464 | celecoxib results in decreased expression of BCL2 protein | CTD | PMID:15911099 more ... |
| celecoxib | decreases expression | EXP | | 6480464 | celecoxib results in decreased expression of BCL2 protein | CTD | PMID:17612393 more ... |
| celecoxib | increases expression | EXP | | 6480464 | celecoxib results in increased expression of BCL2 mRNA | CTD | PMID:17342322 |
| celecoxib | decreases expression | EXP | | 6480464 | celecoxib results in decreased expression of BCL2 protein | CTD | PMID:16391871 more ... |
| celecoxib | multiple interactions | ISO | RGD:10230 | 6480464 | celecoxib promotes the reaction [Dihematoporphyrin Ether results in increased cleavage of BCL2 protein] | CTD | PMID:16230411 |
| celecoxib | decreases expression | EXP | | 6480464 | celecoxib results in decreased expression of BCL2 protein | CTD | PMID:16391871 more ... |
| celecoxib | multiple interactions | EXP | | 6480464 | celecoxib promotes the reaction [docetaxel results in increased expression of BCL2 protein]; more ... | CTD | PMID:15688368 |
| cetrorelix | decreases expression | EXP | | 6480464 | cetrorelix results in decreased expression of BCL2 protein | CTD | PMID:21062912 |
| chitosan | multiple interactions | ISO | RGD:10230 | 6480464 | [Fluorouracil co-treated with Chitosan co-treated with polyaspartate] results in decreased expression of BCL2 protein | CTD | PMID:18567086 |
| chlorambucil | decreases expression | EXP | | 6480464 | Chlorambucil results in decreased expression of BCL2 protein | CTD | PMID:8822937 PMID:11699414 |
| chlorambucil | multiple interactions | EXP | | 6480464 | IL4 protein inhibits the reaction [Chlorambucil results in decreased expression of BCL2 protein] | CTD | PMID:8822937 |
| chlorambucil | decreases expression | EXP | | 6480464 | Chlorambucil results in decreased expression of BCL2 protein | CTD | PMID:11699414 PMID:8822937 |
| chlorambucil | decreases expression | EXP | | 6480464 | Chlorambucil results in decreased expression of BCL2 mRNA | CTD | PMID:8822937 |
| chlordecone | increases expression | ISO | RGD:10230 | 6480464 | Chlordecone results in increased expression of BCL2 mRNA | CTD | PMID:17578864 |
| chloroacetic acid | decreases expression | ISO | RGD:10230 | 6480464 | chloroacetic acid results in decreased expression of BCL2 mRNA | CTD | PMID:23103613 |
| chloroacetic acid | multiple interactions | ISO | RGD:10230 | 6480464 | SB 203580 inhibits the reaction [chloroacetic acid results in decreased expression of BCL2 mRNA] | CTD | PMID:23103613 |
| chloroprene | decreases expression | ISO | RGD:10230 | 6480464 | Chloroprene results in decreased expression of BCL2 mRNA | CTD | PMID:23125180 |
| chlorpyrifos | decreases expression | EXP | | 6480464 | Chlorpyrifos results in decreased expression of BCL2 mRNA | CTD | PMID:18155347 |
| cholesterol | decreases expression | ISO | RGD:2199 | 6480464 | Cholesterol analog results in decreased expression of BCL2 mRNA | CTD | PMID:19477266 |
| choline | multiple interactions | ISO | RGD:10230 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of BCL2; more ... | CTD | PMID:20938992 |
| chromium(6+) | increases expression | EXP | | 6480464 | chromium hexavalent ion results in increased expression of BCL2 protein | CTD | PMID:22666341 |
| chrysazin | decreases expression | EXP | | 6480464 | danthron results in decreased expression of BCL2 protein | CTD | PMID:21126053 |
| cidofovir anhydrous | decreases expression | EXP | | 6480464 | cidofovir results in decreased expression of BCL2 | CTD | PMID:12700662 |
| ciglitazone | decreases expression | EXP | | 6480464 | ciglitazone results in decreased expression of BCL2 protein | CTD | PMID:15492468 |
| cilostazol | multiple interactions | EXP | | 6480464 | cilostazol inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] | CTD | PMID:16822680 |
| cilostazol | affects expression | ISO | RGD:2199 | 6480464 | cilostazol affects the expression of BCL2 protein | CTD | PMID:15978173 |
| cilostazol | decreases expression | EXP | | 6480464 | cilostazol results in decreased expression of BCL2 protein | CTD | PMID:20131233 |
| cimetidine | decreases expression | EXP | | 6480464 | Cimetidine results in decreased expression of BCL2 protein | CTD | PMID:20127008 |
| ciprofloxacin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Ciprofloxacin results in increased localization of BAX protein] | CTD | PMID:11832715 |
| ciprofloxacin | multiple interactions | EXP | | 6480464 | [Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein | CTD | PMID:12063570 |
| cisplatin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Cisplatin | CTD | PMID:21160028 PMID:16009487 |
| cisplatin | multiple interactions | ISO | RGD:2199 | 6480464 | Cisplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein; more ... | CTD | PMID:19428505 |
| cisplatin | multiple interactions | ISO | RGD:10230 | 6480464 | ABCB1 protein inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] | CTD | PMID:22269388 |
| cisplatin | multiple interactions | EXP | | 6480464 | ABCB1 protein inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] | CTD | PMID:22269388 |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:20566416 more ... |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:20566416 more ... |
| cisplatin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Cisplatin | CTD | PMID:16009487 more ... |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:10891529 more ... |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:21526214 more ... |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:10891529 more ... |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:14512787 more ... |
| cisplatin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Cisplatin | CTD | PMID:20162574 more ... |
| cisplatin | multiple interactions | ISO | RGD:10230 | 6480464 | IL6 gene mutant form promotes the reaction [Cisplatin results in increased expression of BCL2 mRNA] | CTD | PMID:19833167 |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:20566416 more ... |
| cisplatin | increases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in increased expression of BCL2 mRNA | CTD | PMID:19833167 |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:20883750 more ... |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:9664115 more ... |
| cisplatin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Cisplatin | CTD | PMID:20162574 more ... |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:21526214 more ... |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:21052098 more ... |
| cisplatin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Cisplatin | CTD | PMID:16009487 more ... |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:20883750 more ... |
| cisplatin | multiple interactions | EXP | | 6480464 | [Theophylline co-treated with Cisplatin] results in decreased expression of BCL2 protein | CTD | PMID:10891529 PMID:15645133 |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 mRNA | CTD | PMID:17404015 PMID:20878077 |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:21940343 more ... |
| cisplatin | decreases response to substance | EXP | | 6480464 | BCL2 results in decreased susceptibility to Cisplatin | CTD | PMID:10896673 PMID:21618512 |
| cisplatin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Cisplatin | CTD | PMID:21160028 more ... |
| cisplatin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [[Cisplatin co-treated with FASLG protein] results in increased activity of CASP3 protein]; more ... | CTD | PMID:17574045 |
| cisplatin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Cisplatin affects the localization of BAX protein] | CTD | PMID:16009487 |
| cisplatin | multiple interactions | EXP | | 6480464 | BCL2 inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; more ... | CTD | PMID:21618512 |
| cisplatin | decreases expression | ISO | RGD:2199 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:12690470 |
| cisplatin | decreases expression | ISO | RGD:2199 | 6480464 | Cisplatin results in decreased expression of BCL2 | CTD | PMID:21795690 |
| cisplatin | multiple interactions | ISO | RGD:2199 | 6480464 | chelerythrine inhibits the reaction [sodium arsenite inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]]; more ... | CTD | PMID:12690470 |
| cisplatin | multiple interactions | ISO | RGD:10230 | 6480464 | rosemarinic acid inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] | CTD | PMID:21526214 |
| cisplatin | decreases response to substance | ISO | RGD:2199 | 6480464 | BCL2 protein results in decreased susceptibility to Cisplatin | CTD | PMID:15315938 |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:20883750 more ... |
| cisplatin | decreases expression | ISO | RGD:10230 | 6480464 | Cisplatin results in decreased expression of BCL2 mRNA | CTD | PMID:20883750 |
| cisplatin | affects response to substance | ISO | RGD:10230 | 6480464 | BCL2 protein affects the susceptibility to Cisplatin | CTD | PMID:15746559 |
| cisplatin | multiple interactions | EXP | | 6480464 | Y 27632 inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA] | CTD | PMID:20878077 |
| cisplatin | multiple interactions | ISO | RGD:10230 | 6480464 | Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]]; more ... | CTD | PMID:21616140 |
| cisplatin | multiple interactions | EXP | | 6480464 | [tubeimoside I co-treated with Cisplatin] results in decreased expression of BCL2 protein | CTD | PMID:21687949 |
| cisplatin | multiple interactions | EXP | | 6480464 | [TNFSF10 protein co-treated with Cisplatin] results in decreased expression of BCL2 protein | CTD | PMID:21252285 |
| cisplatin | multiple interactions | EXP | | 6480464 | [Theophylline co-treated with Cisplatin] results in decreased expression of BCL2 protein | CTD | PMID:15645133 PMID:10891529 |
| cisplatin | multiple interactions | EXP | | 6480464 | Noscapine promotes the reaction [Cisplatin results in decreased expression of BCL2 protein] | CTD | PMID:20674069 |
| cisplatin | multiple interactions | EXP | | 6480464 | [Quercetin results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2 protein | CTD | PMID:16619537 |
| cisplatin | multiple interactions | EXP | | 6480464 | [Paclitaxel results in increased phosphorylation of BCL2 protein] which results in increased susceptibility to Cisplatin | CTD | PMID:12709826 |
| cisplatin | multiple interactions | EXP | | 6480464 | [MIR497 results in decreased expression of BCL2 protein] which results in increased susceptibility to Cisplatin | CTD | PMID:21258880 |
| cisplatin | multiple interactions | EXP | | 6480464 | ING4 protein promotes the reaction [Cisplatin results in decreased expression of BCL2 protein] | CTD | PMID:21052098 |
| cisplatin | multiple interactions | EXP | | 6480464 | [IL8 results in increased expression of BCL2 protein] which results in decreased susceptibility to Cisplatin; more ... | CTD | PMID:21742513 |
| cisplatin | multiple interactions | EXP | | 6480464 | Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; more ... | CTD | PMID:21940343 |
| cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of BCL2 protein | CTD | PMID:17619073 |
| cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin results in increased expression of MIR630] which results in decreased expression of BCL2 mRNA | CTD | PMID:21274007 |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 protein | CTD | PMID:9664115 more ... |
| cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2 protein | CTD | PMID:21130731 |
| cisplatin | multiple interactions | EXP | | 6480464 | Cisplatin promotes the reaction [Metformin results in decreased expression of BCL2 protein] | CTD | PMID:21388661 |
| cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of BCL2 mRNA | CTD | PMID:20878077 PMID:17404015 |
| cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; more ... | CTD | PMID:19351772 |
| cisplatin | multiple interactions | EXP | | 6480464 | [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein; more ... | CTD | PMID:21214929 |
| cisplatin | decreases response to substance | EXP | | 6480464 | BCL2 results in decreased susceptibility to Cisplatin | CTD | PMID:21618512 PMID:10896673 |
| cisplatin | multiple interactions | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] | CTD | PMID:15917659 |
| citric acid | multiple interactions | EXP | | 6480464 | [Citric Acid co-treated with zinc chloride] results in decreased expression of BCL2 protein | CTD | PMID:16624386 |
| cladribine | multiple interactions | EXP | | 6480464 | BCL2 affects the reaction [Cladribine results in increased cleavage of and results in increased activity of CASP9 protein]; more ... | CTD | PMID:15516989 |
| cladribine | decreases expression | EXP | | 6480464 | Cladribine results in decreased expression of BCL2 protein | CTD | PMID:15582267 |
| cladribine | multiple interactions | EXP | | 6480464 | [Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of BCL2 protein; more ... | CTD | PMID:15582267 |
| clofibrate | multiple interactions | ISO | RGD:10230 | 6480464 | Clofibrate inhibits the reaction [[Fatty Acids, Nonesterified binds to ALB protein] which results in decreased expression of BCL2 protein] | CTD | PMID:21338618 |
| clonazepam | increases expression | ISO | RGD:2199 | 6480464 | Clonazepam results in increased expression of BCL2 protein | CTD | PMID:17456340 |
| clozapine | increases expression | ISO | RGD:2199 | 6480464 | Clozapine results in increased expression of BCL2 mRNA; more ... | CTD | PMID:15126120 |
| cobalt atom | decreases expression | EXP | | 6480464 | Cobalt results in decreased expression of BCL2 protein | CTD | PMID:21598295 |
| cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of BCL2 protein | CTD | PMID:16827160 |
| cobalt dichloride | multiple interactions | EXP | | 6480464 | zinc chloride inhibits the reaction [cobaltous chloride results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:17786326 |
| cobalt dichloride | decreases expression | EXP | | 6480464 | cobaltous chloride results in decreased expression of BCL2 protein; more ... | CTD | PMID:17786326 |
| cobalt dichloride | decreases expression | ISO | RGD:2199 | 6480464 | cobaltous chloride results in decreased expression of BCL2 protein | CTD | PMID:19520152 |
| cobalt dichloride | multiple interactions | EXP | | 6480464 | HIPK2 protein inhibits the reaction [cobaltous chloride promotes the reaction [HIF1A protein results in increased expression of BCL2 mRNA]] | CTD | PMID:19128456 |
| cobalt dichloride | multiple interactions | EXP | | 6480464 | zinc chloride inhibits the reaction [cobaltous chloride results in increased expression of BCL2 mRNA] | CTD | PMID:19714248 |
| cocaine | affects expression | ISO | RGD:10230 | 6480464 | Cocaine affects the expression of BCL2 mRNA | CTD | PMID:15681117 |
| cocaine | decreases expression | ISO | RGD:2199 | 6480464 | Cocaine results in decreased expression of BCL2 protein | CTD | PMID:11392460 more ... |
| cocaine | decreases expression | ISO | RGD:2199 | 6480464 | Cocaine results in decreased expression of BCL2 protein | CTD | PMID:19183502 more ... |
| cocaine | decreases expression | ISO | RGD:2199 | 6480464 | Cocaine results in decreased expression of BCL2 protein | CTD | PMID:19183502 more ... |
| cocaine | decreases expression | ISO | RGD:2199 | 6480464 | Cocaine results in decreased expression of BCL2 protein | CTD | PMID:15685203 more ... |
| cocaine | increases expression | ISO | RGD:2199 | 6480464 | Cocaine results in increased expression of BCL2 protein | CTD | PMID:17084983 PMID:18974856 |
| cocaine | decreases expression | ISO | RGD:2199 | 6480464 | Cocaine results in decreased expression of BCL2 protein | CTD | PMID:19183502 more ... |
| cocaine | increases expression | ISO | RGD:2199 | 6480464 | Cocaine results in increased expression of BCL2 protein | CTD | PMID:18974856 PMID:17084983 |
| cocaine | decreases expression | ISO | RGD:2199 | 6480464 | Cocaine results in decreased expression of BCL2 protein | CTD | PMID:15685203 more ... |
| cocaine | decreases expression | ISO | RGD:2199 | 6480464 | Cocaine results in decreased expression of BCL2 mRNA | CTD | PMID:19183502 |
| codeinone | decreases expression | EXP | | 6480464 | 6-codeinone results in decreased expression of BCL2 protein | CTD | PMID:12894543 |
| coenzyme Q10 | increases expression | ISO | RGD:2199 | 6480464 | coenzyme Q10 results in increased expression of BCL2 mRNA | CTD | PMID:18817789 |
| copper atom | decreases expression | EXP | | 6480464 | Copper results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:16962711 |
| copper atom | decreases expression | EXP | | 6480464 | Copper results in decreased expression of BCL2 mRNA | CTD | PMID:16391388 PMID:16962711 |
| copper atom | multiple interactions | ISO | RGD:2199 | 6480464 | Acetylcysteine inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:22085843 |
| copper atom | decreases expression | EXP | | 6480464 | Copper results in decreased expression of BCL2 mRNA | CTD | PMID:16962711 PMID:16391388 |
| copper atom | decreases expression | ISO | RGD:10230 | 6480464 | Copper analog results in decreased expression of BCL2 protein | CTD | PMID:22000994 |
| copper(0) | decreases expression | EXP | | 6480464 | Copper results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:16962711 |
| copper(0) | decreases expression | EXP | | 6480464 | Copper results in decreased expression of BCL2 mRNA | CTD | PMID:16391388 PMID:16962711 |
| copper(0) | multiple interactions | ISO | RGD:2199 | 6480464 | Acetylcysteine inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:22085843 |
| copper(0) | decreases expression | EXP | | 6480464 | Copper results in decreased expression of BCL2 mRNA | CTD | PMID:16962711 PMID:16391388 |
| copper(0) | decreases expression | ISO | RGD:10230 | 6480464 | Copper analog results in decreased expression of BCL2 protein | CTD | PMID:22000994 |
| copper(2+) sulfate | decreases expression | EXP | | 6480464 | Copper Sulfate results in decreased expression of BCL2 mRNA | CTD | PMID:19549813 |
| copper(2+) sulfate | multiple interactions | EXP | | 6480464 | Copper Sulfate inhibits the reaction [Trientine results in increased expression of BCL2 protein] | CTD | PMID:14513838 |
| copper(II) chloride | multiple interactions | ISO | RGD:2199 | 6480464 | anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in decreased expression of BCL2 protein]; more ... | CTD | PMID:20920558 |
| cordycepin | decreases expression | EXP | | 6480464 | cordycepin results in decreased expression of BCL2 protein | CTD | PMID:21310227 |
| cordycepin | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [cordycepin results in decreased expression of BCL2 protein] | CTD | PMID:21310227 |
| coumarin | decreases expression | EXP | | 6480464 | coumarin results in decreased expression of BCL2 protein | CTD | PMID:15964220 |
| coumestrol | decreases expression | EXP | | 6480464 | Coumestrol results in decreased expression of BCL2 protein | CTD | PMID:20623010 |
| coumestrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2 mRNA | CTD | PMID:19167446 |
| crocidolite asbestos | increases expression | ISO | RGD:2199 | 6480464 | Asbestos, Crocidolite results in increased expression of BCL2 mRNA | CTD | PMID:12909582 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin analog results in decreased expression of BCL2 mRNA | CTD | PMID:19250217 PMID:17671737 |
| curcumin | increases expression | ISO | RGD:10230 | 6480464 | Curcumin results in increased expression of BCL2 protein | CTD | PMID:22714040 |
| curcumin | decreases expression | ISO | RGD:10230 | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:18829502 more ... |
| curcumin | decreases expression | ISO | RGD:10230 | 6480464 | Curcumin results in decreased expression of BCL2 mRNA | CTD | PMID:21397623 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:12497104 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 mRNA | CTD | PMID:17332930 more ... |
| curcumin | multiple interactions | ISO | RGD:2199 | 6480464 | Curcumin inhibits the reaction [Peroxynitrous Acid results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:20869986 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:19235267 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 mRNA | CTD | PMID:21595920 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:18593936 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 mRNA | CTD | PMID:21595920 more ... |
| curcumin | decreases expression | ISO | RGD:10230 | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:18829502 PMID:21594647 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:19372569 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 mRNA | CTD | PMID:17671742 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:17671742 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 mRNA | CTD | PMID:17671742 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:16023083 more ... |
| curcumin | multiple interactions | EXP | | 6480464 | [Curcumin results in increased expression of SERPINB5] which results in decreased expression of BCL2 protein | CTD | PMID:19944674 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 mRNA | CTD | PMID:17671742 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin analog results in decreased expression of BCL2 mRNA | CTD | PMID:17671737 PMID:19250217 |
| curcumin | decreases expression | ISO | RGD:2199 | 6480464 | Curcumin results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:17531121 |
| curcumin | multiple interactions | ISO | RGD:2199 | 6480464 | Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein] | CTD | PMID:15569404 |
| curcumin | multiple interactions | ISO | RGD:10230 | 6480464 | [Curcumin co-treated with gemcitabine] results in decreased expression of BCL2 protein | CTD | PMID:17440100 |
| curcumin | decreases expression | ISO | RGD:10230 | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:21594647 PMID:18829502 |
| curcumin | multiple interactions | ISO | RGD:2199 | 6480464 | 2-chloro-5-nitrobenzanilide inhibits the reaction [Curcumin results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:17531121 |
| curcumin | multiple interactions | EXP | | 6480464 | TNFSF10 protein promotes the reaction [Curcumin results in decreased expression of BCL2 protein] | CTD | PMID:18226269 |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 mRNA | CTD | PMID:19235267 more ... |
| curcumin | decreases expression | EXP | | 6480464 | Curcumin results in decreased expression of BCL2 protein | CTD | PMID:18593936 more ... |
| curcumin | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2 protein] | CTD | PMID:16243823 |
| curcumin | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; more ... | CTD | PMID:17640567 |
| curcumin | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA] | CTD | PMID:16219905 |
| curcumin | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [Nicotine results in increased expression of BCL2 protein] | CTD | PMID:20727180 |
| curcumin | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [docetaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:14724571 |
| curcumin | multiple interactions | EXP | | 6480464 | [Curcumin co-treated with Isoflavones] results in decreased expression of BCL2 protein | CTD | PMID:18640131 |
| curcumin | multiple interactions | EXP | | 6480464 | [Curcumin co-treated with Sirolimus] results in decreased expression of BCL2 | CTD | PMID:19373661 |
| cyanamide | multiple interactions | ISO | RGD:2199 | 6480464 | [Ethanol co-treated with Cyanamide] results in increased expression of BCL2 mRNA | CTD | PMID:12003908 |
| cycloheximide | multiple interactions | EXP | | 6480464 | Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:11726273 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; more ... | CTD | PMID:11723234 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | [Doxorubicin co-treated with Cyclophosphamide] affects the expression of BCL2 mRNA | CTD | PMID:16322899 |
| cyclophosphamide | increases expression | EXP | | 6480464 | Cyclophosphamide results in increased expression of BCL2 mRNA | CTD | PMID:14503796 |
| cyclophosphamide | multiple interactions | EXP | | 6480464 | [Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of BCL2 protein; more ... | CTD | PMID:15582267 |
| cyclosporin A | multiple interactions | EXP | | 6480464 | Cyclosporine promotes the reaction [Paclitaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein] | CTD | PMID:12086014 |
| cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of BCL2 protein; more ... | CTD | PMID:12086014 |
| cyclosporin A | increases expression | ISO | RGD:10230 | 6480464 | Cyclosporine results in increased expression of BCL2 protein | CTD | PMID:10205001 |
| cypermethrin | multiple interactions | ISO | RGD:2199 | 6480464 | HBEGF protein inhibits the reaction [cypermethrin results in decreased expression of BCL2 protein] | CTD | PMID:22048644 |
| cypermethrin | decreases expression | ISO | RGD:2199 | 6480464 | cypermethrin results in decreased expression of BCL2 protein | CTD | PMID:22048644 |
| cytarabine | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Cytarabine results in increased degradation of PARP protein]; more ... | CTD | PMID:8840993 |
| cytarabine | decreases expression | EXP | | 6480464 | Cytarabine results in decreased expression of BCL2 protein | CTD | PMID:16129037 more ... |
| cytarabine | decreases expression | EXP | | 6480464 | Cytarabine results in decreased expression of BCL2 protein | CTD | PMID:16129037 more ... |
| cytarabine | decreases expression | EXP | | 6480464 | Cytarabine results in decreased expression of BCL2 protein | CTD | PMID:17490525 more ... |
| cytarabine | multiple interactions | EXP | | 6480464 | edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein] | CTD | PMID:9295281 |
| cytarabine | increases degradation | EXP | | 6480464 | Cytarabine results in increased degradation of BCL2 protein | CTD | PMID:12853972 |
| cytarabine | decreases expression | EXP | | 6480464 | Cytarabine results in decreased expression of BCL2 mRNA | CTD | PMID:1450413 |
| cytarabine | decreases expression | EXP | | 6480464 | Cytarabine results in decreased expression of BCL2 protein | CTD | PMID:9295281 more ... |
| D-glucose | multiple interactions | EXP | | 6480464 | Catechin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; more ... | CTD | PMID:19557821 |
| D-glucose | multiple interactions | ISO | RGD:10230 | 6480464 | [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:23108914 |
| D-glucose | decreases expression | ISO | RGD:2199 | 6480464 | Glucose results in decreased expression of BCL2 mRNA | CTD | PMID:21818840 |
| D-glucose | multiple interactions | EXP | | 6480464 | [[NS 1619 co-treated with Glucose] results in increased activity of [KCNMA1 protein binds to KCNMB1 protein]] which results in decreased expression of BCL2 protein; more ... | CTD | PMID:21413024 |
| D-glucose | decreases expression | EXP | | 6480464 | Glucose results in decreased expression of BCL2 protein | CTD | PMID:18088078 |
| D-glucose | multiple interactions | EXP | | 6480464 | Gliclazide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; more ... | CTD | PMID:18088078 |
| D-mannitol | increases expression | ISO | RGD:2199 | 6480464 | Mannitol results in increased expression of BCL2 protein | CTD | PMID:15786717 |
| daidzein | decreases expression | EXP | | 6480464 | daidzein results in decreased expression of BCL2 protein | CTD | PMID:12791511 |
| dantrolene | increases expression | ISO | RGD:2199 | 6480464 | Dantrolene results in increased expression of BCL2 protein | CTD | PMID:10854250 |
| dasatinib (anhydrous) | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [[dasatinib co-treated with NVP-AEW541] promotes the reaction [BAX protein binds to BAX protein]]; more ... | CTD | PMID:20664932 |
| dasatinib (anhydrous) | decreases expression | EXP | | 6480464 | dasatinib results in decreased expression of BCL2 protein | CTD | PMID:18550857 more ... |
| dasatinib (anhydrous) | decreases expression | EXP | | 6480464 | dasatinib results in decreased expression of BCL2 protein | CTD | PMID:20629079 more ... |
| dasatinib (anhydrous) | decreases expression | EXP | | 6480464 | dasatinib results in decreased expression of BCL2 protein | CTD | PMID:20664932 more ... |
| dasatinib (anhydrous) | decreases expression | EXP | | 6480464 | dasatinib results in decreased expression of BCL2 protein | CTD | PMID:20629079 more ... |
| dasatinib (anhydrous) | decreases expression | EXP | | 6480464 | dasatinib results in decreased expression of BCL2 mRNA | CTD | PMID:20629079 |
| daunorubicin | multiple interactions | EXP | | 6480464 | [bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA | CTD | PMID:21302442 |
| daunorubicin | multiple interactions | EXP | | 6480464 | [Daunorubicin co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA | CTD | PMID:19918366 |
| daunorubicin | decreases expression | EXP | | 6480464 | Daunorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:19421372 |
| daunorubicin | multiple interactions | EXP | | 6480464 | [Daunorubicin co-treated with bromotetrandrine co-treated with Magnetite Nanoparticles] results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:21720514 |
| daunorubicin | multiple interactions | EXP | | 6480464 | [bromotetrandrine co-treated with Daunorubicin] results in decreased expression of BCL2 protein; more ... | CTD | PMID:19421372 |
| daunorubicin | decreases response to substance | EXP | | 6480464 | BCL2 results in decreased susceptibility to Daunorubicin | CTD | PMID:21595920 |
| DDE | increases expression | EXP | | 6480464 | Dichlorodiphenyl Dichloroethylene results in increased expression of BCL2 protein; more ... | CTD | PMID:19545618 |
| DDT | multiple interactions | EXP | | 6480464 | [DDT results in increased activity of ESR1 protein] which results in increased expression of BCL2 mRNA | CTD | PMID:22403704 |
| dehydroascorbic acid | multiple interactions | EXP | | 6480464 | [Dehydroascorbic Acid co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein | CTD | PMID:20166893 |
| dehydroascorbic acid | increases expression | EXP | | 6480464 | Dehydroascorbic Acid results in increased expression of BCL2 protein | CTD | PMID:20166893 |
| dehydroepiandrosterone | multiple interactions | ISO | RGD:2199 | 6480464 | Dexamethasone inhibits the reaction [Dehydroepiandrosterone results in increased expression of BCL2 protein]; more ... | CTD | PMID:16407456 |
| dehydroepiandrosterone | increases expression | ISO | RGD:2199 | 6480464 | Dehydroepiandrosterone results in increased expression of BCL2 protein | CTD | PMID:16407456 |
| dehydroepiandrosterone sulfate | increases expression | ISO | RGD:2199 | 6480464 | Dehydroepiandrosterone Sulfate results in increased expression of BCL2 protein | CTD | PMID:16407456 |
| dehydroepiandrosterone sulfate | multiple interactions | ISO | RGD:2199 | 6480464 | Pertussis Toxin inhibits the reaction [Dehydroepiandrosterone Sulfate results in increased expression of BCL2 protein] | CTD | PMID:16407456 |
| delphinidin | decreases expression | EXP | | 6480464 | delphinidin results in decreased expression of BCL2 protein | CTD | PMID:15740068 |
| delphinidin | increases expression | EXP | | 6480464 | delphinidin results in increased expression of BCL2 protein | CTD | PMID:19818742 |
| deoxycholic acid | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Deoxycholic Acid | CTD | PMID:12507930 |
| desipramine | increases expression | ISO | RGD:2199 | 6480464 | Desipramine results in increased expression of BCL2 mRNA; more ... | CTD | PMID:17510525 |
| dexamethasone | multiple interactions | EXP | | 6480464 | Dexamethasone inhibits the reaction [Cisplatin results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:21940343 |
| dexamethasone | multiple interactions | ISO | RGD:10230 | 6480464 | [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased expression of BCL2 protein | CTD | PMID:11751460 |
| dexamethasone | increases expression | ISO | RGD:10230 | 6480464 | Dexamethasone results in increased expression of BCL2 mRNA | CTD | PMID:21041162 |
| dexamethasone | decreases expression | ISO | RGD:10230 | 6480464 | Dexamethasone results in decreased expression of BCL2 mRNA | CTD | PMID:16644695 PMID:7517174 |
| dexamethasone | increases expression | ISO | RGD:2199 | 6480464 | Dexamethasone results in increased expression of BCL2 protein | CTD | PMID:11319611 |
| dexamethasone | decreases expression | ISO | RGD:2199 | 6480464 | Dexamethasone results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:19080409 |
| dexamethasone | multiple interactions | ISO | RGD:2199 | 6480464 | Dexamethasone inhibits the reaction [Dehydroepiandrosterone results in increased expression of BCL2 protein] | CTD | PMID:16407456 |
| dexamethasone | multiple interactions | ISO | RGD:10230 | 6480464 | Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:16644695 |
| dexamethasone | decreases expression | ISO | RGD:10230 | 6480464 | Dexamethasone results in decreased expression of BCL2 protein | CTD | PMID:16644695 |
| dexamethasone | decreases expression | ISO | RGD:10230 | 6480464 | Dexamethasone results in decreased expression of BCL2 mRNA | CTD | PMID:7517174 PMID:16644695 |
| dexamethasone | multiple interactions | ISO | RGD:10230 | 6480464 | BCL2 gene inhibits the reaction [Dexamethasone results in decreased activity of CAT protein]; more ... | CTD | PMID:17180084 |
| dexamethasone | multiple interactions | EXP | | 6480464 | mycophenolate mofetil inhibits the reaction [BCL2 protein results in decreased susceptibility to Dexamethasone] | CTD | PMID:16505121 |
| dexamethasone | multiple interactions | EXP | | 6480464 | Mifepristone inhibits the reaction [Dexamethasone results in increased expression of BCL2] | CTD | PMID:21244764 |
| dexamethasone | multiple interactions | EXP | | 6480464 | [oblimersen co-treated with Thalidomide co-treated with Dexamethasone] results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:15867202 |
| dexamethasone | increases expression | EXP | | 6480464 | Dexamethasone results in increased expression of BCL2 protein | CTD | PMID:11319611 |
| dexamethasone | multiple interactions | EXP | | 6480464 | Dexamethasone inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA] | CTD | PMID:21420233 |
| dexamethasone | increases expression | EXP | | 6480464 | Dexamethasone results in increased expression of BCL2 | CTD | PMID:21244764 |
| dexamethasone | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Dexamethasone | CTD | PMID:16505121 |
| dexamethasone | increases response to substance | EXP | | 6480464 | BCL2 protein results in increased susceptibility to Dexamethasone | CTD | PMID:10200551 |
| dexmedetomidine | multiple interactions | ISO | RGD:2199 | 6480464 | Dexmedetomidine inhibits the reaction [Isoflurane results in decreased expression of BCL2 protein] | CTD | PMID:20003127 |
| diallyl disulfide | decreases expression | ISO | RGD:2199 | 6480464 | diallyl disulfide results in decreased expression of BCL2 protein | CTD | PMID:16052692 |
| diallyl disulfide | decreases expression | EXP | | 6480464 | diallyl disulfide results in decreased expression of BCL2 protein | CTD | PMID:14522920 |
| diarsenic trioxide | decreases expression | ISO | RGD:10230 | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:21565247 more ... |
| diarsenic trioxide | decreases response to substance | EXP | | 6480464 | BCL2 results in decreased susceptibility to arsenic trioxide | CTD | PMID:18412143 |
| diarsenic trioxide | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to arsenic trioxide | CTD | PMID:10648417 |
| diarsenic trioxide | increases response to substance | EXP | | 6480464 | BCL2 mutant form results in increased susceptibility to arsenic trioxide | CTD | PMID:14642526 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | BCL2 inhibits the reaction [[arsenic trioxide co-treated with TNF protein] results in decreased expression of CFLAR protein]; more ... | CTD | PMID:17673311 |
| diarsenic trioxide | increases phosphorylation | EXP | | 6480464 | arsenic trioxide results in increased phosphorylation of BCL2 protein | CTD | PMID:12181429 PMID:18412143 |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 | CTD | PMID:21473291 more ... |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [arsenic trioxide results in increased phosphorylation of BCL2 protein]; more ... | CTD | PMID:18412143 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | [arsenic trioxide co-treated with BCL2 mutant form] results in increased expression of BCL2 protein | CTD | PMID:14642526 PMID:14642526 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with arsenic trioxide] results in decreased expression of BCL2 mRNA | CTD | PMID:15894607 |
| diarsenic trioxide | affects expression | ISO | RGD:2199 | 6480464 | arsenic trioxide affects the expression of BCL2 mRNA | CTD | PMID:18618274 |
| diarsenic trioxide | increases expression | ISO | RGD:10230 | 6480464 | arsenic trioxide results in increased expression of BCL2 protein | CTD | PMID:10712780 |
| diarsenic trioxide | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to arsenic trioxide | CTD | PMID:11775218 more ... |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [arsenic trioxide results in increased activity of CASP3 protein] | CTD | PMID:12168106 |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:11135700 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:11775218 more ... |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | arsenic trioxide promotes the reaction [Genistein results in decreased expression of BCL2 protein]; more ... | CTD | PMID:20219070 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | arsenic trioxide inhibits the reaction [BCL2 protein binds to BAX protein binds to VDAC1 protein]; more ... | CTD | PMID:17374990 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [[arsenic trioxide co-treated with lonidamine] results in increased cleavage of and results in increased activity of CASP8 protein]; more ... | CTD | PMID:21889928 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [[arsenic trioxide co-treated with Quercetin] results in increased cleavage of and results in increased activity of CASP8 protein] | CTD | PMID:18359480 |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:11135700 more ... |
| diarsenic trioxide | decreases expression | ISO | RGD:2199 | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:21145380 |
| diarsenic trioxide | decreases expression | ISO | RGD:10230 | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:10721769 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:11135700 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:11775218 more ... |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | [arsenic trioxide co-treated with epigallocatechin gallate] results in decreased expression of BCL2 protein | CTD | PMID:20950636 |
| diarsenic trioxide | affects expression | EXP | | 6480464 | arsenic trioxide affects the expression of BCL2 protein | CTD | PMID:16010437 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:20458559 more ... |
| diarsenic trioxide | affects expression | EXP | | 6480464 | arsenic trioxide affects the expression of BCL2 protein | CTD | PMID:18357729 more ... |
| diarsenic trioxide | decreases expression | ISO | RGD:10230 | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:9716575 more ... |
| diarsenic trioxide | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to arsenic trioxide | CTD | PMID:11775218 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:19695276 more ... |
| diarsenic trioxide | decreases expression | ISO | RGD:10230 | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:10721769 PMID:9716575 |
| diarsenic trioxide | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to arsenic trioxide | CTD | PMID:16904648 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:19489279 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:20458559 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:11780464 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:8704214 more ... |
| diarsenic trioxide | affects expression | EXP | | 6480464 | arsenic trioxide affects the expression of BCL2 protein | CTD | PMID:16010437 more ... |
| diarsenic trioxide | multiple interactions | ISO | RGD:2199 | 6480464 | pifithrin inhibits the reaction [arsenic trioxide results in increased expression of BCL2 mRNA] | CTD | PMID:17487067 |
| diarsenic trioxide | increases expression | ISO | RGD:2199 | 6480464 | arsenic trioxide results in increased expression of BCL2 mRNA | CTD | PMID:17487067 |
| diarsenic trioxide | decreases expression | ISO | RGD:2199 | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:19260322 |
| diarsenic trioxide | affects expression | ISO | RGD:2199 | 6480464 | arsenic trioxide affects the expression of BCL2 protein | CTD | PMID:12725324 |
| diarsenic trioxide | multiple interactions | ISO | RGD:10230 | 6480464 | [Genistein co-treated with arsenic trioxide] results in decreased expression of BCL2 protein | CTD | PMID:21078540 |
| diarsenic trioxide | increases cleavage | ISO | RGD:10230 | 6480464 | arsenic trioxide results in increased cleavage of BCL2 protein | CTD | PMID:15761769 |
| diarsenic trioxide | decreases expression | ISO | RGD:10230 | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:9716575 PMID:10721769 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | SB 203580 promotes the reaction [arsenic trioxide results in decreased expression of BCL2 protein] | CTD | PMID:16818652 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | [Genistein co-treated with arsenic trioxide] results in decreased expression of BCL2 protein | CTD | PMID:21078540 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | [bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein | CTD | PMID:18718063 |
| diarsenic trioxide | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to arsenic trioxide | CTD | PMID:11775218 more ... |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [arsenic trioxide results in increased activity of BAX protein] | CTD | PMID:15735709 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [arsenic trioxide results in decreased expression of MYC mRNA] | CTD | PMID:11775218 |
| diarsenic trioxide | increases phosphorylation | EXP | | 6480464 | arsenic trioxide results in increased phosphorylation of BCL2 protein | CTD | PMID:12181429 |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:9716575 more ... |
| diarsenic trioxide | increases expression | EXP | | 6480464 | arsenic trioxide results in increased expression of BCL2 protein | CTD | PMID:19208092 |
| diarsenic trioxide | increases cleavage | EXP | | 6480464 | arsenic trioxide results in increased cleavage of BCL2 protein | CTD | PMID:11739184 |
| diarsenic trioxide | increases expression | EXP | | 6480464 | arsenic trioxide results in increased expression of BCL2 mRNA | CTD | PMID:16966277 |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:11775218 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 | CTD | PMID:21473291 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | arsenic trioxide promotes the reaction [puerarin results in decreased expression of BCL2 mRNA] | CTD | PMID:20416161 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | [arsenic trioxide co-treated with PML protein] results in decreased expression of BCL2 | CTD | PMID:20377131 |
| diarsenic trioxide | multiple interactions | EXP | | 6480464 | [arsenic trioxide co-treated with bortezomib] results in decreased expression of BCL2 mRNA | CTD | PMID:20471514 |
| diarsenic trioxide | affects folding | EXP | | 6480464 | arsenic trioxide affects the folding of BCL2 protein | CTD | PMID:20403207 |
| diarsenic trioxide | affects expression | EXP | | 6480464 | arsenic trioxide affects the expression of BCL2 protein | CTD | PMID:16010437 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:12883267 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:11775218 more ... |
| diarsenic trioxide | decreases expression | ISO | RGD:10230 | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:10721769 more ... |
| diarsenic trioxide | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to arsenic trioxide | CTD | PMID:16904648 more ... |
| diarsenic trioxide | affects expression | EXP | | 6480464 | arsenic trioxide affects the expression of BCL2 protein | CTD | PMID:20200477 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 protein | CTD | PMID:11775218 more ... |
| diarsenic trioxide | decreases expression | EXP | | 6480464 | arsenic trioxide results in decreased expression of BCL2 mRNA | CTD | PMID:15622746 more ... |
| diarsenic trioxide | affects expression | EXP | | 6480464 | arsenic trioxide affects the expression of BCL2 protein | CTD | PMID:16867262 more ... |
| diazoxide | multiple interactions | ISO | RGD:2199 | 6480464 | Diazoxide inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein] | CTD | PMID:20650802 |
| diazoxide | increases expression | ISO | RGD:2199 | 6480464 | Isoproterenol results in increased expression of BCL2 mRNA | CTD | PMID:11218852 |
| diazoxide | decreases expression | ISO | RGD:2199 | 6480464 | Isoproterenol results in decreased expression of BCL2 protein | CTD | PMID:12791704 |
| diazoxide | decreases expression | ISO | RGD:10230 | 6480464 | Isoproterenol results in decreased expression of BCL2 protein | CTD | PMID:15052282 |
| diazoxide | multiple interactions | ISO | RGD:2199 | 6480464 | echinocystic acid affects the reaction [Isoproterenol affects the expression of BCL2 mRNA] | CTD | PMID:19573579 |
| dibutyl phthalate | increases expression | ISO | RGD:10230 | 6480464 | Dibutyl Phthalate results in increased expression of BCL2 mRNA | CTD | PMID:21266533 |
| dichloroacetic acid | decreases expression | ISO | RGD:10230 | 6480464 | Dichloroacetic Acid results in decreased expression of BCL2 protein | CTD | PMID:22705712 |
| dieldrin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Dieldrin results in increased activity of PRKCD protein] | CTD | PMID:15033812 |
| dieldrin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Dieldrin results in increased activity of CASP3 protein] | CTD | PMID:15033812 PMID:15183012 |
| dieldrin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Dieldrin | CTD | PMID:15183012 |
| dieldrin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Dieldrin results in increased activity of CASP3 protein] | CTD | PMID:15183012 PMID:15033812 |
| diethylstilbestrol | increases expression | ISO | RGD:10230 | 6480464 | Diethylstilbestrol results in increased expression of BCL2 mRNA | CTD | PMID:17943652 |
| diethylstilbestrol | decreases expression | ISO | RGD:10230 | 6480464 | Diethylstilbestrol results in decreased expression of BCL2 mRNA | CTD | PMID:15545218 |
| diethylstilbestrol | decreases expression | ISO | RGD:2199 | 6480464 | Diethylstilbestrol results in decreased expression of BCL2 protein | CTD | PMID:17009535 |
| diiodine | multiple interactions | EXP | | 6480464 | [Diatrizoate co-treated with Iodine] results in increased expression of BCL2 protein | CTD | PMID:17173243 |
| dimethylarsinic acid | increases expression | ISO | RGD:10230 | 6480464 | Cacodylic Acid results in increased expression of BCL2 mRNA; more ... | CTD | PMID:22246474 |
| dioxygen | multiple interactions | ISO | RGD:2199 | 6480464 | Isoflurane promotes the reaction [Oxygen deficiency results in increased expression of BCL2 protein] | CTD | PMID:16249675 |
| dioxygen | multiple interactions | ISO | RGD:10230 | 6480464 | [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:23108914 |
| dioxygen | multiple interactions | ISO | RGD:2199 | 6480464 | Phenylephrine inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:11042672 |
| dioxygen | increases expression | ISO | RGD:2199 | 6480464 | Oxygen deficiency results in increased expression of BCL2 protein | CTD | PMID:16249675 |
| dioxygen | decreases expression | ISO | RGD:2199 | 6480464 | Oxygen deficiency results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:11042672 |
| disodium selenite | decreases expression | ISO | RGD:10230 | 6480464 | Sodium Selenite results in decreased expression of BCL2 mRNA | CTD | PMID:16542727 more ... |
| disodium selenite | multiple interactions | ISO | RGD:2199 | 6480464 | Sodium Selenite inhibits the reaction [2-cresol results in increased expression of BCL2 mRNA] | CTD | PMID:21705299 |
| disodium selenite | decreases expression | ISO | RGD:10230 | 6480464 | Sodium Selenite results in decreased expression of BCL2 mRNA | CTD | PMID:19363675 more ... |
| disodium selenite | decreases expression | ISO | RGD:10230 | 6480464 | Sodium Selenite results in decreased expression of BCL2 mRNA | CTD | PMID:16542727 more ... |
| disodium selenite | decreases expression | ISO | RGD:10230 | 6480464 | Sodium Selenite results in decreased expression of BCL2 mRNA | CTD | PMID:17989939 more ... |
| disodium selenite | multiple interactions | ISO | RGD:2199 | 6480464 | Sodium Selenite inhibits the reaction [cholestane-3,5,6-triol results in increased expression of BCL2 mRNA] | CTD | PMID:16039982 |
| disodium selenite | increases expression | ISO | RGD:2199 | 6480464 | Sodium Selenite results in increased expression of BCL2 protein | CTD | PMID:18209489 |
| disodium selenite | multiple interactions | ISO | RGD:10230 | 6480464 | Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in decreased expression of BCL2 mRNA] | CTD | PMID:17989939 |
| dobutamine | decreases expression | ISO | RGD:10230 | 6480464 | Dobutamine results in decreased expression of BCL2 protein | CTD | PMID:15052282 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [docetaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:14724571 PMID:17317842 |
| docetaxel anhydrous | increases phosphorylation | EXP | | 6480464 | docetaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:17317842 PMID:14724571 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [docetaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:17317842 PMID:14724571 |
| docetaxel anhydrous | multiple interactions | ISO | RGD:10230 | 6480464 | [docetaxel results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein] | CTD | PMID:10606283 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | [zoledronic acid co-treated with docetaxel] results in decreased expression of BCL2 protein | CTD | PMID:19103299 |
| docetaxel anhydrous | affects response to substance | ISO | RGD:10230 | 6480464 | BCL2 affects the susceptibility to docetaxel | CTD | PMID:10606283 |
| docetaxel anhydrous | increases phosphorylation | ISO | RGD:10230 | 6480464 | docetaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:10606283 |
| docetaxel anhydrous | increases phosphorylation | EXP | | 6480464 | docetaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:14724571 PMID:17317842 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | U 0126 inhibits the reaction [docetaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:17317842 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | docetaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein; more ... | CTD | PMID:14506750 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [docetaxel results in increased phosphorylation of BCL2 protein]; more ... | CTD | PMID:14724571 |
| docetaxel anhydrous | increases expression | EXP | | 6480464 | docetaxel results in increased expression of BCL2 protein | CTD | PMID:15688368 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | celecoxib promotes the reaction [docetaxel results in increased expression of BCL2 protein] | CTD | PMID:15688368 |
| docetaxel anhydrous | multiple interactions | EXP | | 6480464 | BCL2 inhibits the reaction [docetaxel affects the folding of and results in increased activity of BAK1 protein]; more ... | CTD | PMID:17308071 |
| donepezil hydrochloride | multiple interactions | ISO | RGD:2199 | 6480464 | donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] | CTD | PMID:19345205 |
| dopamine | decreases expression | EXP | | 6480464 | Dopamine results in decreased expression of BCL2 protein | CTD | PMID:17603292 |
| dopamine | multiple interactions | EXP | | 6480464 | resveratrol inhibits the reaction [Dopamine results in decreased expression of BCL2 protein] | CTD | PMID:17603292 |
| doxazosin | multiple interactions | EXP | | 6480464 | BCL2 inhibits the reaction [Doxazosin results in decreased expression of VEGFA] | CTD | PMID:12576871 |
| doxorubicin | multiple interactions | EXP | | 6480464 | [Amifostine co-treated with Doxorubicin] results in decreased expression of BCL2 mRNA | CTD | PMID:15985719 |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:12505058 more ... |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | Doxorubicin promotes the reaction [TP53 protein binds to BCL2 promoter] | CTD | PMID:22155320 |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | Propofol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:22015447 |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:11779855 more ... |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:14736733 more ... |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:12505058 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:12505058 more ... |
| doxorubicin | decreases expression | ISO | RGD:10230 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:18627295 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 protein | CTD | PMID:15571967 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 mRNA | CTD | PMID:19757172 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:19746155 more ... |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:12505058 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:17542780 more ... |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:18775851 more ... |
| doxorubicin | multiple interactions | ISO | RGD:10230 | 6480464 | zinc chloride inhibits the reaction [Doxorubicin results in increased expression of BCL2 mRNA] | CTD | PMID:19714248 |
| doxorubicin | increases expression | ISO | RGD:10230 | 6480464 | Doxorubicin results in increased expression of BCL2 mRNA | CTD | PMID:15505089 PMID:19714248 |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:17924179 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 protein | CTD | PMID:19270784 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 mRNA | CTD | PMID:15939500 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:16001973 more ... |
| doxorubicin | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Doxorubicin | CTD | PMID:16450387 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:11779855 more ... |
| doxorubicin | decreases expression | ISO | RGD:10230 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:17673183 more ... |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:18611398 more ... |
| doxorubicin | increases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in increased expression of BCL2 protein | CTD | PMID:11291592 PMID:17520333 |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:17234320 more ... |
| doxorubicin | decreases expression | ISO | RGD:10230 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:15811867 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 protein | CTD | PMID:15571967 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:11779855 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:17404015 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:18560228 more ... |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:15380674 more ... |
| doxorubicin | decreases expression | ISO | RGD:10230 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:17673183 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 protein | CTD | PMID:8781438 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 mRNA | CTD | PMID:8781438 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:17542780 more ... |
| doxorubicin | multiple interactions | EXP | | 6480464 | [Doxorubicin co-treated with bisphenol A] results in increased expression of BCL2 protein | CTD | PMID:19270784 |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:18632596 more ... |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:18611398 more ... |
| doxorubicin | decreases expression | ISO | RGD:10230 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:15811867 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 protein | CTD | PMID:15571967 PMID:8781438 |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:19746155 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:17959036 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 mRNA | CTD | PMID:15939500 more ... |
| doxorubicin | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Doxorubicin | CTD | PMID:16322301 more ... |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | Withanolides inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein] | CTD | PMID:17520333 |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | pifithrin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; more ... | CTD | PMID:18775851 |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | Ginkgo biloba extract 761 inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:18632596 |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | EPO protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:17924179 |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | GHRL protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:18400355 |
| doxorubicin | increases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in increased expression of BCL2 protein | CTD | PMID:17520333 PMID:11291592 |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:18632596 more ... |
| doxorubicin | decreases expression | ISO | RGD:2199 | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:12505058 more ... |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | Catechin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:18611398 |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | carvedilol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA] | CTD | PMID:15380674 |
| doxorubicin | multiple interactions | ISO | RGD:10230 | 6480464 | [zoledronic acid co-treated with Doxorubicin] results in decreased expression of BCL2 protein | CTD | PMID:19789217 |
| doxorubicin | multiple interactions | ISO | RGD:2199 | 6480464 | Amlodipine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:17234320 |
| doxorubicin | multiple interactions | ISO | RGD:10230 | 6480464 | sildenafil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:15811867 |
| doxorubicin | multiple interactions | ISO | RGD:10230 | 6480464 | tadalafil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:20543097 |
| doxorubicin | increases expression | ISO | RGD:10230 | 6480464 | Doxorubicin results in increased expression of BCL2 mRNA | CTD | PMID:15505089 |
| doxorubicin | multiple interactions | ISO | RGD:10230 | 6480464 | Doxycycline inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:17673183 |
| doxorubicin | decreases expression | ISO | RGD:10230 | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:15811867 more ... |
| doxorubicin | multiple interactions | ISO | RGD:10230 | 6480464 | BDKRB1 protein affects the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:18627295 |
| doxorubicin | multiple interactions | EXP | | 6480464 | Tamoxifen promotes the reaction [Doxorubicin results in increased expression of BCL2 mRNA] | CTD | PMID:19757172 |
| doxorubicin | multiple interactions | EXP | | 6480464 | Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein] | CTD | PMID:15571967 |
| doxorubicin | multiple interactions | EXP | | 6480464 | pluronic block copolymer p85 inhibits the reaction [Doxorubicin results in increased expression of BCL2 mRNA] | CTD | PMID:15939500 |
| doxorubicin | multiple interactions | EXP | | 6480464 | IFNA1 protein promotes the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:17959036 |
| doxorubicin | multiple interactions | EXP | | 6480464 | GSTA1 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:16890185 |
| doxorubicin | multiple interactions | EXP | | 6480464 | [F3 protein affects the expression of BCL2 protein] which affects the susceptibility to Doxorubicin; more ... | CTD | PMID:18325115 |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 protein | CTD | PMID:8781438 PMID:15571967 |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 protein | CTD | PMID:17959036 more ... |
| doxorubicin | increases expression | EXP | | 6480464 | Doxorubicin results in increased expression of BCL2 mRNA | CTD | PMID:19757172 more ... |
| doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of BCL2 mRNA | CTD | PMID:17404015 more ... |
| doxorubicin | multiple interactions | EXP | | 6480464 | Doxorubicin promotes the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:16168113 |
| doxorubicin | multiple interactions | EXP | | 6480464 | [Doxorubicin co-treated with Melatonin] results in decreased expression of BCL2 protein | CTD | PMID:20333787 |
| doxorubicin | multiple interactions | EXP | | 6480464 | [Doxorubicin co-treated with Cyclophosphamide] affects the expression of BCL2 mRNA | CTD | PMID:16322899 |
| doxorubicin | multiple interactions | EXP | | 6480464 | [[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:21214929 |
| doxorubicin | affects expression | EXP | | 6480464 | Doxorubicin affects the expression of BCL2 mRNA | CTD | PMID:16705698 |
| doxorubicin | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Doxorubicin | CTD | PMID:8781438 |
| doxorubicin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of and results in increased localization of BID protein]]; more ... | CTD | PMID:20856197 |
| doxorubicin | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Doxorubicin | CTD | PMID:16322301 more ... |
| doxorubicin | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; more ... | CTD | PMID:17542780 |
| doxycycline | multiple interactions | ISO | RGD:10230 | 6480464 | Doxycycline inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:17673183 |
| elemental selenium | decreases expression | EXP | | 6480464 | Selenium results in decreased expression of BCL2 protein | CTD | PMID:17523932 |
| ellagic acid | multiple interactions | ISO | RGD:10230 | 6480464 | [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA] | CTD | PMID:20103723 |
| ellagic acid | increases expression | EXP | | 6480464 | Ellagic Acid results in increased expression of BCL2 protein | CTD | PMID:22386815 |
| enalapril | increases expression | ISO | RGD:2199 | 6480464 | Enalapril results in increased expression of BCL2 protein | CTD | PMID:21153712 |
| enalaprilat dihydrate | increases expression | ISO | RGD:10230 | 6480464 | Enalaprilat results in increased expression of BCL2 mRNA | CTD | PMID:17342403 |
| endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of BCL2 protein | CTD | PMID:10821422 |
| erythromycin estolate | increases expression | ISO | RGD:2199 | 6480464 | Erythromycin Estolate results in increased expression of BCL2 mRNA | CTD | PMID:12883083 |
| estramustine | increases phosphorylation | EXP | | 6480464 | Estramustine results in increased phosphorylation of BCL2 protein | CTD | PMID:11763419 |
| ethanol | increases expression | EXP | | 6480464 | Ethanol results in increased expression of BCL2 protein | CTD | PMID:21410490 |
| ethanol | decreases expression | ISO | RGD:10230 | 6480464 | Ethanol results in decreased expression of BCL2 mRNA | CTD | PMID:22535522 |
| ethanol | decreases expression | ISO | RGD:10230 | 6480464 | Ethanol results in decreased expression of BCL2 protein | CTD | PMID:19429258 |
| ethanol | multiple interactions | ISO | RGD:2199 | 6480464 | Colchicine inhibits the reaction [Ethanol results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:22446813 |
| ethanol | multiple interactions | EXP | | 6480464 | ALDH2 protein inhibits the reaction [Ethanol results in decreased expression of BCL2 protein] | CTD | PMID:19429258 |
| ethanol | increases expression | ISO | RGD:2199 | 6480464 | Ethanol results in increased expression of BCL2 mRNA | CTD | PMID:22446813 |
| ethanol | multiple interactions | EXP | | 6480464 | 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Ethanol results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:21878650 |
| ethanol | decreases expression | EXP | | 6480464 | Ethanol results in decreased expression of BCL2 mRNA | CTD | PMID:21878650 |
| ethanol | decreases expression | ISO | RGD:2199 | 6480464 | Ethanol results in decreased expression of BCL2 mRNA | CTD | PMID:15353170 |
| ethanol | multiple interactions | ISO | RGD:2199 | 6480464 | [Ethanol co-treated with Cyanamide] results in increased expression of BCL2 mRNA | CTD | PMID:12003908 |
| ethanol | multiple interactions | ISO | RGD:2199 | 6480464 | Ethanol affects the reaction [BAX protein binds to BCL2 protein] | CTD | PMID:16035105 |
| ethanol | multiple interactions | ISO | RGD:2199 | 6480464 | [Ethanol co-treated with Carbon Tetrachloride] results in increased expression of BCL2 mRNA; more ... | CTD | PMID:16426832 |
| ethanol | affects localization | ISO | RGD:2199 | 6480464 | Ethanol affects the localization of BCL2 protein | CTD | PMID:16035105 |
| ethanol | multiple interactions | EXP | | 6480464 | Sirolimus promotes the reaction [Ethanol results in increased expression of BCL2 protein]; more ... | CTD | PMID:21410490 |
| ethidium | multiple interactions | EXP | | 6480464 | Ethidium inhibits the reaction [Estradiol results in increased expression of BCL2 mRNA] | CTD | PMID:15897899 |
| ethylbenzene | decreases expression | ISO | RGD:2199 | 6480464 | ethylbenzene results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:20156836 |
| etodolac | decreases expression | EXP | | 6480464 | Etodolac results in decreased expression of BCL2 protein; more ... | CTD | PMID:16046235 PMID:16104877 |
| etodolac | decreases expression | EXP | | 6480464 | Etodolac results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:16104877 PMID:16046235 |
| etoposide | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; more ... | CTD | PMID:8840993 |
| etoposide | multiple interactions | ISO | RGD:10230 | 6480464 | [G(M3) Ganglioside results in increased expression of BCL2 protein] which results in decreased susceptibility to Etoposide | CTD | PMID:16571667 |
| etoposide | decreases expression | ISO | RGD:10230 | 6480464 | Etoposide results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:19408126 |
| etoposide | multiple interactions | ISO | RGD:10230 | 6480464 | BCL2 protein affects the reaction [[Etoposide results in increased activity of GSK3B protein] which results in increased activity of CASP3 protein]; more ... | CTD | PMID:19408126 |
| etoposide | multiple interactions | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide] | CTD | PMID:15917659 |
| etoposide | multiple interactions | EXP | | 6480464 | [Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein | CTD | PMID:12063570 |
| eugenol | multiple interactions | EXP | | 6480464 | [Eugenol results in increased activity of sulforafan] which results in decreased expression of BCL2; more ... | CTD | PMID:21382956 |
| eugenol | multiple interactions | ISO | RGD:10230 | 6480464 | Eugenol inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2 protein]; more ... | CTD | PMID:20434464 |
| eugenol | multiple interactions | ISO | RGD:10230 | 6480464 | Eugenol inhibits the reaction [[9,10-Dimethyl-1,2-benzanthracene co-treated with Croton Oil] results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:20537511 |
| eugenol | decreases expression | EXP | | 6480464 | Eugenol results in decreased expression of BCL2 mRNA | CTD | PMID:21939359 |
| fenitrothion | increases expression | EXP | | 6480464 | Fenitrothion results in increased expression of BCL2 | CTD | PMID:21137095 |
| fenitrothion | increases expression | EXP | | 6480464 | Fenitrothion results in increased expression of BCL2 mRNA | CTD | PMID:21298709 |
| fenofibrate | decreases expression | EXP | | 6480464 | Fenofibrate results in decreased expression of BCL2 mRNA | CTD | PMID:15843896 |
| fipronil | decreases expression | EXP | | 6480464 | fipronil results in decreased expression of BCL2 protein | CTD | PMID:21296133 |
| flucytosine | decreases expression | EXP | | 6480464 | Flucytosine results in decreased expression of BCL2 protein | CTD | PMID:15592511 |
| fluoxetine | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Fluoxetine | CTD | PMID:16076491 |
| fluoxetine | decreases expression | ISO | RGD:2199 | 6480464 | Fluoxetine results in decreased expression of BCL2 protein | CTD | PMID:19298536 |
| fluoxetine | decreases expression | ISO | RGD:10230 | 6480464 | Fluoxetine results in decreased expression of BCL2 mRNA | CTD | PMID:21497159 |
| flutamide | increases expression | ISO | RGD:2199 | 6480464 | Flutamide results in increased expression of BCL2 mRNA; more ... | CTD | PMID:20850791 |
| folic acid | affects expression | EXP | | 6480464 | Folic Acid affects the expression of BCL2 mRNA | CTD | PMID:16611376 |
| folic acid | multiple interactions | ISO | RGD:10230 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of BCL2 mRNA; more ... | CTD | PMID:20938992 |
| folic acid | multiple interactions | ISO | RGD:2199 | 6480464 | [Vitamin E co-treated with Folic Acid] affects the expression of BCL2 protein | CTD | PMID:16933212 |
| folic acid | multiple interactions | ISO | RGD:2199 | 6480464 | [Folic Acid co-treated with Isoflavones] results in increased expression of BCL2 protein | CTD | PMID:20060418 |
| folic acid | affects expression | ISO | RGD:2199 | 6480464 | Folic Acid affects the expression of BCL2 protein | CTD | PMID:16933212 |
| folic acid | multiple interactions | ISO | RGD:10230 | 6480464 | PTHLH protein inhibits the reaction [Folic Acid results in increased expression of BCL2 protein] | CTD | PMID:16672315 |
| folic acid | multiple interactions | ISO | RGD:2199 | 6480464 | [Carbon Tetrachloride co-treated with Folic Acid] results in decreased expression of BCL2 mRNA | CTD | PMID:18156304 |
| formaldehyde | increases expression | EXP | | 6480464 | Formaldehyde results in increased expression of BCL2 protein | CTD | PMID:20347000 |
| formaldehyde | increases expression | ISO | RGD:10230 | 6480464 | Formaldehyde results in increased expression of BCL2 protein | CTD | PMID:16888403 |
| formaldehyde | multiple interactions | EXP | | 6480464 | PRDX2 protein inhibits the reaction [Formaldehyde results in increased expression of BCL2 protein] | CTD | PMID:20347000 |
| formoterol | decreases expression | EXP | | 6480464 | formoterol results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:14687023 |
| fulvestrant | multiple interactions | EXP | | 6480464 | ARTN protein inhibits the reaction [fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein]]; more ... | CTD | PMID:20305694 |
| fulvestrant | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:20305694 more ... |
| fulvestrant | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:10545406 more ... |
| fulvestrant | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:15870704 more ... |
| fulvestrant | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [Estradiol results in increased expression of BCL2 protein] | CTD | PMID:20305694 more ... |
| fulvestrant | multiple interactions | EXP | | 6480464 | fulvestrant inhibits the reaction [alachlor results in increased expression of BCL2 protein]; more ... | CTD | PMID:10545406 |
| fumagillin | multiple interactions | ISO | RGD:2199 | 6480464 | fumagillin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 mRNA] | CTD | PMID:15682466 |
| furan | increases expression | ISO | RGD:2199 | 6480464 | furan results in increased expression of BCL2 mRNA | CTD | PMID:22079235 |
| furosemide | affects expression | ISO | RGD:2199 | 6480464 | Furosemide affects the expression of BCL2 mRNA | CTD | PMID:17497460 |
| galactose | decreases expression | EXP | | 6480464 | Galactose results in decreased expression of BCL2 protein | CTD | PMID:23036742 |
| galactose | multiple interactions | EXP | | 6480464 | Phycocyanin inhibits the reaction [Galactose results in decreased expression of BCL2 protein] | CTD | PMID:23036742 |
| gallic acid | decreases expression | ISO | RGD:2199 | 6480464 | Gallic Acid results in decreased expression of BCL2 protein | CTD | PMID:19723098 |
| gallic acid | decreases expression | EXP | | 6480464 | Gallic Acid results in decreased expression of BCL2 protein | CTD | PMID:22245431 |
| gallic acid | multiple interactions | EXP | | 6480464 | Gallic Acid inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA] | CTD | PMID:21420233 |
| gallic acid | multiple interactions | ISO | RGD:2199 | 6480464 | resveratrol inhibits the reaction [Gallic Acid results in decreased expression of BCL2 protein] | CTD | PMID:19723098 |
| gamma-hexachlorocyclohexane | decreases expression | EXP | | 6480464 | Lindane results in decreased expression of BCL2 protein | CTD | PMID:14688026 |
| gamma-hexachlorocyclohexane | increases expression | EXP | | 6480464 | Lindane results in increased expression of BCL2 protein | CTD | PMID:14688026 PMID:18174961 |
| gamma-hexachlorocyclohexane | multiple interactions | EXP | | 6480464 | [Lindane co-treated with Estradiol] results in increased expression of BCL2 protein | CTD | PMID:18174961 |
| gamma-hexachlorocyclohexane | multiple interactions | ISO | RGD:2199 | 6480464 | Lindane promotes the reaction [BECN1 protein binds to BCL2 protein] | CTD | PMID:19041923 |
| gamma-hexachlorocyclohexane | increases expression | EXP | | 6480464 | Lindane results in increased expression of BCL2 protein; more ... | CTD | PMID:14688026 |
| ganciclovir | decreases expression | EXP | | 6480464 | Ganciclovir results in decreased expression of BCL2 protein | CTD | PMID:15592511 |
| geldanamycin | multiple interactions | EXP | | 6480464 | [geldanamycin co-treated with bortezomib] results in decreased expression of BCL2 protein | CTD | PMID:15781649 |
| genistein | multiple interactions | EXP | | 6480464 | [Calcitriol co-treated with Genistein] results in decreased expression of BCL2 mRNA | CTD | PMID:15955619 |
| genistein | multiple interactions | EXP | | 6480464 | arsenic trioxide promotes the reaction [Genistein results in decreased expression of BCL2 protein]; more ... | CTD | PMID:20219070 |
| genistein | decreases expression | EXP | | 6480464 | Genistein results in decreased expression of BCL2 protein | CTD | PMID:12791511 more ... |
| genistein | decreases expression | EXP | | 6480464 | Genistein results in decreased expression of BCL2 protein | CTD | PMID:12791511 PMID:21078540 |
| genistein | decreases expression | ISO | RGD:10230 | 6480464 | Genistein results in decreased expression of BCL2 protein | CTD | PMID:21078540 |
| genistein | multiple interactions | ISO | RGD:10230 | 6480464 | [Genistein co-treated with arsenic trioxide] results in decreased expression of BCL2 protein | CTD | PMID:21078540 |
| genistein | multiple interactions | EXP | | 6480464 | Genistein inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:15907805 |
| genistein | multiple interactions | EXP | | 6480464 | Genistein inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein] | CTD | PMID:15288519 |
| genistein | decreases expression | EXP | | 6480464 | Genistein results in decreased expression of BCL2 protein | CTD | PMID:21078540 PMID:12791511 |
| genistein | multiple interactions | EXP | | 6480464 | [Genistein co-treated with TNFSF10 protein] results in decreased expression of BCL2 protein | CTD | PMID:19497411 |
| genistein | multiple interactions | EXP | | 6480464 | [Genistein co-treated with arsenic trioxide] results in decreased expression of BCL2 protein | CTD | PMID:21078540 |
| gliclazide | multiple interactions | EXP | | 6480464 | Gliclazide inhibits the reaction [Glucose results in decreased expression of BCL2 protein] | CTD | PMID:18088078 |
| glucose | multiple interactions | EXP | | 6480464 | Catechin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein]; more ... | CTD | PMID:19557821 |
| glucose | multiple interactions | ISO | RGD:10230 | 6480464 | [Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:23108914 |
| glucose | decreases expression | ISO | RGD:2199 | 6480464 | Glucose results in decreased expression of BCL2 mRNA | CTD | PMID:21818840 |
| glucose | multiple interactions | EXP | | 6480464 | [[NS 1619 co-treated with Glucose] results in increased activity of [KCNMA1 protein binds to KCNMB1 protein]] which results in decreased expression of BCL2 protein; more ... | CTD | PMID:21413024 |
| glucose | decreases expression | EXP | | 6480464 | Glucose results in decreased expression of BCL2 protein | CTD | PMID:18088078 |
| glucose | multiple interactions | EXP | | 6480464 | Gliclazide inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; more ... | CTD | PMID:18088078 |
| glutathione | multiple interactions | EXP | | 6480464 | Glutathione inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]] | CTD | PMID:17640567 |
| glutathione | decreases export | ISO | RGD:10230 | 6480464 | BCL2 protein results in decreased export of Glutathione | CTD | PMID:15561710 |
| haloperidol | increases expression | ISO | RGD:2199 | 6480464 | Haloperidol results in increased expression of BCL2 protein | CTD | PMID:17069804 |
| heparin | increases expression | EXP | | 6480464 | Heparin results in increased expression of BCL2 protein | CTD | PMID:15671997 more ... |
| heparin | increases expression | EXP | | 6480464 | Heparin results in increased expression of BCL2 protein | CTD | PMID:11787776 more ... |
| heparin | increases expression | EXP | | 6480464 | Heparin results in increased expression of BCL2 protein | CTD | PMID:15671997 more ... |
| heparin | increases expression | EXP | | 6480464 | Heparin results in increased expression of BCL2 protein | CTD | PMID:11787776 more ... |
| heptachlor | increases expression | ISO | RGD:2199 | 6480464 | Heptachlor results in increased expression of BCL2 protein | CTD | PMID:14678745 |
| heptadecafluorononanoic acid | decreases expression | ISO | RGD:2199 | 6480464 | perfluoro-n-nonanoic acid results in decreased expression of BCL2 mRNA | CTD | PMID:19196829 |
| heptadecafluorononanoic acid | decreases expression | ISO | RGD:2199 | 6480464 | perfluoro-n-nonanoic acid results in decreased expression of BCL2 mRNA | CTD | PMID:19196829 PMID:19646514 |
| heptadecafluorononanoic acid | decreases expression | ISO | RGD:2199 | 6480464 | perfluoro-n-nonanoic acid results in decreased expression of BCL2 protein | CTD | PMID:19878704 |
| hesperetin | affects expression | EXP | | 6480464 | hesperetin affects the expression of BCL2 protein | CTD | PMID:15975156 |
| hesperetin | decreases expression | EXP | | 6480464 | hesperetin analog results in decreased expression of BCL2 protein; more ... | CTD | PMID:22142698 |
| hesperetin | decreases expression | ISO | RGD:2199 | 6480464 | hesperetin analog results in decreased expression of BCL2 mRNA | CTD | PMID:20564462 |
| hesperidin | multiple interactions | ISO | RGD:2199 | 6480464 | Hesperidin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:22093918 |
| hexane | increases expression | ISO | RGD:2199 | 6480464 | n-hexane metabolite results in increased expression of BCL2 protein | CTD | PMID:17492505 |
| hydrogen peroxide | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Hydrogen Peroxide | CTD | PMID:9989825 |
| hydrogen peroxide | decreases expression | EXP | | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:12672908 more ... |
| hydrogen peroxide | multiple interactions | EXP | | 6480464 | bathophenanthroline disulfonic acid inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; more ... | CTD | PMID:20096349 |
| hydrogen peroxide | multiple interactions | EXP | | 6480464 | RELA protein promotes the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; more ... | CTD | PMID:21347231 |
| hydrogen peroxide | decreases expression | EXP | | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 mRNA | CTD | PMID:21347231 PMID:22245672 |
| hydrogen peroxide | decreases expression | EXP | | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:12672908 PMID:21347231 |
| hydrogen peroxide | decreases expression | EXP | | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 mRNA | CTD | PMID:22245672 |
| hydrogen peroxide | decreases expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:16249675 more ... |
| hydrogen peroxide | decreases expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:22081883 more ... |
| hydrogen peroxide | decreases expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:20041988 more ... |
| hydrogen peroxide | decreases expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:22081883 more ... |
| hydrogen peroxide | multiple interactions | ISO | RGD:2199 | 6480464 | calycopterin results in decreased susceptibility to [Hydrogen Peroxide results in decreased expression of BCL2 protein] | CTD | PMID:22081883 |
| hydrogen peroxide | decreases expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:19703415 more ... |
| hydrogen peroxide | decreases expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:20041988 more ... |
| hydrogen peroxide | affects expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide affects the expression of BCL2 mRNA; more ... | CTD | PMID:17204550 PMID:17570061 |
| hydrogen peroxide | multiple interactions | ISO | RGD:2199 | 6480464 | [[pirinixic acid results in increased expression of UCP2 protein] which results in increased abundance of Hydrogen Peroxide] which results in decreased expression of BCL2 protein | CTD | PMID:19361538 |
| hydrogen peroxide | multiple interactions | ISO | RGD:2199 | 6480464 | RLN2 protein affects the reaction [Hydrogen Peroxide affects the expression of BCL2 mRNA]; more ... | CTD | PMID:17204550 |
| hydrogen peroxide | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] | CTD | PMID:20041988 |
| hydrogen peroxide | multiple interactions | ISO | RGD:2199 | 6480464 | Isoflurane inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] | CTD | PMID:16249675 |
| hydrogen peroxide | increases expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide results in increased expression of BCL2 protein | CTD | PMID:16157298 |
| hydrogen peroxide | decreases expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:19345205 more ... |
| hydrogen peroxide | multiple interactions | ISO | RGD:2199 | 6480464 | Indomethacin inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2 mRNA]; more ... | CTD | PMID:17570061 |
| hydrogen peroxide | affects expression | ISO | RGD:2199 | 6480464 | Hydrogen Peroxide affects the expression of BCL2 mRNA; more ... | CTD | PMID:17570061 PMID:17204550 |
| hydrogen peroxide | multiple interactions | ISO | RGD:2199 | 6480464 | 2-(4-((dimethylamino)methyl)benzylidene)-5,6-dimethoxy-2,3-dihydroinden-1-one inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; more ... | CTD | PMID:19345205 |
| hydrogen peroxide | affects response to substance | ISO | RGD:10230 | 6480464 | BCL2 protein affects the susceptibility to Hydrogen Peroxide | CTD | PMID:15746559 |
| hydrogen peroxide | multiple interactions | EXP | | 6480464 | [Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2 protein] results in increased expression of BCL2 mRNA; more ... | CTD | PMID:20606027 |
| hydrogen peroxide | increases expression | EXP | | 6480464 | Hydrogen Peroxide results in increased expression of BCL2 protein | CTD | PMID:8781438 |
| hydrogen peroxide | multiple interactions | EXP | | 6480464 | epigallocatechin gallate inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; more ... | CTD | PMID:12672908 |
| hydrogen peroxide | decreases expression | EXP | | 6480464 | Hydrogen Peroxide results in decreased expression of BCL2 protein | CTD | PMID:12672908 |
| hydroxytyrosol | increases phosphorylation | EXP | | 6480464 | 3,4-dihydroxyphenylethanol results in increased phosphorylation of BCL2 protein | CTD | PMID:12482581 |
| hypoxanthine | multiple interactions | EXP | | 6480464 | [3-hydrogenkwadaphnin co-treated with Hypoxanthine] results in decreased expression of BCL2 protein; more ... | CTD | PMID:21396949 |
| ifosfamide | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Ifosfamide results in increased activity of CASP9 protein] | CTD | PMID:11723234 |
| imiquimod | decreases expression | EXP | | 6480464 | imiquimod results in decreased expression of BCL2 protein | CTD | PMID:20033192 |
| indole-3-methanol | decreases expression | EXP | | 6480464 | indole-3-carbinol results in decreased expression of BCL2 | CTD | PMID:16082211 |
| indole-3-methanol | multiple interactions | EXP | | 6480464 | indole-3-carbinol inhibits the reaction [TNF protein results in increased expression of BCL2 protein] | CTD | PMID:15811958 |
| indomethacin | decreases expression | EXP | | 6480464 | Indomethacin results in decreased expression of BCL2 mRNA | CTD | PMID:10785260 PMID:11721434 |
| indomethacin | multiple interactions | ISO | RGD:2199 | 6480464 | tryptamine analog inhibits the reaction [Indomethacin results in decreased expression of BCL2 mRNA] | CTD | PMID:22157011 |
| indomethacin | decreases expression | ISO | RGD:2199 | 6480464 | Indomethacin results in decreased expression of BCL2 mRNA | CTD | PMID:19220725 PMID:22157011 |
| indomethacin | decreases expression | EXP | | 6480464 | Indomethacin results in decreased expression of BCL2 protein | CTD | PMID:18678619 PMID:10785260 |
| indomethacin | decreases expression | EXP | | 6480464 | Indomethacin results in decreased expression of BCL2 mRNA | CTD | PMID:11721434 PMID:10785260 |
| indomethacin | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [Indomethacin results in decreased expression of BCL2 mRNA] | CTD | PMID:19220725 |
| indomethacin | multiple interactions | ISO | RGD:2199 | 6480464 | lansoprazole inhibits the reaction [Indomethacin results in decreased expression of BCL2 protein] | CTD | PMID:18375387 |
| indomethacin | decreases expression | ISO | RGD:2199 | 6480464 | Indomethacin results in decreased expression of BCL2 protein | CTD | PMID:18375387 |
| indomethacin | decreases expression | ISO | RGD:2199 | 6480464 | Indomethacin results in decreased expression of BCL2 mRNA | CTD | PMID:19220725 |
| indomethacin | multiple interactions | ISO | RGD:2199 | 6480464 | Indomethacin inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2 mRNA]; more ... | CTD | PMID:17570061 |
| indomethacin | decreases expression | EXP | | 6480464 | Indomethacin results in decreased expression of BCL2 protein | CTD | PMID:10785260 PMID:18678619 |
| irbesartan | multiple interactions | ISO | RGD:2199 | 6480464 | irbesartan inhibits the reaction [ioversol results in decreased expression of BCL2 mRNA] | CTD | PMID:16828304 |
| iron atom | multiple interactions | EXP | | 6480464 | [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; more ... | CTD | PMID:19620254 |
| isoflurane | multiple interactions | ISO | RGD:2199 | 6480464 | Isoflurane inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; more ... | CTD | PMID:16249675 |
| isoflurane | multiple interactions | ISO | RGD:2199 | 6480464 | Dexmedetomidine inhibits the reaction [Isoflurane results in decreased expression of BCL2 protein] | CTD | PMID:20003127 |
| isoflurane | decreases expression | ISO | RGD:2199 | 6480464 | Isoflurane results in decreased expression of BCL2 protein | CTD | PMID:20003127 |
| isoniazide | multiple interactions | ISO | RGD:10230 | 6480464 | [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; more ... | CTD | PMID:21419764 |
| isoorientin | multiple interactions | ISO | RGD:2199 | 6480464 | homoorientin inhibits the reaction [Ethanol results in increased expression of BCL2 mRNA] | CTD | PMID:22446813 |
| isoprenaline | decreases expression | ISO | RGD:10230 | 6480464 | Isoproterenol results in decreased expression of BCL2 protein | CTD | PMID:15052282 |
| isoprenaline | multiple interactions | ISO | RGD:2199 | 6480464 | echinocystic acid affects the reaction [Isoproterenol affects the expression of BCL2 mRNA] | CTD | PMID:19573579 |
| isoprenaline | increases expression | ISO | RGD:2199 | 6480464 | Isoproterenol results in increased expression of BCL2 mRNA | CTD | PMID:11218852 |
| isoprenaline | decreases expression | ISO | RGD:2199 | 6480464 | Isoproterenol results in decreased expression of BCL2 protein | CTD | PMID:12791704 |
| isotretinoin | decreases expression | EXP | | 6480464 | Isotretinoin results in decreased expression of BCL2 | CTD | PMID:16909596 |
| isotretinoin | decreases expression | ISO | RGD:10230 | 6480464 | Isotretinoin results in decreased expression of BCL2 mRNA | CTD | PMID:18380168 |
| isotretinoin | decreases expression | ISO | RGD:10230 | 6480464 | Isotretinoin results in decreased expression of BCL2 | CTD | PMID:18652567 |
| isotretinoin | increases expression | EXP | | 6480464 | Isotretinoin results in increased expression of BCL2 mRNA; more ... | CTD | PMID:21159604 |
| isotretinoin | decreases expression | EXP | | 6480464 | Isotretinoin results in decreased expression of BCL2 protein | CTD | PMID:16109544 |
| kaempferol | decreases expression | EXP | | 6480464 | kaempferol results in decreased expression of BCL2 protein | CTD | PMID:19028473 |
| L-ascorbic acid | multiple interactions | EXP | | 6480464 | Ascorbic Acid inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein] | CTD | PMID:17166419 |
| L-ascorbic acid | multiple interactions | ISO | RGD:2199 | 6480464 | Ascorbic Acid inhibits the reaction [Humic Substances results in decreased expression of BCL2 protein] | CTD | PMID:18683188 |
| L-ascorbic acid | multiple interactions | EXP | | 6480464 | Ascorbic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of BCL2 protein]; more ... | CTD | PMID:22245848 |
| L-ascorbic acid | multiple interactions | ISO | RGD:2199 | 6480464 | Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BCL2 protein] | CTD | PMID:21262251 |
| L-ascorbic acid | multiple interactions | ISO | RGD:2199 | 6480464 | Ascorbic Acid inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein] | CTD | PMID:18758938 |
| L-ascorbic acid | multiple interactions | ISO | RGD:2199 | 6480464 | Ascorbic Acid promotes the reaction [lead acetate results in increased expression of BCL2 protein] | CTD | PMID:17959157 |
| L-ascorbic acid | increases abundance | EXP | | 6480464 | BCL2 protein results in increased abundance of Ascorbic Acid | CTD | PMID:15449323 |
| L-ascorbic acid | decreases expression | EXP | | 6480464 | Ascorbic Acid results in decreased expression of BCL2 mRNA | CTD | PMID:21919647 |
| L-dehydroascorbic acid | multiple interactions | EXP | | 6480464 | [Dehydroascorbic Acid co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein | CTD | PMID:20166893 |
| L-dehydroascorbic acid | increases expression | EXP | | 6480464 | Dehydroascorbic Acid results in increased expression of BCL2 protein | CTD | PMID:20166893 |
| L-methionine | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [Methionine results in decreased expression of BCL2 protein] | CTD | PMID:16213988 |
| L-methionine | multiple interactions | ISO | RGD:10230 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of and results in increased expression of BCL2; more ... | CTD | PMID:20938992 |
| L-methionine | decreases expression | ISO | RGD:2199 | 6480464 | Methionine results in decreased expression of BCL2 protein | CTD | PMID:16213988 |
| L-mimosine | affects expression | EXP | | 6480464 | Mimosine affects the expression of BCL2 protein | CTD | PMID:18058236 |
| lactacystin | decreases expression | ISO | RGD:2199 | 6480464 | lactacystin results in decreased expression of BCL2 protein | CTD | PMID:18640276 |
| lactacystin | multiple interactions | ISO | RGD:2199 | 6480464 | Sirolimus inhibits the reaction [lactacystin results in decreased expression of BCL2 protein] | CTD | PMID:18640276 |
| lactacystin | multiple interactions | ISO | RGD:2199 | 6480464 | lactacystin inhibits the reaction [[pirinixic acid results in increased expression of UCP2 protein] which results in increased degradation of BCL2 protein] | CTD | PMID:19361538 |
| lamivudine | multiple interactions | ISO | RGD:10230 | 6480464 | [Zidovudine co-treated with Lamivudine] results in decreased expression of BCL2 mRNA | CTD | PMID:18313992 |
| lamotrigine | increases expression | ISO | RGD:2199 | 6480464 | lamotrigine results in increased expression of BCL2 mRNA; more ... | CTD | PMID:18719996 |
| lansoprazole | multiple interactions | ISO | RGD:2199 | 6480464 | lansoprazole inhibits the reaction [Indomethacin results in decreased expression of BCL2 protein] | CTD | PMID:18375387 |
| lead diacetate | increases expression | ISO | RGD:2199 | 6480464 | lead acetate results in increased expression of BCL2 protein | CTD | PMID:17959157 |
| lead diacetate | decreases expression | ISO | RGD:2199 | 6480464 | lead acetate results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:23146751 |
| lead diacetate | increases expression | ISO | RGD:10230 | 6480464 | lead acetate results in increased expression of BCL2 mRNA | CTD | PMID:22609695 |
| lead diacetate | affects expression | ISO | RGD:2199 | 6480464 | lead acetate affects the expression of BCL2 mRNA | CTD | PMID:18618274 |
| lead diacetate | increases expression | ISO | RGD:2199 | 6480464 | lead acetate results in increased expression of BCL2 protein | CTD | PMID:17959157 PMID:19026729 |
| lead diacetate | multiple interactions | ISO | RGD:2199 | 6480464 | Ascorbic Acid promotes the reaction [lead acetate results in increased expression of BCL2 protein] | CTD | PMID:17959157 |
| lead(0) | decreases expression | ISO | RGD:2199 | 6480464 | Lead results in decreased expression of BCL2 protein | CTD | PMID:22129743 |
| lead(0) | multiple interactions | ISO | RGD:2199 | 6480464 | Plant Extracts inhibits the reaction [Lead results in decreased expression of BCL2 protein] | CTD | PMID:22129743 |
| leptomycin B | multiple interactions | EXP | | 6480464 | leptomycin B inhibits the reaction [Tretinoin results in decreased expression of BCL2 protein] | CTD | PMID:14592536 |
| levonorgestrel | decreases expression | EXP | | 6480464 | Levonorgestrel results in decreased expression of BCL2 protein | CTD | PMID:16019350 |
| limonene | decreases expression | EXP | | 6480464 | limonene results in decreased expression of BCL2 protein | CTD | PMID:12921557 |
| lipoic acid | multiple interactions | EXP | | 6480464 | Thioctic Acid results in increased degradation of and results in decreased expression of BCL2 protein | CTD | PMID:16990509 |
| lipoic acid | multiple interactions | EXP | | 6480464 | Thioctic Acid inhibits the reaction [Zinc deficiency results in decreased expression of BCL2 protein] | CTD | PMID:21600978 |
| lipoic acid | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Thioctic Acid | CTD | PMID:16990509 |
| lisinopril dihydrate | decreases expression | EXP | | 6480464 | Lisinopril results in decreased expression of BCL2 | CTD | PMID:10075388 |
| lithium atom | multiple interactions | ISO | RGD:2199 | 6480464 | Lithium inhibits the reaction [APP protein alternative form results in decreased expression of BCL2 protein] | CTD | PMID:10762662 |
| lithium atom | multiple interactions | EXP | | 6480464 | Lithium inhibits the reaction [Ethanol results in decreased expression of BCL2 mRNA] | CTD | PMID:21878650 |
| lithium atom | multiple interactions | ISO | RGD:2199 | 6480464 | Lithium inhibits the reaction [Cadmium results in decreased expression of BCL2 protein] | CTD | PMID:20455018 |
| lithium atom | increases expression | ISO | RGD:2199 | 6480464 | Lithium results in increased expression of BCL2 protein | CTD | PMID:10762662 |
| lithium atom | increases expression | ISO | RGD:2199 | 6480464 | Lithium results in increased expression of BCL2 mRNA | CTD | PMID:16288908 |
| lithium atom | increases expression | ISO | RGD:2199 | 6480464 | Lithium results in increased expression of BCL2 | CTD | PMID:15581403 |
| lithium atom | multiple interactions | ISO | RGD:2199 | 6480464 | Lithium inhibits the reaction [Morphine results in decreased expression of BCL2 mRNA] | CTD | PMID:18976035 |
| lithium atom | multiple interactions | ISO | RGD:2199 | 6480464 | Lithium inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein] | CTD | PMID:19149911 |
| lithium chloride | increases expression | EXP | | 6480464 | Lithium Chloride results in increased expression of BCL2 mRNA | CTD | PMID:19101580 |
| lithium chloride | increases expression | ISO | RGD:2199 | 6480464 | Lithium Chloride results in increased expression of BCL2 mRNA | CTD | PMID:17404573 |
| lithium chloride | multiple interactions | ISO | RGD:10230 | 6480464 | Lithium Chloride inhibits the reaction [Etoposide results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:19408126 |
| lithium chloride | increases expression | EXP | | 6480464 | Lithium Chloride results in increased expression of BCL2 protein | CTD | PMID:18830594 |
| lonidamine | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [[arsenic trioxide co-treated with lonidamine] results in increased cleavage of and results in increased activity of CASP8 protein]; more ... | CTD | PMID:21889928 |
| losartan | multiple interactions | ISO | RGD:2199 | 6480464 | Losartan promotes the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of BCL2 mRNA] | CTD | PMID:15502641 |
| losartan | affects expression | ISO | RGD:2199 | 6480464 | Losartan affects the expression of BCL2 protein | CTD | PMID:22000973 |
| losartan | increases expression | ISO | RGD:2199 | 6480464 | Losartan results in increased expression of BCL2 protein | CTD | PMID:19298698 PMID:21153712 |
| losartan | increases expression | ISO | RGD:2199 | 6480464 | Losartan results in increased expression of BCL2 protein | CTD | PMID:21153712 PMID:19298698 |
| losartan | increases expression | ISO | RGD:2199 | 6480464 | Losartan results in increased expression of BCL2 protein | CTD | PMID:19298698 |
| losartan | decreases expression | ISO | RGD:2199 | 6480464 | Losartan results in decreased expression of BCL2 protein | CTD | PMID:12623880 |
| lovastatin | decreases expression | ISO | RGD:2199 | 6480464 | Lovastatin results in decreased expression of BCL2 protein | CTD | PMID:11178870 |
| lovastatin | decreases expression | EXP | | 6480464 | Lovastatin results in decreased expression of BCL2 protein | CTD | PMID:12094262 PMID:10473109 |
| lovastatin | multiple interactions | ISO | RGD:2199 | 6480464 | Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] | CTD | PMID:11178870 |
| lovastatin | multiple interactions | EXP | | 6480464 | Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] | CTD | PMID:12094262 |
| lovastatin | decreases expression | EXP | | 6480464 | Lovastatin results in decreased expression of BCL2 protein | CTD | PMID:10473109 PMID:12094262 |
| lutein | decreases expression | EXP | | 6480464 | Lutein results in decreased expression of BCL2 protein | CTD | PMID:17455471 |
| luteolin | multiple interactions | EXP | | 6480464 | Luteolin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] | CTD | PMID:19557821 |
| LY294002 | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of and results in increased localization of BID protein]]; more ... | CTD | PMID:20856197 |
| LY294002 | multiple interactions | EXP | | 6480464 | [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Tamoxifen] results in decreased expression of BCL2 protein; more ... | CTD | PMID:22046442 |
| LY294002 | increases expression | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of BCL2 mRNA | CTD | PMID:22046442 |
| LY294002 | increases phosphorylation | ISO | RGD:2199 | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased phosphorylation of BCL2 protein | CTD | PMID:16018989 |
| LY294002 | decreases expression | EXP | | 6480464 | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BCL2 protein | CTD | PMID:21130731 |
| lycopene | multiple interactions | ISO | RGD:2199 | 6480464 | lycopene inhibits the reaction [[Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in increased expression of BCL2 protein]; more ... | CTD | PMID:16030430 |
| malonic acid | decreases expression | ISO | RGD:2199 | 6480464 | malonic acid results in decreased expression of BCL2 mRNA | CTD | PMID:16242643 |
| manganese(II) chloride | decreases expression | ISO | RGD:2199 | 6480464 | manganese chloride results in decreased expression of BCL2 mRNA | CTD | PMID:17623882 |
| mangiferin | multiple interactions | EXP | | 6480464 | mangiferin inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA] | CTD | PMID:21420233 |
| mebendazole | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Mebendazole | CTD | PMID:18667591 |
| mebendazole | multiple interactions | EXP | | 6480464 | [Mebendazole results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein] | CTD | PMID:18667591 |
| mebendazole | increases phosphorylation | EXP | | 6480464 | Mebendazole results in increased phosphorylation of BCL2 protein | CTD | PMID:18667591 |
| mechlorethamine | decreases expression | EXP | | 6480464 | Mechlorethamine results in decreased expression of BCL2 protein | CTD | PMID:16738803 |
| meglumine amidotrizoate | increases expression | EXP | | 6480464 | Diatrizoate Meglumine results in increased expression of BCL2 protein | CTD | PMID:17173243 |
| melamine | decreases expression | EXP | | 6480464 | melamine results in decreased expression of BCL2 protein | CTD | PMID:22915474 |
| melatonin | multiple interactions | EXP | | 6480464 | [Doxorubicin co-treated with Melatonin] results in decreased expression of BCL2 protein | CTD | PMID:20333787 |
| melatonin | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [decamethrin results in decreased expression of BCL2 protein] | CTD | PMID:18724894 |
| melatonin | decreases expression | ISO | RGD:2199 | 6480464 | Melatonin results in decreased expression of BCL2 mRNA | CTD | PMID:16499559 |
| melatonin | multiple interactions | ISO | RGD:2199 | 6480464 | [Puromycin Aminonucleoside co-treated with Melatonin] results in increased expression of BCL2 protein | CTD | PMID:14993511 |
| melatonin | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein] | CTD | PMID:17645694 |
| melatonin | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [sodium arsenite results in increased activity of BCL2 protein] | CTD | PMID:18715270 |
| melatonin | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [Methionine results in decreased expression of BCL2 protein] | CTD | PMID:16213988 |
| melatonin | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] | CTD | PMID:20041988 |
| melatonin | multiple interactions | ISO | RGD:2199 | 6480464 | Melatonin inhibits the reaction [Indomethacin results in decreased expression of BCL2 mRNA] | CTD | PMID:19220725 |
| melatonin | decreases expression | ISO | RGD:10230 | 6480464 | Melatonin results in decreased expression of BCL2 protein | CTD | PMID:14690559 |
| melatonin | multiple interactions | ISO | RGD:10230 | 6480464 | Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 protein] | CTD | PMID:21138475 |
| melatonin | increases expression | ISO | RGD:10230 | 6480464 | Melatonin results in increased expression of BCL2 protein | CTD | PMID:12220328 |
| melatonin | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with Melatonin] results in decreased expression of BCL2 protein | CTD | PMID:9649124 |
| melatonin | increases expression | EXP | | 6480464 | Melatonin results in increased expression of BCL2 protein | CTD | PMID:18078454 |
| melatonin | multiple interactions | EXP | | 6480464 | Melatonin promotes the reaction [Puromycin results in decreased expression of BCL2 protein] | CTD | PMID:21244482 |
| melatonin | affects localization | EXP | | 6480464 | Melatonin affects the localization of BCL2 protein | CTD | PMID:18339127 |
| melatonin | multiple interactions | EXP | | 6480464 | [Melatonin co-treated with Tretinoin] results in decreased expression of BCL2 protein | CTD | PMID:10965999 |
| menadione | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in decreased expression of BCL2 protein] | CTD | PMID:19082730 |
| menadione | decreases expression | ISO | RGD:2199 | 6480464 | Vitamin K 3 results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:19265712 |
| menadione | multiple interactions | ISO | RGD:2199 | 6480464 | Acetaminophen inhibits the reaction [Vitamin K 3 results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:19265712 |
| mercaptopurine | decreases expression | ISO | RGD:10230 | 6480464 | 6-Mercaptopurine results in decreased expression of BCL2 protein | CTD | PMID:9058596 |
| mercury atom | decreases expression | ISO | RGD:2199 | 6480464 | Mercury results in decreased expression of BCL2 protein | CTD | PMID:21186712 |
| mercury dichloride | decreases expression | ISO | RGD:10230 | 6480464 | Mercuric Chloride results in decreased expression of BCL2 protein | CTD | PMID:21373768 |
| mercury dichloride | increases expression | EXP | | 6480464 | Mercuric Chloride results in increased expression of BCL2 protein | CTD | PMID:11068922 |
| mercury(0) | decreases expression | ISO | RGD:2199 | 6480464 | Mercury results in decreased expression of BCL2 protein | CTD | PMID:21186712 |
| metformin | decreases expression | EXP | | 6480464 | Metformin results in decreased expression of BCL2 protein | CTD | PMID:21388661 |
| metformin | multiple interactions | EXP | | 6480464 | Cisplatin promotes the reaction [Metformin results in decreased expression of BCL2 protein] | CTD | PMID:21388661 |
| methamphetamine | affects response to substance | ISO | RGD:10230 | 6480464 | BCL2 protein affects the susceptibility to Methamphetamine | CTD | PMID:12050851 |
| methamphetamine | multiple interactions | ISO | RGD:10230 | 6480464 | NOS1 protein affects the reaction [Methamphetamine results in decreased expression of BCL2 protein]; more ... | CTD | PMID:11457507 |
| methamphetamine | decreases expression | ISO | RGD:10230 | 6480464 | Methamphetamine results in decreased expression of BCL2 protein | CTD | PMID:11457507 |
| methamphetamine | decreases expression | ISO | RGD:2199 | 6480464 | Methamphetamine results in decreased expression of BCL2 protein | CTD | PMID:19149911 PMID:15276877 |
| methamphetamine | multiple interactions | ISO | RGD:2199 | 6480464 | olanzapine inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein] | CTD | PMID:15276877 |
| methamphetamine | decreases expression | ISO | RGD:2199 | 6480464 | Methamphetamine results in decreased expression of BCL2 protein | CTD | PMID:15276877 PMID:19149911 |
| methamphetamine | multiple interactions | ISO | RGD:2199 | 6480464 | Lithium inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; more ... | CTD | PMID:19149911 |
| methotrexate | decreases expression | EXP | | 6480464 | Methotrexate results in decreased expression of BCL2 mRNA | CTD | PMID:17132110 |
| methoxsalen | multiple interactions | EXP | | 6480464 | Methoxsalen inhibits the reaction [Aflatoxin B1 results in decreased expression of BCL2 protein] | CTD | PMID:22743290 |
| methoxsalen | decreases expression | EXP | | 6480464 | Methoxsalen results in decreased expression of BCL2 protein | CTD | PMID:22796345 |
| methoxychlor | decreases response to substance | ISO | RGD:10230 | 6480464 | BCL2 protein results in decreased susceptibility to Methoxychlor | CTD | PMID:14973267 PMID:16081520 |
| methoxychlor | multiple interactions | ISO | RGD:10230 | 6480464 | [ESR1 gene mutant form results in increased susceptibility to Methoxychlor] which results in increased expression of BCL2 mRNA | CTD | PMID:22306526 |
| methoxychlor | decreases response to substance | ISO | RGD:10230 | 6480464 | BCL2 protein results in decreased susceptibility to Methoxychlor | CTD | PMID:16081520 PMID:14973267 |
| methoxychlor | increases expression | ISO | RGD:10230 | 6480464 | Methoxychlor metabolite results in increased expression of BCL2 protein; more ... | CTD | PMID:15525693 |
| methoxychlor | decreases expression | ISO | RGD:10230 | 6480464 | Methoxychlor results in decreased expression of BCL2 mRNA | CTD | PMID:16081520 |
| methyl methanesulfonate | decreases expression | ISO | RGD:10230 | 6480464 | Methyl Methanesulfonate results in decreased expression of BCL2 protein | CTD | PMID:16019050 |
| metipranolol | multiple interactions | ISO | RGD:2199 | 6480464 | Metipranolol inhibits the reaction [Zinc results in increased expression of BCL2 protein]; more ... | CTD | PMID:16799065 |
| mevalonic acid | multiple interactions | ISO | RGD:2199 | 6480464 | Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] | CTD | PMID:11178870 |
| mevalonic acid | multiple interactions | EXP | | 6480464 | Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] | CTD | PMID:12094262 |
| microcystin-LR | increases expression | EXP | | 6480464 | cyanoginosin LR results in increased expression of BCL2 | CTD | PMID:16624733 |
| microcystin-LR | decreases expression | EXP | | 6480464 | cyanoginosin LR results in decreased expression of BCL2 protein | CTD | PMID:18214937 |
| mifepristone | multiple interactions | EXP | | 6480464 | Mifepristone inhibits the reaction [Dexamethasone results in increased expression of BCL2] | CTD | PMID:21244764 |
| mifepristone | decreases expression | EXP | | 6480464 | Mifepristone results in decreased expression of BCL2 protein | CTD | PMID:16638347 PMID:16525653 |
| mifepristone | multiple interactions | ISO | RGD:10230 | 6480464 | Mifepristone inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein]; more ... | CTD | PMID:16644695 |
| mifepristone | decreases expression | EXP | | 6480464 | Mifepristone results in decreased expression of BCL2 protein | CTD | PMID:16525653 PMID:16638347 |
| mifepristone | decreases expression | EXP | | 6480464 | Mifepristone results in decreased expression of BCL2 mRNA | CTD | PMID:16009178 |
| minocycline | multiple interactions | EXP | | 6480464 | [Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2 protein] results in increased expression of BCL2 mRNA; more ... | CTD | PMID:20606027 |
| minocycline | increases expression | ISO | RGD:2199 | 6480464 | Minocycline results in increased expression of BCL2 protein | CTD | PMID:20711699 more ... |
| minocycline | increases expression | ISO | RGD:2199 | 6480464 | Minocycline results in increased expression of BCL2 protein | CTD | PMID:20711699 more ... |
| minocycline | increases expression | ISO | RGD:2199 | 6480464 | Minocycline results in increased expression of BCL2 protein | CTD | PMID:15004018 more ... |
| minocycline | increases expression | ISO | RGD:2199 | 6480464 | Minocycline results in increased expression of BCL2 protein | CTD | PMID:15004018 more ... |
| minocycline | multiple interactions | ISO | RGD:2199 | 6480464 | [Minocycline results in increased expression of BCL2 protein] which binds to BAK1 protein; more ... | CTD | PMID:15004018 |
| minocycline | increases expression | ISO | RGD:2199 | 6480464 | Minocycline results in increased expression of BCL2 mRNA | CTD | PMID:15004018 |
| minocycline | increases expression | ISO | RGD:2199 | 6480464 | Minocycline results in increased expression of BCL2 protein | CTD | PMID:19807907 more ... |
| mitomycin C | affects expression | EXP | | 6480464 | Mitomycin affects the expression of BCL2 | CTD | PMID:19834285 |
| mitomycin C | increases expression | EXP | | 6480464 | Mitomycin results in increased expression of BCL2 protein | CTD | PMID:15793875 PMID:11867586 |
| mitomycin C | multiple interactions | EXP | | 6480464 | Tamoxifen promotes the reaction [Mitomycin results in increased expression of BCL2 mRNA] | CTD | PMID:19757172 |
| mitomycin C | multiple interactions | EXP | | 6480464 | silybin inhibits the reaction [Mitomycin affects the expression of BCL2] | CTD | PMID:19834285 |
| mitomycin C | increases expression | EXP | | 6480464 | Mitomycin results in increased expression of BCL2 protein | CTD | PMID:11867586 PMID:15793875 |
| mitomycin C | increases expression | EXP | | 6480464 | Mitomycin results in increased expression of BCL2 mRNA | CTD | PMID:19757172 |
| mitoxantrone | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [Mitoxantrone results in increased degradation of PARP protein]; more ... | CTD | PMID:8840993 |
| mitoxantrone | decreases expression | EXP | | 6480464 | Mitoxantrone results in decreased expression of BCL2 mRNA | CTD | PMID:8219202 |
| mitoxantrone | multiple interactions | EXP | | 6480464 | [Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of BCL2 protein | CTD | PMID:15582267 |
| mono(2-ethylhexyl) phthalate | decreases expression | EXP | | 6480464 | mono-(2-ethylhexyl)phthalate results in decreased expression of BCL2 mRNA | CTD | PMID:12927354 |
| monocrotophos | decreases expression | ISO | RGD:2199 | 6480464 | Monocrotophos results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:20957986 |
| monocrotophos | increases expression | ISO | RGD:2199 | 6480464 | Monocrotophos results in increased expression of BCL2 mRNA; more ... | CTD | PMID:21445290 |
| morphine | multiple interactions | EXP | | 6480464 | Morphine inhibits the reaction [BECN1 protein binds to BCL2 protein] | CTD | PMID:20190558 |
| morphine | multiple interactions | EXP | | 6480464 | PDGFB protein inhibits the reaction [Morphine results in decreased expression of BCL2 protein] | CTD | PMID:21483469 |
| morphine | decreases expression | EXP | | 6480464 | Morphine results in decreased expression of BCL2 protein | CTD | PMID:10534122 more ... |
| morphine | decreases expression | EXP | | 6480464 | Morphine results in decreased expression of BCL2 protein | CTD | PMID:19292871 PMID:10534122 |
| morphine | decreases expression | ISO | RGD:2199 | 6480464 | Morphine results in decreased expression of BCL2 protein | CTD | PMID:12196588 |
| morphine | decreases expression | ISO | RGD:2199 | 6480464 | Morphine results in decreased expression of BCL2 mRNA | CTD | PMID:18976035 |
| morphine | decreases expression | EXP | | 6480464 | Morphine results in decreased expression of BCL2 protein | CTD | PMID:10534122 PMID:19292871 |
| morphine | multiple interactions | ISO | RGD:2199 | 6480464 | Lithium inhibits the reaction [Morphine results in decreased expression of BCL2 mRNA] | CTD | PMID:18976035 |
| morphine | multiple interactions | EXP | | 6480464 | [[Morphine results in increased expression of BAX protein] co-treated with [Morphine results in decreased expression of BCL2 protein]] results in increased activity of CASP3 protein | CTD | PMID:10534122 |
| morphine | multiple interactions | EXP | | 6480464 | Morphine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:17542780 |
| morphine | multiple interactions | EXP | | 6480464 | Morphine inhibits the reaction [Dactinomycin results in decreased expression of BCL2 protein]; more ... | CTD | PMID:12927789 |
| mycophenolate mofetil | multiple interactions | EXP | | 6480464 | mycophenolate mofetil inhibits the reaction [BCL2 protein results in decreased susceptibility to Dexamethasone] | CTD | PMID:16505121 |
| mycophenolic acid | multiple interactions | EXP | | 6480464 | [Mycophenolic Acid co-treated with Hypoxanthine] results in decreased expression of BCL2 protein | CTD | PMID:21396949 |
| myricetin | decreases expression | EXP | | 6480464 | myricetin results in decreased expression of BCL2 protein | CTD | PMID:15748703 |
| myricetin | multiple interactions | EXP | | 6480464 | Tetradecanoylphorbol Acetate inhibits the reaction [myricetin results in decreased expression of BCL2 protein] | CTD | PMID:15748703 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein] | CTD | PMID:11341981 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [tert-butyl-2-(4,5-dihydrogen-4,4,5,5-tetramethyl-3-O-1H-imidazole-3-cationic-1-oxyl-2-pyrrolidine-1-carboxylic ester) affects the expression of BCL2 protein] | CTD | PMID:22704995 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [arsenic trioxide results in increased phosphorylation of BCL2 protein] | CTD | PMID:18412143 |
| N-acetyl-L-cysteine | multiple interactions | ISO | RGD:2199 | 6480464 | Acetylcysteine inhibits the reaction [arsenite results in increased expression of BCL2 protein] | CTD | PMID:18077580 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [Zinc deficiency results in decreased expression of BCL2 protein] | CTD | PMID:21600978 |
| N-acetyl-L-cysteine | multiple interactions | ISO | RGD:2199 | 6480464 | Acetylcysteine inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:22085843 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [cordycepin results in decreased expression of BCL2 protein] | CTD | PMID:21310227 |
| N-acetyl-L-cysteine | multiple interactions | ISO | RGD:10230 | 6480464 | Acetylcysteine inhibits the reaction [Methylmercury Compounds results in decreased expression of BCL2 mRNA] | CTD | PMID:21549813 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine results in decreased susceptibility to [1-(3',4',5'-trimethoxyphenyl)-3-(3'',4''-dimethoxy-2'-hydroxyphenyl)propane results in decreased expression of BCL2 protein] | CTD | PMID:20674558 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [surfactin peptide results in decreased expression of BCL2 protein] | CTD | PMID:19954742 |
| N-acetyl-L-cysteine | multiple interactions | ISO | RGD:2199 | 6480464 | Acetylcysteine inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein] | CTD | PMID:17041759 |
| N-acetyl-L-cysteine | multiple interactions | ISO | RGD:10230 | 6480464 | Acetylcysteine inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; more ... | CTD | PMID:21616140 |
| N-acetyl-L-cysteine | decreases response to substance | EXP | | 6480464 | BCL2 results in decreased susceptibility to Acetylcysteine | CTD | PMID:17395010 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [Tosylphenylalanyl Chloromethyl Ketone results in increased cleavage of BCL2 protein] | CTD | PMID:19679660 |
| N-acetyl-L-cysteine | decreases expression | EXP | | 6480464 | Acetylcysteine results in decreased expression of BCL2 protein | CTD | PMID:17395010 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:17542780 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in decreased expression of BCL2 protein] | CTD | PMID:19082730 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [nickel acetate results in decreased expression of BCL2 protein] | CTD | PMID:22245127 |
| N-methyl-4-phenylpyridinium | decreases expression | ISO | RGD:10230 | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein | CTD | PMID:12880480 |
| N-methyl-4-phenylpyridinium | decreases expression | ISO | RGD:2199 | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 mRNA | CTD | PMID:19524685 |
| N-methyl-4-phenylpyridinium | decreases expression | ISO | RGD:2199 | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein | CTD | PMID:18496573 more ... |
| N-methyl-4-phenylpyridinium | multiple interactions | ISO | RGD:2199 | 6480464 | Drugs, Chinese Herbal inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:19524685 |
| N-methyl-4-phenylpyridinium | multiple interactions | EXP | | 6480464 | Quercetin inhibits the reaction [squamosamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]] | CTD | PMID:21295016 |
| N-methyl-4-phenylpyridinium | decreases expression | EXP | | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein | CTD | PMID:21295016 |
| N-methyl-4-phenylpyridinium | decreases expression | ISO | RGD:2199 | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein | CTD | PMID:19135049 PMID:21748658 |
| N-methyl-4-phenylpyridinium | multiple interactions | EXP | | 6480464 | rosiglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 mRNA] | CTD | PMID:17266988 |
| N-methyl-4-phenylpyridinium | decreases expression | EXP | | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 mRNA | CTD | PMID:17266988 |
| N-methyl-4-phenylpyridinium | multiple interactions | ISO | RGD:2199 | 6480464 | Amitriptyline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]; more ... | CTD | PMID:19135049 |
| N-methyl-4-phenylpyridinium | decreases expression | ISO | RGD:2199 | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein | CTD | PMID:19135049 |
| N-methyl-4-phenylpyridinium | multiple interactions | ISO | RGD:2199 | 6480464 | [1-Methyl-4-phenylpyridinium co-treated with Quercetin] results in increased expression of BCL2 mRNA; more ... | CTD | PMID:19466539 |
| N-methyl-N'-nitro-N-nitrosoguanidine | decreases expression | ISO | RGD:10230 | 6480464 | Methylnitronitrosoguanidine results in decreased expression of BCL2 protein | CTD | PMID:16019050 |
| N-methyl-N'-nitro-N-nitrosoguanidine | increases expression | ISO | RGD:10230 | 6480464 | Methylnitronitrosoguanidine results in increased expression of BCL2 protein; more ... | CTD | PMID:20434464 |
| N-methyl-N'-nitro-N-nitrosoguanidine | multiple interactions | ISO | RGD:10230 | 6480464 | Eugenol inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:20434464 |
| N-methyl-N'-nitro-N-nitrosoguanidine | multiple interactions | ISO | RGD:2199 | 6480464 | [Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in increased expression of BCL2 protein; more ... | CTD | PMID:16030430 |
| N-methyl-N-nitrosurea | increases expression | ISO | RGD:10230 | 6480464 | Methylnitrosourea results in increased expression of BCL2 mRNA | CTD | PMID:15240709 |
| N-methyl-N-nitrosurea | decreases expression | ISO | RGD:2199 | 6480464 | Methylnitrosourea results in decreased expression of BCL2 protein | CTD | PMID:16011256 PMID:16047940 |
| N-methyl-N-nitrosurea | decreases expression | ISO | RGD:2199 | 6480464 | Methylnitrosourea results in decreased expression of BCL2 protein | CTD | PMID:16047940 PMID:16011256 |
| N-methyl-N-nitrosurea | multiple interactions | ISO | RGD:2199 | 6480464 | FGF1 protein modified form inhibits the reaction [Methylnitrosourea results in decreased expression of BCL2 protein] | CTD | PMID:16011256 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:10230 | 6480464 | BCL2 protein inhibits the reaction [TGFA protein results in increased susceptibility to Diethylnitrosamine] | CTD | PMID:12000706 |
| N-nitrosodiethylamine | increases expression | EXP | | 6480464 | Diethylnitrosamine results in increased expression of BCL2 protein | CTD | PMID:21776270 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:2199 | 6480464 | Diethylnitrosamine results in increased expression of BCL2 protein | CTD | PMID:19931519 PMID:19073162 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:2199 | 6480464 | morin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein] | CTD | PMID:19931519 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:2199 | 6480464 | Diethylnitrosamine results in increased expression of BCL2 protein | CTD | PMID:19073162 PMID:19931519 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:2199 | 6480464 | resveratrol inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein] | CTD | PMID:19073162 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:2199 | 6480464 | fumagillin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 mRNA] | CTD | PMID:15682466 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:2199 | 6480464 | Diethylnitrosamine results in increased expression of BCL2 protein | CTD | PMID:19073162 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:2199 | 6480464 | Diethylnitrosamine results in increased expression of BCL2 mRNA | CTD | PMID:15682466 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:2199 | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of BCL2 mRNA | CTD | PMID:21295105 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:2199 | 6480464 | [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of BCL2 protein; more ... | CTD | PMID:11915028 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:2199 | 6480464 | [2-aminofluorene co-treated with Diethylnitrosamine] results in increased expression of BCL2 protein; more ... | CTD | PMID:20452335 |
| N-nitrosodiethylamine | decreases response to substance | ISO | RGD:10230 | 6480464 | BCL2 protein results in decreased susceptibility to Diethylnitrosamine | CTD | PMID:12000706 |
| N-nitrosodimethylamine | decreases expression | ISO | RGD:2199 | 6480464 | Dimethylnitrosamine results in decreased expression of BCL2 protein | CTD | PMID:14659978 |
| N-nitrosodimethylamine | multiple interactions | ISO | RGD:2199 | 6480464 | Estradiol inhibits the reaction [Dimethylnitrosamine results in decreased expression of BCL2 protein]; more ... | CTD | PMID:14659978 |
| N-tosyl-L-phenylalanyl chloromethyl ketone | increases cleavage | EXP | | 6480464 | Tosylphenylalanyl Chloromethyl Ketone results in increased cleavage of BCL2 protein | CTD | PMID:19679660 |
| N-tosyl-L-phenylalanyl chloromethyl ketone | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [Tosylphenylalanyl Chloromethyl Ketone results in increased cleavage of BCL2 protein] | CTD | PMID:19679660 |
| NAD zwitterion | increases expression | EXP | | 6480464 | NAD results in increased expression of BCL2 protein | CTD | PMID:12390773 |
| NAD(+) | increases expression | EXP | | 6480464 | NAD results in increased expression of BCL2 protein | CTD | PMID:12390773 |
| naloxone | multiple interactions | EXP | | 6480464 | Naloxone inhibits the reaction [Morphine inhibits the reaction [Dactinomycin results in decreased expression of BCL2 protein]] | CTD | PMID:12927789 |
| naloxone | increases expression | ISO | RGD:2199 | 6480464 | Naloxone results in increased expression of BCL2 protein | CTD | PMID:16004788 |
| naphthalene | increases expression | EXP | | 6480464 | naphthalene results in increased expression of BCL2 protein | CTD | PMID:14595851 |
| nickel atom | multiple interactions | EXP | | 6480464 | [Quercetin analog co-treated with Nickel] results in decreased expression of BCL2 protein | CTD | PMID:20577783 |
| nickel dichloride | decreases expression | EXP | | 6480464 | nickel chloride results in decreased expression of BCL2 mRNA | CTD | PMID:17442357 |
| nickel dichloride | decreases expression | ISO | RGD:2199 | 6480464 | nickel chloride results in decreased expression of BCL2 protein | CTD | PMID:20391133 |
| nickel dichloride | increases expression | EXP | | 6480464 | nickel chloride results in increased expression of BCL2 protein | CTD | PMID:21837363 |
| nickel sulfate | increases expression | EXP | | 6480464 | nickel sulfate results in increased expression of BCL2 protein | CTD | PMID:21776270 |
| nifedipine | decreases expression | EXP | | 6480464 | Nifedipine results in decreased expression of BCL2 | CTD | PMID:10075388 |
| nifedipine | multiple interactions | EXP | | 6480464 | Nifedipine results in increased expression of and affects the localization of BCL2 protein | CTD | PMID:10695937 |
| nifedipine | multiple interactions | ISO | RGD:2199 | 6480464 | Nifedipine inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein] | CTD | PMID:19698708 |
| nimesulide | decreases expression | EXP | | 6480464 | nimesulide results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:18564172 |
| nimesulide | decreases expression | ISO | RGD:2199 | 6480464 | nimesulide results in decreased expression of BCL2 protein | CTD | PMID:19772912 |
| nimesulide | affects localization | ISO | RGD:2199 | 6480464 | nimesulide affects the localization of BCL2 protein | CTD | PMID:19772912 |
| nimodipine | decreases expression | EXP | | 6480464 | Nimodipine results in decreased expression of BCL2 protein | CTD | PMID:17490525 |
| nitric oxide | multiple interactions | EXP | | 6480464 | [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in decreased expression of BCL2 protein | CTD | PMID:10828028 |
| nitric oxide | decreases expression | EXP | | 6480464 | Nitric Oxide results in decreased expression of BCL2 protein | CTD | PMID:15126337 |
| nitric oxide | affects expression | ISO | RGD:10230 | 6480464 | Nitric Oxide affects the expression of BCL2 mRNA | CTD | PMID:17135264 |
| nitric oxide | multiple interactions | ISO | RGD:10230 | 6480464 | [3,5-dimethoxy-4'-hydroxystilbene results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:17135264 |
| nitric oxide | multiple interactions | ISO | RGD:10230 | 6480464 | [3-morpholino-sydnonimine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 protein; more ... | CTD | PMID:7706495 |
| nitroglycerin | decreases expression | ISO | RGD:2199 | 6480464 | Nitroglycerin results in decreased expression of BCL2 protein | CTD | PMID:17678976 |
| nitroprusside | decreases expression | EXP | | 6480464 | Nitroprusside results in decreased expression of BCL2 protein | CTD | PMID:15708893 |
| nitroprusside | decreases expression | ISO | RGD:2199 | 6480464 | Nitroprusside results in decreased expression of BCL2 protein | CTD | PMID:10203697 |
| nitroprusside | multiple interactions | ISO | RGD:2199 | 6480464 | IGF1 protein inhibits the reaction [Nitroprusside results in decreased expression of BCL2 protein]; more ... | CTD | PMID:10203697 |
| nocodazole | increases phosphorylation | EXP | | 6480464 | Nocodazole results in increased phosphorylation of BCL2 protein | CTD | PMID:15907805 |
| nocodazole | multiple interactions | EXP | | 6480464 | TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein] | CTD | PMID:15907805 |
| o-cresol | increases expression | ISO | RGD:2199 | 6480464 | 2-cresol results in increased expression of BCL2 mRNA | CTD | PMID:21705299 |
| o-cresol | multiple interactions | ISO | RGD:2199 | 6480464 | Sodium Selenite inhibits the reaction [2-cresol results in increased expression of BCL2 mRNA] | CTD | PMID:21705299 |
| ochratoxin A | decreases expression | ISO | RGD:2199 | 6480464 | ochratoxin A results in decreased expression of BCL2 mRNA | CTD | PMID:12700408 |
| ochratoxin A | increases expression | ISO | RGD:2199 | 6480464 | ochratoxin A results in increased expression of BCL2 mRNA | CTD | PMID:23208426 |
| ochratoxin A | decreases expression | EXP | | 6480464 | ochratoxin A results in decreased expression of BCL2 protein | CTD | PMID:20549612 |
| ochratoxin A | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to ochratoxin A | CTD | PMID:20549612 |
| okadaic acid | decreases expression | EXP | | 6480464 | Okadaic Acid results in decreased expression of BCL2 protein | CTD | PMID:18937299 |
| olanzapine | multiple interactions | ISO | RGD:2199 | 6480464 | olanzapine inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein] | CTD | PMID:15276877 |
| olanzapine | increases expression | ISO | RGD:2199 | 6480464 | olanzapine results in increased expression of BCL2 mRNA; more ... | CTD | PMID:15126120 |
| oroxylin A | decreases expression | EXP | | 6480464 | 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of BCL2 protein | CTD | PMID:19135124 |
| oxaliplatin | decreases expression | EXP | | 6480464 | oxaliplatin results in decreased expression of BCL2 protein | CTD | PMID:16024531 |
| oxaliplatin | multiple interactions | ISO | RGD:2199 | 6480464 | oxaliplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein; more ... | CTD | PMID:19428505 |
| oxomalononitrile | multiple interactions | EXP | | 6480464 | PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to mesoxalonitrile] | CTD | PMID:12730627 |
| oxomalononitrile | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to mesoxalonitrile | CTD | PMID:12730627 |
| paclitaxel | multiple interactions | EXP | | 6480464 | 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein] | CTD | PMID:16580691 |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:10502406 more ... |
| paclitaxel | increases response to substance | EXP | | 6480464 | BCL2 protein mutant form results in increased susceptibility to Paclitaxel | CTD | PMID:20610805 |
| paclitaxel | affects response to substance | EXP | | 6480464 | BCL2 protein affects the susceptibility to Paclitaxel | CTD | PMID:20610805 |
| paclitaxel | multiple interactions | EXP | | 6480464 | resveratrol inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:12510025 |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:10502406 more ... |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:10502406 more ... |
| paclitaxel | decreases expression | EXP | | 6480464 | Paclitaxel results in decreased expression of BCL2 protein | CTD | PMID:10822281 more ... |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:18521433 more ... |
| paclitaxel | decreases expression | EXP | | 6480464 | Paclitaxel results in decreased expression of BCL2 protein | CTD | PMID:19815708 more ... |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:11160861 more ... |
| paclitaxel | decreases expression | EXP | | 6480464 | Paclitaxel results in decreased expression of BCL2 protein | CTD | PMID:19815708 more ... |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:16168113 more ... |
| paclitaxel | decreases expression | EXP | | 6480464 | Paclitaxel results in decreased expression of BCL2 protein | CTD | PMID:15907983 more ... |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:18098270 more ... |
| paclitaxel | decreases expression | EXP | | 6480464 | Paclitaxel results in decreased expression of BCL2 protein | CTD | PMID:19815708 more ... |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:12126962 more ... |
| paclitaxel | decreases expression | EXP | | 6480464 | Paclitaxel results in decreased expression of BCL2 protein | CTD | PMID:16513327 more ... |
| paclitaxel | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein | CTD | PMID:18098270 |
| paclitaxel | multiple interactions | EXP | | 6480464 | [Tretinoin co-treated with Paclitaxel] results in decreased expression of BCL2 protein | CTD | PMID:17701358 |
| paclitaxel | multiple interactions | EXP | | 6480464 | [Paclitaxel results in increased phosphorylation of BCL2 protein] which results in increased susceptibility to Cisplatin | CTD | PMID:12709826 |
| paclitaxel | multiple interactions | EXP | | 6480464 | [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein | CTD | PMID:18516295 |
| paclitaxel | increases phosphorylation | EXP | | 6480464 | Paclitaxel results in increased phosphorylation of BCL2 protein | CTD | PMID:16168113 more ... |
| paclitaxel | increases cleavage | EXP | | 6480464 | Paclitaxel results in increased cleavage of BCL2 protein | CTD | PMID:10822281 |
| paclitaxel | decreases expression | EXP | | 6480464 | Paclitaxel results in decreased expression of BCL2 protein | CTD | PMID:16580691 more ... |
| paclitaxel | decreases expression | EXP | | 6480464 | Paclitaxel results in decreased expression of BCL2 mRNA | CTD | PMID:10822281 |
| paclitaxel | multiple interactions | EXP | | 6480464 | Paclitaxel results in decreased expression of and affects the phosphorylation of BCL2 protein | CTD | PMID:10822281 |
| paclitaxel | decreases degradation | EXP | | 6480464 | Paclitaxel results in decreased degradation of BCL2 protein | CTD | PMID:12126962 |
| paclitaxel | decreases activity | EXP | | 6480464 | Paclitaxel results in decreased activity of BCL2 protein | CTD | PMID:10881025 |
| paclitaxel | multiple interactions | EXP | | 6480464 | [Paclitaxel co-treated with sorafenib] results in decreased expression of BCL2 protein | CTD | PMID:19664330 |
| paclitaxel | affects localization | EXP | | 6480464 | Paclitaxel affects the localization of BCL2 protein | CTD | PMID:12126962 |
| paclitaxel | multiple interactions | EXP | | 6480464 | [IL8 results in increased expression of BCL2 mRNA] which results in decreased susceptibility to Paclitaxel; more ... | CTD | PMID:21742513 |
| paclitaxel | multiple interactions | EXP | | 6480464 | Genistein inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; more ... | CTD | PMID:15907805 |
| paclitaxel | multiple interactions | EXP | | 6480464 | Doxorubicin promotes the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:16168113 |
| paclitaxel | multiple interactions | EXP | | 6480464 | Cyclosporine promotes the reaction [Paclitaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein] | CTD | PMID:12086014 |
| paclitaxel | multiple interactions | EXP | | 6480464 | Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; more ... | CTD | PMID:11726273 |
| paclitaxel | multiple interactions | EXP | | 6480464 | Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2 protein] | CTD | PMID:16243823 |
| paclitaxel | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Paclitaxel | CTD | PMID:16275990 |
| paclitaxel | decreases response to substance | EXP | | 6480464 | BCL2 mRNA results in decreased susceptibility to Paclitaxel | CTD | PMID:16322897 |
| paclitaxel | multiple interactions | EXP | | 6480464 | aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; more ... | CTD | PMID:11160861 |
| palmitic acid | decreases expression | EXP | | 6480464 | Palmitic Acid results in decreased expression of BCL2 | CTD | PMID:15945276 |
| palmitic acid | decreases expression | ISO | RGD:2199 | 6480464 | Palmitic Acid results in decreased expression of BCL2 | CTD | PMID:15945276 |
| paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of BCL2 mRNA | CTD | PMID:9444671 |
| paracetamol | multiple interactions | ISO | RGD:10230 | 6480464 | dioscin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein] | CTD | PMID:22939915 |
| paracetamol | decreases expression | ISO | RGD:10230 | 6480464 | Acetaminophen results in decreased expression of BCL2 protein | CTD | PMID:18467506 PMID:22939915 |
| paracetamol | multiple interactions | ISO | RGD:2199 | 6480464 | Hesperidin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:22093918 |
| paracetamol | decreases expression | ISO | RGD:2199 | 6480464 | Acetaminophen results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:22093918 |
| paracetamol | multiple interactions | ISO | RGD:2199 | 6480464 | anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Acetaminophen results in increased expression of BCL2 protein modified form]; more ... | CTD | PMID:20166895 |
| paracetamol | increases expression | ISO | RGD:2199 | 6480464 | Acetaminophen results in increased expression of BCL2 protein modified form | CTD | PMID:20166895 |
| paracetamol | multiple interactions | ISO | RGD:2199 | 6480464 | Acetaminophen inhibits the reaction [Vitamin K 3 results in decreased expression of BCL2 protein]; more ... | CTD | PMID:19265712 |
| paracetamol | multiple interactions | ISO | RGD:10230 | 6480464 | O(2)-vinyl-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate inhibits the reaction [Acetaminophen results in increased expression of BCL2 mRNA] | CTD | PMID:12540782 |
| paracetamol | increases expression | ISO | RGD:10230 | 6480464 | Acetaminophen results in increased expression of BCL2 mRNA | CTD | PMID:12540782 |
| paracetamol | decreases expression | ISO | RGD:10230 | 6480464 | Acetaminophen results in decreased expression of BCL2 protein | CTD | PMID:18467506 |
| paracetamol | multiple interactions | ISO | RGD:10230 | 6480464 | KITL protein inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein] | CTD | PMID:18467506 |
| paraquat | multiple interactions | ISO | RGD:10230 | 6480464 | GPX1 protein affects the reaction [Paraquat affects the expression of BCL2 mRNA] | CTD | PMID:12654481 |
| paraquat | decreases expression | EXP | | 6480464 | Paraquat results in decreased expression of BCL2 mRNA | CTD | PMID:18836921 |
| paraquat | multiple interactions | ISO | RGD:2199 | 6480464 | [Paraquat co-treated with decitabine] results in decreased expression of BCL2 protein | CTD | PMID:22796470 |
| paraquat | multiple interactions | ISO | RGD:2199 | 6480464 | NFE2L2 mutant form inhibits the reaction [Paraquat results in decreased expression of BCL2 mRNA] | CTD | PMID:22678742 |
| paraquat | decreases expression | ISO | RGD:2199 | 6480464 | Paraquat results in decreased expression of BCL2 mRNA | CTD | PMID:22678742 |
| paraquat | increases expression | EXP | | 6480464 | Paraquat results in increased expression of BCL2 mRNA | CTD | PMID:22230393 |
| paraquat | decreases expression | ISO | RGD:2199 | 6480464 | Paraquat results in decreased expression of BCL2 protein | CTD | PMID:12714668 |
| paraquat | multiple interactions | ISO | RGD:2199 | 6480464 | Docosahexaenoic Acids inhibits the reaction [Paraquat results in decreased expression of BCL2 protein] | CTD | PMID:12714668 |
| pemetrexed | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with pemetrexed co-treated with vorinostat] results in decreased expression of BCL2 protein; more ... | CTD | PMID:19351772 |
| pentobarbital | increases expression | ISO | RGD:2199 | 6480464 | Pentobarbital results in increased expression of BCL2 | CTD | PMID:17715682 |
| perfluorooctane-1-sulfonic acid | decreases expression | EXP | | 6480464 | perfluorooctane sulfonic acid results in decreased expression of BCL2 mRNA | CTD | PMID:19468714 |
| perfluorooctane-1-sulfonic acid | decreases expression | ISO | RGD:10230 | 6480464 | perfluorooctane sulfonic acid results in decreased expression of BCL2 mRNA | CTD | PMID:21115943 |
| perfluorooctanoic acid | decreases expression | EXP | | 6480464 | perfluorooctanoic acid results in decreased expression of BCL2 mRNA | CTD | PMID:19468714 |
| perillyl alcohol | multiple interactions | ISO | RGD:10230 | 6480464 | perilla alcohol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein] | CTD | PMID:19161993 |
| peroxynitrous acid | decreases expression | ISO | RGD:2199 | 6480464 | Peroxynitrous Acid results in decreased expression of BCL2 protein; more ... | CTD | PMID:20869986 |
| peroxynitrous acid | multiple interactions | ISO | RGD:2199 | 6480464 | Curcumin inhibits the reaction [Peroxynitrous Acid results in decreased expression of BCL2 protein]; more ... | CTD | PMID:20869986 |
| phenethyl isothiocyanate | decreases expression | EXP | | 6480464 | phenethyl isothiocyanate results in decreased expression of BCL2 protein | CTD | PMID:16054126 |
| phenobarbital | multiple interactions | ISO | RGD:10230 | 6480464 | Phenobarbital inhibits the reaction [MYC protein results in decreased expression of BCL2 protein] | CTD | PMID:10449034 |
| phenobarbital | increases expression | ISO | RGD:2199 | 6480464 | Phenobarbital results in increased expression of BCL2 protein | CTD | PMID:17456340 |
| phenobarbital | increases expression | ISO | RGD:10230 | 6480464 | Phenobarbital results in increased expression of BCL2 protein | CTD | PMID:10426811 |
| phenylephrine | multiple interactions | ISO | RGD:2199 | 6480464 | BCL2 protein affects the reaction [Phenylephrine results in increased expression of TIMP1 protein]; more ... | CTD | PMID:19910689 |
| phenylephrine | increases expression | ISO | RGD:2199 | 6480464 | Phenylephrine results in increased expression of BCL2 mRNA; more ... | CTD | PMID:19910689 |
| phenylephrine | multiple interactions | ISO | RGD:2199 | 6480464 | Phenylephrine inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:11042672 |
| phenytoin | multiple interactions | EXP | | 6480464 | Phenytoin results in increased expression of and affects the localization of BCL2 protein | CTD | PMID:10695937 |
| phenytoin | decreases expression | ISO | RGD:10230 | 6480464 | Phenytoin results in decreased expression of BCL2 mRNA | CTD | PMID:9118846 |
| phloroglucinol | decreases expression | EXP | | 6480464 | Phloroglucinol metabolite results in decreased expression of BCL2 protein | CTD | PMID:22796323 |
| phorbol 13-acetate 12-myristate | multiple interactions | ISO | RGD:10230 | 6480464 | perilla alcohol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein] | CTD | PMID:19161993 |
| phorbol 13-acetate 12-myristate | multiple interactions | EXP | | 6480464 | [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of BCL2 mRNA | CTD | PMID:16979875 |
| phorbol 13-acetate 12-myristate | decreases expression | EXP | | 6480464 | Tetradecanoylphorbol Acetate results in decreased expression of BCL2 protein | CTD | PMID:11139146 |
| phorbol 13-acetate 12-myristate | increases expression | EXP | | 6480464 | Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein | CTD | PMID:9295281 |
| phorbol 13-acetate 12-myristate | multiple interactions | EXP | | 6480464 | Tetradecanoylphorbol Acetate inhibits the reaction [myricetin results in decreased expression of BCL2 protein] | CTD | PMID:15748703 |
| phorbol 13-acetate 12-myristate | multiple interactions | EXP | | 6480464 | Tetradecanoylphorbol Acetate inhibits the reaction [Trichlorfon results in decreased expression of BCL2 protein] | CTD | PMID:19631781 |
| phorbol 13-acetate 12-myristate | multiple interactions | EXP | | 6480464 | edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein] | CTD | PMID:9295281 |
| phorbol 13-acetate 12-myristate | increases expression | ISO | RGD:10230 | 6480464 | Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein | CTD | PMID:19161993 |
| phylloquinone | multiple interactions | EXP | | 6480464 | [sorafenib co-treated with Vitamin K 1] results in decreased expression of BCL2 protein | CTD | PMID:20301194 |
| pimozide | decreases expression | EXP | | 6480464 | Pimozide results in decreased expression of BCL2 mRNA | CTD | PMID:12130671 |
| piperidine | multiple interactions | ISO | RGD:10230 | 6480464 | piperidine inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] | CTD | PMID:17706638 |
| pirinixic acid | multiple interactions | ISO | RGD:2199 | 6480464 | lactacystin inhibits the reaction [[pirinixic acid results in increased expression of UCP2 protein] which results in increased degradation of BCL2 protein]; more ... | CTD | PMID:19361538 |
| pirinixic acid | increases expression | ISO | RGD:10230 | 6480464 | pirinixic acid results in increased expression of BCL2 protein | CTD | PMID:10426811 |
| potassium cyanide | decreases response to substance | ISO | RGD:2199 | 6480464 | BCL2 protein results in decreased susceptibility to Potassium Cyanide | CTD | PMID:19361538 |
| potassium cyanide | multiple interactions | ISO | RGD:2199 | 6480464 | Potassium Cyanide promotes the reaction [[pirinixic acid results in increased expression of UCP2 protein] which results in increased degradation of BCL2 protein]; more ... | CTD | PMID:19361538 |
| potassium dichromate | decreases expression | ISO | RGD:2199 | 6480464 | Potassium Dichromate results in decreased expression of BCL2 protein | CTD | PMID:21262251 |
| potassium dichromate | decreases expression | ISO | RGD:10230 | 6480464 | Potassium Dichromate results in decreased expression of BCL2 protein | CTD | PMID:19219935 |
| potassium dichromate | multiple interactions | ISO | RGD:2199 | 6480464 | Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BCL2 protein] | CTD | PMID:21262251 |
| potassium dichromate | affects localization | ISO | RGD:2199 | 6480464 | Potassium Dichromate affects the localization of BCL2 protein | CTD | PMID:21262251 |
| pregnenolone 16alpha-carbonitrile | increases expression | ISO | RGD:2199 | 6480464 | Pregnenolone Carbonitrile results in increased expression of BCL2 mRNA | CTD | PMID:19162173 |
| progesterone | increases expression | ISO | RGD:2199 | 6480464 | Progesterone results in increased expression of BCL2 mRNA; more ... | CTD | PMID:15941375 |
| progesterone | multiple interactions | EXP | | 6480464 | [Progesterone co-treated with Estrogens, Conjugated (USP)] results in increased expression of BCL2 protein | CTD | PMID:15779298 |
| propofol | increases expression | ISO | RGD:2199 | 6480464 | Propofol results in increased expression of BCL2 mRNA; more ... | CTD | PMID:19703415 |
| propofol | increases expression | ISO | RGD:10230 | 6480464 | Propofol results in increased expression of BCL2 protein | CTD | PMID:21786383 |
| propofol | multiple interactions | ISO | RGD:2199 | 6480464 | Propofol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:22015447 |
| propofol | multiple interactions | ISO | RGD:2199 | 6480464 | wortmannin inhibits the reaction [Propofol results in increased expression of BCL2 protein] | CTD | PMID:19703415 |
| propranolol | increases expression | ISO | RGD:2199 | 6480464 | Propranolol results in increased expression of BCL2 mRNA | CTD | PMID:11218852 |
| prostaglandin E2 | increases expression | EXP | | 6480464 | Dinoprostone results in increased expression of BCL2 protein | CTD | PMID:9443418 |
| pterostilbene | multiple interactions | EXP | | 6480464 | [pterostilbene co-treated with Quercetin] results in decreased expression of BCL2 protein; more ... | CTD | PMID:18852136 |
| pterostilbene | increases expression | ISO | RGD:10230 | 6480464 | pterostilbene results in increased expression of BCL2 protein | CTD | PMID:20681671 |
| pterostilbene | decreases expression | EXP | | 6480464 | pterostilbene results in decreased expression of BCL2 protein; more ... | CTD | PMID:20152895 |
| purine-6-thiol | decreases expression | ISO | RGD:10230 | 6480464 | 6-Mercaptopurine results in decreased expression of BCL2 protein | CTD | PMID:9058596 |
| puromycin | decreases expression | EXP | | 6480464 | Puromycin results in decreased expression of BCL2 protein | CTD | PMID:21244482 |
| puromycin | multiple interactions | EXP | | 6480464 | Melatonin promotes the reaction [Puromycin results in decreased expression of BCL2 protein] | CTD | PMID:21244482 |
| putrescine | decreases expression | ISO | RGD:2199 | 6480464 | Putrescine results in decreased expression of BCL2 protein | CTD | PMID:17606387 |
| pyridaben | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to pyridaben | CTD | PMID:12730627 |
| pyridaben | multiple interactions | EXP | | 6480464 | PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to pyridaben] | CTD | PMID:12730627 |
| pyridoxal 5'-phosphate | decreases expression | ISO | RGD:2199 | 6480464 | Pyridoxal Phosphate results in decreased expression of BCL2 protein | CTD | PMID:16690808 |
| quercetin | multiple interactions | EXP | | 6480464 | [pterostilbene co-treated with Quercetin] results in decreased expression of BCL2 protein; more ... | CTD | PMID:18852136 |
| quercetin | increases expression | ISO | RGD:2199 | 6480464 | Quercetin results in increased expression of BCL2 mRNA | CTD | PMID:23281070 |
| quercetin | decreases expression | ISO | RGD:2199 | 6480464 | Quercetin results in decreased expression of BCL2 protein | CTD | PMID:23281070 |
| quercetin | multiple interactions | ISO | RGD:2199 | 6480464 | Quercetin inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:23281070 |
| quercetin | multiple interactions | EXP | | 6480464 | Quercetin inhibits the reaction [squamosamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]] | CTD | PMID:21295016 |
| quercetin | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [[arsenic trioxide co-treated with Quercetin] results in increased cleavage of and results in increased activity of CASP8 protein] | CTD | PMID:18359480 |
| quercetin | multiple interactions | ISO | RGD:2199 | 6480464 | Quercetin inhibits the reaction [Thioacetamide affects the expression of BCL2 protein modified form] | CTD | PMID:21885874 |
| quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of BCL2 protein | CTD | PMID:15741050 more ... |
| quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of BCL2 protein | CTD | PMID:15741050 more ... |
| quercetin | multiple interactions | EXP | | 6480464 | [Quercetin analog co-treated with Nickel] results in decreased expression of BCL2 protein | CTD | PMID:20577783 |
| quercetin | affects expression | ISO | RGD:2199 | 6480464 | Quercetin affects the expression of BCL2 protein | CTD | PMID:22000973 |
| quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of BCL2 protein | CTD | PMID:18787224 more ... |
| quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of BCL2 protein | CTD | PMID:16049707 more ... |
| quercetin | multiple interactions | ISO | RGD:2199 | 6480464 | [1-Methyl-4-phenylpyridinium co-treated with Quercetin] results in increased expression of BCL2 mRNA | CTD | PMID:19466539 |
| quercetin | decreases expression | ISO | RGD:10230 | 6480464 | Quercetin results in decreased expression of BCL2 protein | CTD | PMID:17039455 |
| quercetin | multiple interactions | ISO | RGD:10230 | 6480464 | 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Quercetin results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:17135264 |
| quercetin | multiple interactions | EXP | | 6480464 | [Quercetin results in increased susceptibility to Cisplatin] which results in decreased expression of BCL2 protein | CTD | PMID:16619537 |
| quercetin | increases phosphorylation | EXP | | 6480464 | Quercetin results in increased phosphorylation of BCL2 protein | CTD | PMID:16059641 |
| quercetin | decreases expression | EXP | | 6480464 | Quercetin metabolite results in decreased expression of BCL2 protein | CTD | PMID:16280456 |
| quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of BCL2 protein | CTD | PMID:15741050 more ... |
| quercetin | multiple interactions | EXP | | 6480464 | Quercetin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] | CTD | PMID:12672908 |
| quercetin | multiple interactions | EXP | | 6480464 | Quercetin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] | CTD | PMID:19557821 |
| quercetin | affects expression | EXP | | 6480464 | Quercetin affects the expression of BCL2 protein | CTD | PMID:15975156 |
| raloxifene | affects expression | EXP | | 6480464 | Raloxifene affects the expression of BCL2 protein | CTD | PMID:16009171 |
| raloxifene | decreases expression | EXP | | 6480464 | Raloxifene results in decreased expression of BCL2 protein | CTD | PMID:17220163 more ... |
| raloxifene | decreases expression | EXP | | 6480464 | Raloxifene results in decreased expression of BCL2 protein | CTD | PMID:20945400 more ... |
| raloxifene | decreases expression | EXP | | 6480464 | Raloxifene results in decreased expression of BCL2 protein | CTD | PMID:16566921 more ... |
| raloxifene | decreases expression | EXP | | 6480464 | Raloxifene results in decreased expression of BCL2 mRNA | CTD | PMID:16566921 PMID:20945400 |
| raloxifene | decreases expression | EXP | | 6480464 | Raloxifene results in decreased expression of BCL2 protein | CTD | PMID:20945400 more ... |
| raloxifene | decreases expression | EXP | | 6480464 | Raloxifene results in decreased expression of BCL2 protein | CTD | PMID:17220163 more ... |
| raloxifene | increases expression | EXP | | 6480464 | Raloxifene results in increased expression of BCL2 protein | CTD | PMID:16973256 |
| raloxifene | decreases expression | EXP | | 6480464 | Raloxifene results in decreased expression of BCL2 mRNA | CTD | PMID:20945400 PMID:16566921 |
| ramipril | affects expression | ISO | RGD:2199 | 6480464 | Ramipril affects the expression of BCL2 protein | CTD | PMID:10728395 |
| ranitidine | multiple interactions | EXP | | 6480464 | Ranitidine inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] | CTD | PMID:19723537 |
| reserpine | multiple interactions | ISO | RGD:2199 | 6480464 | IAPP protein inhibits the reaction [Reserpine results in decreased expression of BCL2 protein] | CTD | PMID:19463876 |
| reserpine | decreases expression | ISO | RGD:2199 | 6480464 | Reserpine results in decreased expression of BCL2 protein | CTD | PMID:19463876 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 mRNA | CTD | PMID:15633232 more ... |
| resveratrol | increases expression | ISO | RGD:2199 | 6480464 | resveratrol results in increased expression of BCL2 protein | CTD | PMID:21111721 |
| resveratrol | multiple interactions | EXP | | 6480464 | pyrrolidine dithiocarbamic acid inhibits the reaction [resveratrol results in increased expression of BCL2 mRNA] | CTD | PMID:21161674 |
| resveratrol | multiple interactions | EXP | | 6480464 | NQO2 protein promotes the reaction [resveratrol results in decreased expression of BCL2 protein] | CTD | PMID:19661309 |
| resveratrol | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to resveratrol | CTD | PMID:11577002 PMID:19631782 |
| resveratrol | increases expression | ISO | RGD:10230 | 6480464 | resveratrol results in increased expression of BCL2 protein | CTD | PMID:23090186 |
| resveratrol | increases expression | ISO | RGD:10230 | 6480464 | resveratrol results in increased expression of BCL2 mRNA | CTD | PMID:22878646 |
| resveratrol | decreases expression | ISO | RGD:10230 | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:15637762 PMID:18201729 |
| resveratrol | multiple interactions | ISO | RGD:10230 | 6480464 | resveratrol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein] | CTD | PMID:18791811 |
| resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of BCL2 mRNA | CTD | PMID:17261084 more ... |
| resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of BCL2 protein | CTD | PMID:18592012 PMID:19549761 |
| resveratrol | decreases expression | EXP | | 6480464 | [resveratrol results in decreased expression of MTA1 protein] which results in decreased expression of BCL2 protein | CTD | PMID:19810103 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:12632486 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 | CTD | PMID:16209266 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 mRNA | CTD | PMID:15633232 more ... |
| resveratrol | multiple interactions | EXP | | 6480464 | resveratrol inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:12510025 |
| resveratrol | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [resveratrol promotes the reaction [[CASP3 protein results in increased cleavage of aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide] which results in increased chemical synthesis of 4-nitroaniline]]; more ... | CTD | PMID:11577002 |
| resveratrol | multiple interactions | EXP | | 6480464 | [allyl sulfide co-treated with resveratrol] results in decreased expression of BCL2 mRNA | CTD | PMID:18512326 |
| resveratrol | increases phosphorylation | ISO | RGD:2199 | 6480464 | resveratrol results in increased phosphorylation of BCL2 protein | CTD | PMID:15345477 |
| resveratrol | multiple interactions | ISO | RGD:2199 | 6480464 | [MRS 1191 results in decreased activity of ADORA3 protein] inhibits the reaction [resveratrol results in increased phosphorylation of BCL2 protein] | CTD | PMID:15345477 |
| resveratrol | increases expression | ISO | RGD:2199 | 6480464 | resveratrol results in increased expression of BCL2 | CTD | PMID:15345477 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:15633232 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 mRNA | CTD | PMID:15633232 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:15688415 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:16731767 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:19631782 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:19631782 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:17636462 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:15688415 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 | CTD | PMID:16209266 PMID:21743969 |
| resveratrol | multiple interactions | ISO | RGD:2199 | 6480464 | [1-Methyl-4-phenylpyridinium co-treated with resveratrol] results in increased expression of BCL2 mRNA | CTD | PMID:19466539 |
| resveratrol | multiple interactions | ISO | RGD:2199 | 6480464 | resveratrol inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein] | CTD | PMID:19073162 |
| resveratrol | decreases expression | ISO | RGD:10230 | 6480464 | resveratrol results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:15637762 |
| resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of BCL2 mRNA | CTD | PMID:17261084 |
| resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of BCL2 protein | CTD | PMID:19549761 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:17164350 more ... |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 | CTD | PMID:21743969 PMID:16209266 |
| resveratrol | multiple interactions | EXP | | 6480464 | resveratrol inhibits the reaction [Dopamine results in decreased expression of BCL2 protein] | CTD | PMID:17603292 |
| resveratrol | multiple interactions | EXP | | 6480464 | [resveratrol co-treated with beta-1,3-glucan] results in increased expression of BCL2 mRNA | CTD | PMID:17690738 |
| resveratrol | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to resveratrol | CTD | PMID:19631782 |
| resveratrol | multiple interactions | EXP | | 6480464 | BCL2 protein inhibits the reaction [resveratrol promotes the reaction [PML protein binds to CREBBP protein]]; more ... | CTD | PMID:19631782 |
| resveratrol | decreases expression | EXP | | 6480464 | resveratrol results in decreased expression of BCL2 protein | CTD | PMID:12060119 more ... |
| resveratrol | multiple interactions | EXP | | 6480464 | resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein] | CTD | PMID:19620254 |
| resveratrol | multiple interactions | ISO | RGD:2199 | 6480464 | resveratrol inhibits the reaction [Gallic Acid results in decreased expression of BCL2 protein] | CTD | PMID:19723098 |
| resveratrol | increases expression | ISO | RGD:10230 | 6480464 | resveratrol results in increased expression of BCL2 mRNA | CTD | PMID:18819863 PMID:22878646 |
| resveratrol | increases expression | ISO | RGD:2199 | 6480464 | resveratrol results in increased expression of BCL2 protein | CTD | PMID:20861279 PMID:21111721 |
| resveratrol | multiple interactions | ISO | RGD:10230 | 6480464 | [Plant Extracts co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; more ... | CTD | PMID:20103723 |
| riboflavin | decreases expression | EXP | | 6480464 | Riboflavin results in decreased expression of BCL2 protein | CTD | PMID:12654180 |
| rifampicin | increases expression | EXP | | 6480464 | Rifampin results in increased expression of BCL2 protein | CTD | PMID:11958592 |
| rifampicin | multiple interactions | ISO | RGD:10230 | 6480464 | Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein] | CTD | PMID:21419764 |
| ropinirole | increases expression | EXP | | 6480464 | ropinirole results in increased expression of BCL2 protein | CTD | PMID:18242171 |
| rosiglitazone | multiple interactions | EXP | | 6480464 | 2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone results in decreased expression of BCL2 protein] | CTD | PMID:17461445 |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 protein | CTD | PMID:17018897 more ... |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 protein | CTD | PMID:17018897 more ... |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 protein | CTD | PMID:17461445 more ... |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 protein | CTD | PMID:17018897 more ... |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 protein | CTD | PMID:17461445 more ... |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 mRNA | CTD | PMID:19955217 PMID:19056168 |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 protein | CTD | PMID:19056168 more ... |
| rosiglitazone | multiple interactions | EXP | | 6480464 | rosiglitazone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 mRNA] | CTD | PMID:17266988 |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 mRNA | CTD | PMID:19056168 PMID:19955217 |
| rosiglitazone | multiple interactions | EXP | | 6480464 | 2-chloro-5-nitrobenzanilide inhibits the reaction [rosiglitazone inhibits the reaction [Glycosylation End Products, Advanced results in decreased expression of BCL2 mRNA]]; more ... | CTD | PMID:21765445 |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 protein | CTD | PMID:19056168 more ... |
| rosiglitazone | decreases expression | EXP | | 6480464 | rosiglitazone results in decreased expression of BCL2 mRNA | CTD | PMID:19056168 |
| rosiglitazone | multiple interactions | EXP | | 6480464 | [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with rosiglitazone] results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:19056168 |
| rosuvastatin | decreases expression | EXP | | 6480464 | rosuvastatin results in decreased expression of BCL2 protein | CTD | PMID:20852871 |
| rotenone | decreases response to substance | EXP | | 6480464 | BCL2 protein results in decreased susceptibility to Rotenone | CTD | PMID:12730627 |
| rotenone | increases expression | EXP | | 6480464 | Rotenone results in increased expression of BCL2 protein; more ... | CTD | PMID:16679036 PMID:16815102 |
| rotenone | decreases expression | ISO | RGD:2199 | 6480464 | Rotenone results in decreased expression of BCL2 mRNA | CTD | PMID:21807080 |
| rotenone | multiple interactions | ISO | RGD:2199 | 6480464 | Antiparkinson Agents inhibits the reaction [Rotenone results in decreased expression of BCL2 mRNA] | CTD | PMID:21807080 |
| rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of BCL2 protein | CTD | PMID:19539006 more ... |
| rotenone | multiple interactions | EXP | | 6480464 | Ranitidine inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] | CTD | PMID:19723537 |
| rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of BCL2 protein | CTD | PMID:19539006 PMID:19777565 |
| rotenone | multiple interactions | EXP | | 6480464 | Tranexamic Acid inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] | CTD | PMID:19539006 |
| rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of BCL2 protein | CTD | PMID:19777565 PMID:19539006 |
| rotenone | increases expression | ISO | RGD:2199 | 6480464 | Rotenone results in increased expression of BCL2 mRNA | CTD | PMID:18817789 |
| rotenone | decreases expression | ISO | RGD:2199 | 6480464 | Rotenone results in decreased expression of BCL2 protein | CTD | PMID:18082360 |
| rotenone | multiple interactions | ISO | RGD:2199 | 6480464 | protocatechuic acid inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] | CTD | PMID:18082360 |
| rotenone | increases expression | EXP | | 6480464 | Rotenone results in increased expression of BCL2 mRNA; more ... | CTD | PMID:16815102 |
| rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of BCL2 protein | CTD | PMID:19777565 |
| rotenone | multiple interactions | EXP | | 6480464 | PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to Rotenone] | CTD | PMID:12730627 |
| rutin | affects expression | EXP | | 6480464 | Rutin affects the expression of BCL2 protein | CTD | PMID:15975156 |
| rutin | multiple interactions | EXP | | 6480464 | Rutin inhibits the reaction [Glucose results in increased degradation of and results in decreased expression of BCL2 protein] | CTD | PMID:19557821 |
| S-(1,2-dichlorovinyl)-L-cysteine | increases expression | EXP | | 6480464 | S-(1,2-dichlorovinyl)cysteine results in increased expression of BCL2 protein | CTD | PMID:15967204 |
| S-butyl-DL-homocysteine (S,R)-sulfoximine | decreases expression | ISO | RGD:10230 | 6480464 | Buthionine Sulfoximine results in decreased expression of BCL2 protein | CTD | PMID:18552690 |
| S-butyl-DL-homocysteine (S,R)-sulfoximine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein] | CTD | PMID:11341981 |
| S-butyl-DL-homocysteine (S,R)-sulfoximine | multiple interactions | ISO | RGD:10230 | 6480464 | Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in decreased expression of BCL2 mRNA] | CTD | PMID:17989939 |
| S-butyl-DL-homocysteine (S,R)-sulfoximine | decreases expression | ISO | RGD:10230 | 6480464 | Buthionine Sulfoximine results in decreased expression of BCL2 mRNA | CTD | PMID:17989939 |
| S-nitrosoglutathione | multiple interactions | EXP | | 6480464 | [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in decreased expression of BCL2 protein | CTD | PMID:10828028 |
| salmeterol | decreases expression | EXP | | 6480464 | salmeterol results in decreased expression of BCL2 mRNA; more ... | CTD | PMID:14687023 |
| sanguinarine | decreases expression | EXP | | 6480464 | sanguinarine results in decreased expression of BCL2 protein | CTD | PMID:22215411 |
| sappanchalcone | decreases expression | EXP | | 6480464 | sappanchalcone results in decreased expression of BCL2 protein | CTD | PMID:21963806 |
| scopolamine | decreases expression | ISO | RGD:10230 | 6480464 | Scopolamine Hydrobromide results in decreased expression of BCL2 protein | CTD | PMID:17120751 |
| Se-methyl-L-selenocysteine | decreases expression | EXP | | 6480464 | selenomethylselenocysteine results in decreased expression of BCL2 mRNA | CTD | PMID:19360359 |
| Se-methyl-L-selenocysteine | decreases expression | ISO | RGD:2199 | 6480464 | selenomethylselenocysteine results in decreased expression of BCL2 protein | CTD | PMID:11396176 |
| Se-methyl-L-selenocysteine | multiple interactions | EXP | | 6480464 | [selenomethylselenocysteine results in decreased expression of BCL2 mRNA] which results in increased activity of TNFSF10 protein | CTD | PMID:19360359 |
| Se-methylselenocysteine | decreases expression | EXP | | 6480464 | selenomethylselenocysteine results in decreased expression of BCL2 mRNA | CTD | PMID:19360359 |
| Se-methylselenocysteine | decreases expression | ISO | RGD:2199 | 6480464 | selenomethylselenocysteine results in decreased expression of BCL2 protein | CTD | PMID:11396176 |
| Se-methylselenocysteine | multiple interactions | EXP | | 6480464 | [selenomethylselenocysteine results in decreased expression of BCL2 mRNA] which results in increased activity of TNFSF10 protein | CTD | PMID:19360359 |
| selenium atom | decreases expression | EXP | | 6480464 | Selenium results in decreased expression of BCL2 protein | CTD | PMID:17523932 |
| sertraline | affects expression | ISO | RGD:10230 | 6480464 | Sertraline affects the expression of BCL2 protein | CTD | PMID:18403212 |
| sildenafil | multiple interactions | ISO | RGD:10230 | 6480464 | sildenafil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] | CTD | PMID:15811867 |
| sildenafil | increases expression | ISO | RGD:2199 | 6480464 | sildenafil results in increased expression of BCL2 | CTD | PMID:18373738 |
| sildenafil | multiple interactions | ISO | RGD:2199 | 6480464 | sildenafil inhibits the reaction [Streptozocin results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:20574430 |
| silibinin | multiple interactions | EXP | | 6480464 | silybin inhibits the reaction [Mitomycin affects the expression of BCL2] | CTD | PMID:19834285 |
| silicon dioxide | multiple interactions | ISO | RGD:10230 | 6480464 | CASP1 protein affects the reaction [[Silicon Dioxide co-treated with Lipopolysaccharides] results in decreased expression of BCL2 mRNA]; more ... | CTD | PMID:22273745 |
| silicon dioxide | decreases expression | EXP | | 6480464 | Silicon Dioxide results in decreased expression of BCL2 mRNA | CTD | PMID:22245848 |
| silicon dioxide | decreases expression | EXP | | 6480464 | Silicon Dioxide results in decreased expression of BCL2 protein | CTD | PMID:21723938 PMID:22245848 |
| silicon dioxide | multiple interactions | EXP | | 6480464 | Ascorbic Acid inhibits the reaction [Silicon Dioxide results in decreased expression of BCL2 protein]; more ... | CTD | PMID:22245848 |
| silicon dioxide | decreases expression | EXP | | 6480464 | Silicon Dioxide results in decreased expression of BCL2 protein | CTD | PMID:21723938 |
| silver atom | decreases expression | EXP | | 6480464 | Silver results in decreased expression of BCL2 mRNA | CTD | PMID:21611810 |
| silver(0) | decreases expression | EXP | | 6480464 | Silver results in decreased expression of BCL2 mRNA | CTD | PMID:21611810 |
| simvastatin | multiple interactions | EXP | | 6480464 | geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA] | CTD | PMID:18031796 |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 protein | CTD | PMID:17901590 more ... |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 mRNA | CTD | PMID:21729534 more ... |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 mRNA | CTD | PMID:18031796 more ... |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 protein | CTD | PMID:21729534 more ... |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 mRNA | CTD | PMID:17901590 more ... |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 protein | CTD | PMID:18521906 more ... |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 protein | CTD | PMID:21729534 more ... |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 mRNA | CTD | PMID:17901590 more ... |
| simvastatin | increases expression | ISO | RGD:10230 | 6480464 | Simvastatin results in increased expression of BCL2 mRNA; more ... | CTD | PMID:17241114 |
| simvastatin | increases expression | EXP | | 6480464 | Simvastatin results in increased expression of BCL2 protein | CTD | PMID:17241114 |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 protein | CTD | PMID:17901590 more ... |
| simvastatin | multiple interactions | EXP | | 6480464 | Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter] | CTD | PMID:20369390 |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 mRNA | CTD | PMID:21729534 more ... |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 protein | CTD | PMID:18521906 |
| simvastatin | decreases expression | EXP | | 6480464 | Simvastatin results in decreased expression of BCL2 mRNA | CTD | PMID:18031796 |
| simvastatin | multiple interactions | EXP | | 6480464 | Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein] | CTD | PMID:17277159 |
| sirolimus | multiple interactions | EXP | | 6480464 | [Curcumin co-treated with Sirolimus] results in decreased expression of BCL2 | CTD | PMID:19373661 |
| sirolimus | multiple interactions | ISO | RGD:2199 | 6480464 | Sirolimus inhibits the reaction [lactacystin results in decreased expression of BCL2 protein] | CTD | PMID:18640276 |
| sirolimus | multiple interactions | ISO | RGD:10230 | 6480464 | [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA | CTD | PMID:11355896 |
| sirolimus | decreases expression | EXP | | 6480464 | Sirolimus results in decreased expression of BCL2 protein | CTD | PMID:19815708 |
| sirolimus | decreases expression | EXP | | 6480464 | Sirolimus results in decreased expression of BCL2 mRNA | CTD | PMID:19764996 |
| sirolimus | multiple interactions | EXP | | 6480464 | Sirolimus promotes the reaction [Ethanol results in increased expression of BCL2 protein] | CTD | PMID:21410490 |
| sirolimus | multiple interactions | EXP | | 6480464 | Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein] | CTD | PMID:15571967 |
| sodium azide | multiple interactions | ISO | RGD:2199 | 6480464 | Sodium Azide inhibits the reaction [Minocycline results in increased expression of BCL2 protein] | CTD | PMID:15004018 |
| sodium chloride | multiple interactions | ISO | RGD:2199 | 6480464 | [Methylnitronitrosoguanidine co-treated with Sodium Chloride] results in increased expression of BCL2 protein; more ... | CTD | PMID:16030430 |
| sodium chloride | multiple interactions | ISO | RGD:2199 | 6480464 | acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of BCL2 protein]; more ... | CTD | PMID:22431579 |
| sodium dichromate | decreases expression | ISO | RGD:10230 | 6480464 | sodium bichromate results in decreased expression of BCL2 protein | CTD | PMID:21047991 |
| sodium dichromate | decreases expression | ISO | RGD:10230 | 6480464 | sodium bichromate results in decreased expression of BCL2 protein | CTD | PMID:20298709 PMID:21047991 |
| sodium dichromate | multiple interactions | ISO | RGD:10230 | 6480464 | CAT protein inhibits the reaction [sodium bichromate results in decreased expression of BCL2 protein]; more ... | CTD | PMID:20298709 |
| sodium fluoride | multiple interactions | EXP | | 6480464 | [Sodium Fluoride inhibits the reaction [CA2 protein binds to BAD protein]] promotes the reaction [BAD protein binds to BCL2 protein]; more ... | CTD | PMID:21708216 |
| spermine | increases expression | ISO | RGD:2199 | 6480464 | Spermine results in increased expression of BCL2 protein | CTD | PMID:17606387 |
| spermine | decreases expression | EXP | | 6480464 | Spermine results in decreased expression of BCL2 protein | CTD | PMID:16151648 |
| spironolactone | increases expression | ISO | RGD:2199 | 6480464 | Spironolactone results in increased expression of BCL2 protein | CTD | PMID:19114643 |
| staurosporine | multiple interactions | EXP | | 6480464 | Staurosporine inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] | CTD | PMID:15907805 |
| stavudine | decreases expression | EXP | | 6480464 | Stavudine results in decreased expression of BCL2 protein | CTD | PMID:9007205 |
| streptozocin | multiple interactions | ISO | RGD:2199 | 6480464 | arjunolic acid inhibits the reaction [Streptozocin results in increased expression of BCL2 protein] | CTD | PMID:19682444 |
| streptozocin | decreases expression | ISO | RGD:2199 | 6480464 | Streptozocin results in decreased expression of BCL2 protein | CTD | PMID:15056984 more ... |
| streptozocin | multiple interactions | ISO | RGD:2199 | 6480464 | Angiotensin-Converting Enzyme Inhibitors inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein]; more ... | CTD | PMID:22429817 |
| streptozocin | decreases expression | ISO | RGD:2199 | 6480464 | Streptozocin results in decreased expression of BCL2 protein | CTD | PMID:15056984 more ... |
| streptozocin | decreases expression | ISO | RGD:2199 | 6480464 | Streptozocin results in decreased expression of BCL2 mRNA | CTD | PMID:15587404 more ... |
| streptozocin | decreases expression | ISO | RGD:2199 | 6480464 | Streptozocin results in decreased expression of BCL2 mRNA | CTD | PMID:20574430 more ... |
| streptozocin | decreases expression | ISO | RGD:2199 | 6480464 | Streptozocin results in decreased expression of BCL2 protein | CTD | PMID:18758938 more ... |
| streptozocin | decreases expression | ISO | RGD:2199 | 6480464 | Streptozocin results in decreased expression of BCL2 mRNA | CTD | PMID:20574430 more ... |
| streptozocin | decreases expression | ISO | RGD:2199 | 6480464 | Streptozocin results in decreased expression of BCL2 protein | CTD | PMID:20650802 more ... |
| streptozocin | decreases expression | ISO | RGD:2199 | 6480464 | Streptozocin results in decreased expression of BCL2 protein | CTD | PMID:20650802 |